data_1yez_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1yez _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo . . . . . 0 N--CA 1.463 -0.306 0 N-CA-C 112.78 0.261 . . . . 0.0 112.78 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.5 m -126.29 146.62 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.225 0.536 . . . . 0.0 112.268 -172.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -121.07 171.51 8.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 174.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.559 ' HG2' ' HA ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -66.54 125.12 24.74 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.239 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 23.06 17.37 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 116.203 -0.453 . . . . 0.0 113.633 173.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.438 ' O ' ' HD2' ' A' ' 53' ' ' LYS . 45.0 mt-10 -105.28 171.65 7.21 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.278 0.539 . . . . 0.0 110.924 -177.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 7.1 p -141.97 129.28 20.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.857 0.361 . . . . 0.0 110.59 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 87.8 m-85 -134.84 142.47 46.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.388 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -82.03 94.3 7.15 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.423 HG23 HD13 ' A' ' 52' ' ' ILE . 32.9 m -111.54 159.11 11.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.304 0.573 . . . . 0.0 111.477 -173.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 m -112.69 125.97 54.88 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.292 -0.867 . . . . 0.0 108.809 172.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.562 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.0 mm -69.59 100.55 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.047 0.451 . . . . 0.0 110.257 -179.356 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -81.51 -34.72 31.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.283 -175.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.512 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 31.2 t0 -138.57 170.36 16.15 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.264 -178.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.415 HG12 ' HA2' ' A' ' 30' ' ' GLY . 27.8 mt -145.37 131.68 14.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.67 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.784 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.594 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 5.5 m-20 . . . . . 0 CA--C 1.516 -0.333 0 CA-C-O 120.664 0.268 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.415 ' HA2' HG12 ' A' ' 24' ' ' ILE . . . -71.73 126.42 12.39 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.632 177.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.545 HG22 HG13 ' A' ' 38' ' ' VAL . 75.5 mt -94.42 107.19 19.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.192 0.52 . . . . 0.0 110.649 -178.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.412 ' HB1' ' HB ' ' A' ' 39' ' ' ILE . . . -99.81 96.32 7.5 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.157 -0.928 . . . . 0.0 109.183 173.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.413 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 14.6 ptm180 -93.26 93.54 8.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.433 -176.276 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 52.5 mt -89.11 109.88 20.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.259 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 57.56 12.89 1.68 Allowed 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.953 -1.022 . . . . 0.0 112.302 -176.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.37 -19.73 12.87 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.313 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.413 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 70.4 t80 -73.72 125.66 28.58 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.545 HG13 HG22 ' A' ' 31' ' ' ILE . 98.0 t -93.18 112.58 26.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.346 0.593 . . . . 0.0 111.652 -173.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.412 ' HB ' ' HB1' ' A' ' 32' ' ' ALA . 57.2 mt -103.21 126.78 57.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.474 173.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -95.17 121.8 37.19 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.011 0.434 . . . . 0.0 111.002 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.511 HG22 ' HB1' ' A' ' 64' ' ' ALA . 21.6 t -120.33 89.9 44.32 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.498 176.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . 0.594 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 17.3 Cg_exo -66.15 127.48 17.65 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.899 2.399 . . . . 0.0 112.536 -175.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.79 43.21 3.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.815 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.562 ' HB ' HG13 ' A' ' 21' ' ' ILE . 6.6 p -128.06 -171.7 2.51 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.588 0.232 . . . . 0.0 111.254 179.033 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -140.06 152.94 46.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.237 -176.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 38.9 t -63.01 118.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.74 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.24 1.85 64.42 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.382 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -76.18 119.43 20.08 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.774 0.321 . . . . 0.0 110.621 -178.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -98.67 108.11 20.72 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.577 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.3 m -139.79 160.25 27.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -174.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -86.14 110.36 19.51 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 44.8 pt -97.55 132.44 42.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.719 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.438 ' HD2' ' O ' ' A' ' 15' ' ' GLU . 51.0 tptt -92.95 104.86 17.05 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 174.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 99.5 t -69.29 97.24 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -65.36 -48.55 72.59 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.559 ' HA ' ' HG2' ' A' ' 13' ' ' GLU . 75.0 mtp180 -150.97 161.77 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.536 -177.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 27.7 m -128.98 135.64 61.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.106 0.479 . . . . 0.0 110.576 179.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -111.61 157.55 39.0 Favored Pre-proline 0 C--N 1.32 -0.682 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.28 -16.42 22.33 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.965 2.443 . . . . 0.0 113.805 -176.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.4 mmtm -117.32 -18.23 9.95 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -176.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -169.88 161.06 8.81 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.425 0.155 . . . . 0.0 110.66 -175.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -120.08 156.63 30.6 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.263 -178.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -114.43 134.2 55.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.346 176.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.511 ' HB1' HG22 ' A' ' 41' ' ' VAL . . . -145.75 154.9 42.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.699 178.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.3 t -128.47 157.14 41.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.041 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 99.1 t -84.25 119.64 33.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.823 -177.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.7 m -104.59 15.88 6.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.083 0.468 . . . . 0.0 110.813 178.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 . . . . . 0 C--O 1.247 0.948 0 CA-C-N 114.547 -1.206 . . . . 0.0 111.307 178.984 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo . . . . . 0 N--CA 1.462 -0.343 0 CA-C-O 120.867 0.278 . . . . 0.0 112.82 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 m -113.33 151.22 15.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.806 -178.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 -92.31 148.74 21.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.499 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.454 ' CG ' HG21 ' A' ' 57' ' ' VAL . 37.5 mt-10 -68.42 109.56 3.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.243 0.544 . . . . 0.0 110.856 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.438 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 105.33 28.87 5.32 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.001 -178.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -87.04 160.03 18.75 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 175.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.513 HG21 ' HG3' ' A' ' 53' ' ' LYS . 46.5 t -139.02 115.48 10.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.673 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -151.25 142.92 23.69 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.404 178.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.573 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 3.7 p-10 -84.47 137.04 33.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.26 0.552 . . . . 0.0 110.446 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 18.2 m -134.63 160.55 41.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.026 -176.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.5 m -103.52 125.92 50.36 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 169.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.547 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.4 mm -67.41 114.38 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -95.75 -32.67 12.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.122 -170.296 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -140.62 165.9 26.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.639 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.524 HD11 ' HA2' ' A' ' 30' ' ' GLY . 43.5 mm -129.79 133.75 64.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.509 ' HB2' HD13 ' A' ' 31' ' ' ILE . . . . . . . . 0 C--N 1.319 -0.756 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -175.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.522 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 38.9 m-20 . . . . . 0 C--O 1.236 0.376 0 CA-C-O 120.692 0.282 . . . . 0.0 110.523 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.524 ' HA2' HD11 ' A' ' 24' ' ' ILE . . . -89.97 150.64 21.13 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.813 -176.073 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.509 HD13 ' HB2' ' A' ' 25' ' ' ALA . 43.0 mm -111.0 117.3 54.69 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.161 0.505 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -119.28 102.94 9.06 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.369 -0.832 . . . . 0.0 108.815 172.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 25.0 ptt85 -107.07 114.84 29.16 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.98 0.419 . . . . 0.0 111.444 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.498 HG21 ' HG3' ' A' ' 35' ' ' GLU . 41.6 mt -99.36 119.51 47.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.996 177.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.498 ' HG3' HG21 ' A' ' 34' ' ' ILE . 32.9 mt-10 62.23 26.06 15.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.994 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.65 -19.82 53.1 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.197 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.419 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 58.8 t80 -72.06 108.84 5.48 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.47 HG13 HG23 ' A' ' 31' ' ' ILE . 59.3 t -76.14 124.18 33.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.106 0.479 . . . . 0.0 111.526 -175.32 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.52 HG12 ' HB2' ' A' ' 62' ' ' ALA . 63.7 mt -118.77 129.77 74.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.187 -0.46 . . . . 0.0 109.885 176.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -92.38 124.66 36.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.736 -177.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.406 ' HA ' ' HD2' ' A' ' 42' ' ' PRO . 38.8 t -111.13 109.15 57.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.819 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . 0.522 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 13.6 Cg_endo -57.24 119.62 6.99 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 122.953 2.435 . . . . 0.0 113.191 -175.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 63.58 74.13 0.47 Allowed Glycine 0 CA--C 1.519 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.862 175.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.547 ' HB ' HG13 ' A' ' 21' ' ' ILE . 1.2 p -143.33 161.52 38.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.802 0.334 . . . . 0.0 110.918 176.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 tptm -120.09 151.95 38.3 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.058 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.44 HG22 HG12 ' A' ' 24' ' ' ILE . 80.6 t -60.11 126.17 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 176.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 103.51 -5.07 47.8 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.893 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.81 107.83 4.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.915 0.388 . . . . 0.0 110.601 174.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -87.94 96.17 10.39 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 173.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.542 ' HB ' HG21 ' A' ' 66' ' ' VAL . 19.1 m -134.48 147.79 29.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -169.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.573 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 0.2 OUTLIER -79.38 120.15 23.41 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.595 174.76 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 2.7 pp -116.88 141.16 36.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.552 178.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.513 ' HG3' HG21 ' A' ' 16' ' ' VAL . 78.4 tttt -101.57 114.72 29.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 172.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.6 t -69.25 99.13 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 173.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -88.52 -37.53 15.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.085 -169.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -150.47 130.99 13.87 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -174.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.454 HG21 ' CG ' ' A' ' 13' ' ' GLU . 26.9 m -112.69 139.24 38.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.17 0.509 . . . . 0.0 111.662 -177.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -118.28 154.31 51.9 Favored Pre-proline 0 C--N 1.322 -0.627 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 170.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.03 -19.57 26.91 Favored 'Trans proline' 0 CA--C 1.533 0.45 0 C-N-CA 122.634 2.222 . . . . 0.0 113.654 -177.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -105.99 -26.32 11.71 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -168.71 163.75 12.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.426 0.155 . . . . 0.0 110.59 -172.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.52 ' HB2' HG12 ' A' ' 39' ' ' ILE . . . -129.88 159.39 36.76 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.117 0.484 . . . . 0.0 111.755 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -105.92 127.82 53.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.565 174.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -141.23 126.89 19.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 11.6 t -100.55 145.92 27.74 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.261 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.542 HG21 ' HB ' ' A' ' 50' ' ' VAL . 4.0 p -82.38 116.67 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.681 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 25.5 m -101.79 4.61 10.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.621 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.527 ' OXT' ' HB2' ' A' ' 51' ' ' ARG . 43.6 mt-10 . . . . . 0 C--O 1.247 0.922 0 CA-C-N 114.254 -1.339 . . . . 0.0 112.361 177.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 CA--C 1.53 0.29 0 N-CA-C 113.535 0.552 . . . . 0.0 113.535 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.2 m -122.23 148.23 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.91 0.386 . . . . 0.0 111.459 -175.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.8 mm-40 -102.33 161.88 13.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.327 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.448 ' HG3' HG21 ' A' ' 57' ' ' VAL . 3.5 mp0 -65.98 119.64 11.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.266 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.3 18.7 27.89 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 116.029 -0.532 . . . . 0.0 113.153 173.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.471 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 33.0 mt-10 -92.61 166.59 12.42 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.036 -176.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.14 127.11 60.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.954 0.407 . . . . 0.0 110.216 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -129.98 140.81 50.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.764 -176.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -79.97 90.38 5.36 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 171.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.3 m -104.73 148.77 8.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.395 0.616 . . . . 0.0 111.72 -172.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.544 HG22 ' HG2' ' A' ' 49' ' ' GLU . 24.6 m -101.72 124.91 48.15 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.318 173.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.526 HG13 ' HB ' ' A' ' 44' ' ' THR . 43.6 mm -70.33 89.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.3 mt-30 -81.93 -33.1 30.51 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.859 -175.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -128.84 170.67 13.09 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.655 179.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.45 ' HB ' ' CG2' ' A' ' 46' ' ' VAL . 8.4 tt -147.73 150.46 14.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.936 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.557 -178.903 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.6 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 56.7 m-20 . . . . . 0 C--O 1.236 0.387 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.53 ' HA3' ' HG1' ' A' ' 44' ' ' THR . . . -74.21 141.37 28.89 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.901 -0.591 . . . . 0.0 113.003 -171.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.526 HG22 HG13 ' A' ' 38' ' ' VAL . 47.9 mm -107.73 104.52 17.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.137 0.494 . . . . 0.0 110.154 178.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -97.53 97.02 8.71 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.636 175.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 29.7 ptt85 -96.05 94.51 7.6 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.289 0.566 . . . . 0.0 111.394 -175.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 55.1 mt -86.51 113.47 24.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.99 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.2 mm-40 54.98 24.34 5.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.729 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.52 -17.99 51.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -75.95 121.74 23.15 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.526 HG13 HG22 ' A' ' 31' ' ' ILE . 57.9 t -83.35 121.66 36.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.197 0.523 . . . . 0.0 112.079 -173.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.548 HG12 ' HB2' ' A' ' 62' ' ' ALA . 48.2 mt -116.61 126.92 74.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.548 174.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -91.22 125.22 35.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.825 0.345 . . . . 0.0 111.136 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.4 t -119.45 111.79 36.19 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.669 176.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . 0.6 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 45.8 Cg_endo -68.65 114.72 3.61 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 122.631 2.22 . . . . 0.0 113.659 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.53 0.35 58.0 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.805 -0.712 . . . . 0.0 114.738 170.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.53 ' HG1' ' HA3' ' A' ' 30' ' ' GLY . 16.7 p -89.12 138.41 31.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 118.09 0.945 . . . . 0.0 111.936 -177.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.4 ' HG2' ' N ' ' A' ' 46' ' ' VAL . 2.5 tmtp? -92.28 155.5 17.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.967 -179.171 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.45 ' CG2' ' HB ' ' A' ' 24' ' ' ILE . 96.9 t -64.4 128.56 27.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-O 121.069 0.461 . . . . 0.0 110.962 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.66 -17.72 42.11 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.214 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.09 115.08 9.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.952 0.406 . . . . 0.0 110.446 178.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.544 ' HG2' HG22 ' A' ' 20' ' ' THR . 37.2 mt-10 -97.6 97.83 9.38 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.315 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.9 167.29 23.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.799 -173.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 60.3 mtt180 -100.25 120.81 40.48 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.13 0.491 . . . . 0.0 109.885 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.7 pt -113.25 144.6 20.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.394 -178.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 46.0 tttp -99.21 108.71 21.36 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.8 t -68.94 98.4 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -86.38 -35.3 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.478 -171.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -141.56 139.5 33.2 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.802 -174.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.448 HG21 ' HG3' ' A' ' 13' ' ' GLU . 15.4 m -123.23 115.51 45.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.4 0.619 . . . . 0.0 110.54 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.4 ' N ' HD22 ' A' ' 58' ' ' LEU . 3.1 mm? -97.65 155.05 37.65 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.234 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.63 -6.96 8.05 Favored 'Trans proline' 0 CA--C 1.531 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 113.304 -178.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.788 ' HZ2' ' HB2' ' A' ' 60' ' ' LYS . 5.0 ttmp? -111.25 -30.72 7.33 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.056 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -170.86 167.48 7.48 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.365 -175.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.548 ' HB2' HG12 ' A' ' 39' ' ' ILE . . . -110.28 156.21 21.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.913 0.387 . . . . 0.0 110.946 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -123.87 136.43 54.36 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 178.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.99 148.61 43.7 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.064 0.459 . . . . 0.0 111.461 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 p -105.82 130.17 53.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.745 174.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.692 HG21 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -77.06 130.51 36.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.056 0.455 . . . . 0.0 110.764 -176.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.5 m -108.24 22.25 4.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.099 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.692 ' H ' HG21 ' A' ' 66' ' ' VAL . 26.5 mm-40 . . . . . 0 C--O 1.246 0.909 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.543 -177.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo . . . . . 0 N--CA 1.456 -0.7 0 N-CA-C 113.316 0.468 . . . . 0.0 113.316 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.1 m -116.67 156.38 17.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.667 0.27 . . . . 0.0 111.001 -175.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -129.1 157.69 41.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.231 -0.441 . . . . 0.0 109.933 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.401 ' HB3' ' HA ' ' A' ' 56' ' ' ARG . 8.8 pt-20 -67.03 127.67 33.47 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.135 0.493 . . . . 0.0 110.978 176.206 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.68 29.45 7.35 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.988 -178.042 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -115.04 170.43 8.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.47 125.35 16.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.182 0.515 . . . . 0.0 110.48 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -136.15 151.51 49.84 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.432 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -91.86 126.52 36.97 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 170.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.9 m -140.48 153.79 21.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.003 0.43 . . . . 0.0 111.552 -174.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -106.75 121.82 45.14 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 171.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.539 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.3 mm -68.95 116.02 8.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 120.886 0.374 . . . . 0.0 110.566 -177.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.86 -54.53 5.52 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.227 -175.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.509 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 47.0 t0 -128.4 176.27 7.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.957 -176.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.512 HD12 ' HA2' ' A' ' 30' ' ' GLY . 43.6 mm -134.36 139.05 48.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.028 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.741 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -175.41 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.652 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 1.8 m-20 . . . . . 0 CA--C 1.517 -0.313 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.512 ' HA2' HD12 ' A' ' 24' ' ' ILE . . . -78.75 146.48 29.85 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.25 179.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.509 ' HB ' ' HB3' ' A' ' 23' ' ' ASP . 50.9 mm -104.52 99.7 8.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.993 0.425 . . . . 0.0 110.457 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -127.22 110.74 13.19 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.591 175.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.551 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 23.7 ptt180 -108.64 139.49 43.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.216 0.531 . . . . 0.0 111.295 -176.452 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 61.6 mt -122.03 119.04 57.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.714 175.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.6 mm-40 58.24 32.54 22.17 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.822 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.14 -31.72 7.4 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.739 179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -76.14 110.16 10.4 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.93 0.395 . . . . 0.0 110.058 -177.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 33' ' ' ARG . 7.2 p -84.7 134.64 26.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.182 0.515 . . . . 0.0 111.753 -174.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.514 HG12 ' HB3' ' A' ' 62' ' ' ALA . 51.5 mt -107.99 126.43 64.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.754 176.331 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -92.95 122.35 35.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.524 178.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.524 HG22 HG23 ' A' ' 52' ' ' ILE . 28.2 t -124.41 95.27 43.52 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.176 -0.466 . . . . 0.0 109.808 178.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 43.3 Cg_endo -68.15 122.19 9.24 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.851 2.367 . . . . 0.0 112.989 -177.279 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.21 27.9 4.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.34 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.539 ' HB ' HG13 ' A' ' 21' ' ' ILE . 17.3 p -118.99 164.34 15.62 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.991 0.424 . . . . 0.0 111.197 -179.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 48' ' ' ASP . 17.7 tptp -116.21 164.03 15.1 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.785 177.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 61.9 t -65.08 120.5 12.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 177.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.91 62.13 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.01 -178.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.512 ' HB2' ' O ' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -69.25 107.92 3.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.754 0.311 . . . . 0.0 110.604 176.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -92.56 100.45 12.98 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 175.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.4 m -135.89 160.07 39.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.256 0.551 . . . . 0.0 112.131 -172.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -91.66 119.48 31.58 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.524 172.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.524 HG23 HG22 ' A' ' 41' ' ' VAL . 47.6 pt -108.74 139.53 30.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.296 0.569 . . . . 0.0 111.566 -175.492 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 50.3 tptt -99.26 106.04 18.13 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.435 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 58.1 t -68.9 113.42 4.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -90.57 -37.23 13.97 Favored 'General case' 0 C--N 1.323 -0.552 0 O-C-N 123.609 0.568 . . . . 0.0 110.911 -174.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.401 ' HA ' ' HB3' ' A' ' 13' ' ' GLU . 73.0 mtp180 -143.07 155.75 44.68 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.976 0.417 . . . . 0.0 111.371 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 54.6 t -126.17 125.71 68.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.973 174.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.561 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 5.8 mp -114.01 162.16 24.34 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.561 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 40.4 Cg_exo -36.77 -44.35 1.05 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.347 3.365 . . . . 0.0 115.686 -174.188 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.578 ' HG3' ' HD1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.74 14.47 5.37 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -175.299 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.578 ' HD1' ' HG3' ' A' ' 60' ' ' LYS . 46.9 p90 -169.25 149.47 4.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.938 0.399 . . . . 0.0 111.19 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.514 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -107.16 165.52 11.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.655 179.204 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -128.17 122.33 31.65 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.463 ' HB1' HG21 ' A' ' 41' ' ' VAL . . . -139.79 164.38 30.12 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.824 0.345 . . . . 0.0 111.508 -176.02 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 9.5 p -133.98 158.82 42.53 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.371 176.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.9 t -83.86 115.51 26.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.786 0.327 . . . . 0.0 110.424 -177.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.7 m -118.24 3.34 7.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.016 0.436 . . . . 0.0 110.937 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 . . . . . 0 C--O 1.245 0.85 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.581 -174.027 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo . . . . . 0 N--CA 1.476 0.463 0 N-CA-C 113.999 0.73 . . . . 0.0 113.999 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.544 ' HB ' HG22 ' A' ' 54' ' ' VAL . 24.5 m -135.13 132.5 52.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -118.77 170.75 8.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.245 0.545 . . . . 0.0 111.748 -177.114 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.424 ' HG3' HG22 ' A' ' 57' ' ' VAL . 28.2 mt-10 -65.6 116.98 7.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.196 -0.911 . . . . 0.0 112.355 -172.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.514 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 94.17 31.69 7.89 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.389 171.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -122.77 153.71 39.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.209 -0.597 . . . . 0.0 110.771 178.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.402 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 3.9 p -110.45 133.1 56.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.403 -178.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -132.38 150.79 52.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.046 -177.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -94.29 107.58 19.52 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 176.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.425 HG11 HD11 ' A' ' 34' ' ' ILE . 29.4 m -118.47 166.65 12.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.531 0.681 . . . . 0.0 111.834 -171.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.9 m -131.38 127.52 37.74 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.358 174.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.513 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.5 mm -69.0 125.07 26.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.78 -174.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 mm-40 -98.83 -41.52 7.6 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.398 -175.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 26.3 m-20 -133.77 173.66 11.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.771 0.319 . . . . 0.0 111.144 -177.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.442 HG12 HG22 ' A' ' 46' ' ' VAL . 45.5 mm -122.36 134.11 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.53 ' HB1' ' HB3' ' A' ' 29' ' ' ASP . . . . . . . . 0 C--N 1.323 -0.562 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.363 -179.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.53 ' HB3' ' HB1' ' A' ' 25' ' ' ALA . 13.5 t70 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.576 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -96.19 112.63 4.47 Favored Glycine 0 N--CA 1.439 -1.158 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 177.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.498 HG22 HG12 ' A' ' 38' ' ' VAL . 74.7 mt -79.14 103.39 6.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.283 0.563 . . . . 0.0 110.71 -175.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.48 ' HB1' HD13 ' A' ' 21' ' ' ILE . . . -105.48 116.43 31.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.221 175.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 25.1 ptt180 -107.5 136.59 47.01 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.476 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.425 HD11 HG11 ' A' ' 19' ' ' VAL . 56.7 mt -124.48 118.25 52.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.608 174.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 59.42 26.94 15.94 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.743 -179.438 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.08 -22.63 39.88 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.762 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -75.55 130.65 39.18 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.498 HG12 HG22 ' A' ' 31' ' ' ILE . 61.9 t -86.26 122.11 38.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.171 0.51 . . . . 0.0 111.689 -175.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.421 HD13 HG12 ' A' ' 11' ' ' VAL . 46.1 mt -115.1 133.4 61.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.182 174.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.449 ' HB3' ' OD2' ' A' ' 29' ' ' ASP . 98.1 m-85 -98.14 130.05 44.91 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.974 0.416 . . . . 0.0 111.206 -177.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 41.6 t -130.34 93.5 32.64 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.862 178.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 26.1 Cg_exo -62.66 129.16 25.45 Favored 'Trans proline' 0 CA--C 1.528 0.221 0 C-N-CA 123.095 2.53 . . . . 0.0 113.333 -174.35 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.44 50.53 3.36 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.609 174.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.576 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 11.1 p -139.72 -178.57 5.48 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.643 -0.327 . . . . 0.0 110.768 177.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.754 ' HZ1' ' HB3' ' A' ' 45' ' ' LYS . 4.9 ttpm? -133.93 153.69 51.59 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.442 HG22 HG12 ' A' ' 24' ' ' ILE . 38.5 t -58.37 117.0 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 175.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.97 -16.44 18.22 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.379 -177.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.535 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.1 m-20 -67.7 115.82 7.7 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.95 178.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.23 90.87 4.49 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.69 174.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.4 m -120.86 169.14 12.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.153 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 64.0 mtp180 -102.07 128.36 48.56 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.474 HG21 ' HA ' ' A' ' 66' ' ' VAL . 2.8 pp -127.02 150.29 32.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.204 -176.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.514 ' HE2' ' HA2' ' A' ' 14' ' ' GLY . 69.6 tttt -106.07 118.78 37.52 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 172.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.544 HG22 ' HB ' ' A' ' 11' ' ' VAL . 87.1 t -69.27 106.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 171.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 13.5 tp10 -84.87 -36.19 21.71 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.294 -170.178 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 56' ' ' ARG . 7.4 ptp85 -156.44 150.07 24.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.293 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.424 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.1 m -121.25 138.92 50.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.098 0.475 . . . . 0.0 110.925 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.7 mp -110.57 157.89 37.04 Favored Pre-proline 0 C--N 1.319 -0.76 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 174.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -58.89 -1.46 0.8 Allowed 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.162 2.575 . . . . 0.0 114.68 -176.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.4 -16.8 2.36 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -169.03 161.08 10.38 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.605 0.241 . . . . 0.0 110.838 -176.026 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -115.04 152.18 32.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.89 0.376 . . . . 0.0 111.515 -177.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.4 t80 -112.14 129.02 56.38 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.416 178.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -128.58 149.52 50.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.313 0.578 . . . . 0.0 111.889 -177.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.3 t -109.74 136.02 49.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.166 175.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.512 HG21 ' H ' ' A' ' 68' ' ' GLU . 6.9 p -82.47 123.23 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.333 0.587 . . . . 0.0 111.063 -176.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.5 m -107.45 28.43 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.512 ' H ' HG21 ' A' ' 66' ' ' VAL . 41.8 mt-10 . . . . . 0 C--O 1.251 1.152 0 CA-C-N 115.073 -0.967 . . . . 0.0 111.256 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo . . . . . 0 N--CA 1.465 -0.169 0 CA-C-O 121.21 0.421 . . . . 0.0 111.234 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.9 m -132.42 151.75 35.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.24 177.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.21 155.66 41.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.036 0.446 . . . . 0.0 110.95 -177.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -66.42 122.52 17.72 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.355 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.71 21.46 33.92 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.957 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -113.76 164.1 14.17 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.755 0.312 . . . . 0.0 110.369 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.67 ' HB ' ' HE3' ' A' ' 53' ' ' LYS . 14.9 p -129.92 131.85 66.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 120.92 0.39 . . . . 0.0 110.373 -176.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -135.96 154.66 51.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.389 -176.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -93.36 123.61 36.77 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 31.9 m -133.37 156.64 42.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.177 0.513 . . . . 0.0 111.709 -173.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.505 HG22 ' HG2' ' A' ' 49' ' ' GLU . 61.0 m -113.16 124.62 52.99 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.248 -0.887 . . . . 0.0 109.622 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.545 HG13 ' HB ' ' A' ' 44' ' ' THR . 48.7 mm -70.41 95.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -86.61 -33.91 20.02 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.315 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.428 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 20.3 t70 -126.73 163.73 22.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.537 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.484 HG13 ' HA2' ' A' ' 30' ' ' GLY . 7.5 tt -141.48 132.19 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 174.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.957 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.428 -175.949 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 . . . . . 0 C--O 1.235 0.318 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.484 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -68.29 133.83 28.59 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.156 -175.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.479 HG23 HG21 ' A' ' 38' ' ' VAL . 48.0 mm -106.68 109.97 29.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.325 0.584 . . . . 0.0 110.583 -178.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.476 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -101.4 149.77 23.72 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.381 175.124 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 1.2 ptm180 -138.37 113.79 9.57 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.98 0.419 . . . . 0.0 110.929 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.0 mt -104.48 105.75 19.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.991 176.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 51.57 27.67 4.09 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.686 -1.143 . . . . 0.0 112.131 -178.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 118.45 -31.81 5.45 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.756 -0.735 . . . . 0.0 113.025 177.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -75.51 125.42 28.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.843 0.354 . . . . 0.0 110.252 -177.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.479 HG21 HG23 ' A' ' 31' ' ' ILE . 7.0 p -88.75 135.38 25.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.287 0.565 . . . . 0.0 111.551 -176.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.534 HG12 ' HB1' ' A' ' 62' ' ' ALA . 42.7 mt -124.29 132.13 71.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.943 178.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -93.17 119.63 32.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.81 0.338 . . . . 0.0 110.576 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.39 100.09 45.06 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.963 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.48 127.36 17.95 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 123.226 2.618 . . . . 0.0 113.118 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.85 -9.13 55.04 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.83 173.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.545 ' HB ' HG13 ' A' ' 21' ' ' ILE . 25.8 p -89.12 156.13 19.01 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 117.355 0.578 . . . . 0.0 111.669 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -111.4 157.61 20.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.764 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 88.1 t -58.99 124.12 12.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.281 177.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 108.44 -13.1 36.31 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.512 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -68.84 117.32 10.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.119 0.485 . . . . 0.0 110.966 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.505 ' HG2' HG22 ' A' ' 20' ' ' THR . 44.3 mt-10 -106.64 97.03 6.87 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.636 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.86 173.74 14.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.063 -173.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.9 mtp85 -103.23 126.49 50.43 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.75 177.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.1 pt -116.17 143.35 26.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.326 -175.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.67 ' HE3' ' HB ' ' A' ' 16' ' ' VAL . 0.9 OUTLIER -97.87 102.84 14.7 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.122 175.824 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.475 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 55.9 t -69.35 108.45 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.56 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.22 -26.41 17.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.738 -173.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 37.8 ttt180 -154.92 144.91 21.72 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.823 0.344 . . . . 0.0 110.731 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 35.7 m -110.19 141.7 24.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.122 175.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.538 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 3.1 mm? -115.59 160.45 34.68 Favored Pre-proline 0 C--N 1.32 -0.687 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.538 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 9.8 Cg_endo -52.69 -28.41 37.5 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.122 2.548 . . . . 0.0 114.177 -175.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -121.79 -2.96 9.24 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -175.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -169.58 162.62 10.01 Favored 'General case' 0 C--O 1.222 -0.382 0 CA-C-N 117.76 0.254 . . . . 0.0 110.941 -175.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB1' HG12 ' A' ' 39' ' ' ILE . . . -113.87 157.47 22.31 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.685 0.279 . . . . 0.0 110.569 177.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -123.2 129.0 50.8 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -146.69 158.5 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.353 . . . . 0.0 111.677 -176.018 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.2 p -115.73 160.08 20.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.551 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 41.4 t -81.62 123.98 38.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.329 -176.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.45 33.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.15 0.5 . . . . 0.0 110.539 179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 . . . . . 0 C--O 1.25 1.116 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.419 177.698 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo . . . . . 0 N--CA 1.463 -0.29 0 CA-C-O 120.554 0.148 . . . . 0.0 112.338 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.464 HG12 HD11 ' A' ' 39' ' ' ILE . 30.3 m -136.63 156.25 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.786 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.548 ' CG ' ' HG3' ' A' ' 15' ' ' GLU . 10.8 pt-20 -133.24 160.45 37.25 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.42 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.432 ' CG ' HG23 ' A' ' 57' ' ' VAL . 39.3 mt-10 -66.83 132.87 48.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.13 0.49 . . . . 0.0 112.15 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.475 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 77.75 36.14 33.82 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.205 -0.907 . . . . 0.0 112.997 174.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.586 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 19.6 mm-40 -125.03 164.62 19.78 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-O 120.791 0.329 . . . . 0.0 111.011 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 55.0 t -121.81 122.99 68.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.719 -174.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 41.9 m-85 -125.89 145.87 50.07 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.86 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -90.92 95.75 10.28 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.517 0.675 . . . . 0.0 109.244 171.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 49' ' ' GLU . 28.5 m -104.76 161.29 4.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.514 -171.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.8 m -110.58 119.57 39.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.041 175.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.464 HG13 ' HB ' ' A' ' 44' ' ' THR . 47.7 mm -69.7 106.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 175.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.804 ' HA ' HE21 ' A' ' 22' ' ' GLN . 0.0 OUTLIER -97.84 -22.13 16.54 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.286 -173.634 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 29.3 t70 -142.88 164.28 30.53 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.895 -0.322 . . . . 0.0 111.263 -174.131 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.416 HG12 HG21 ' A' ' 46' ' ' VAL . 48.5 mm -124.49 131.94 72.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.44 ' HB3' HD13 ' A' ' 31' ' ' ILE . . . . . . . . 0 C--N 1.319 -0.752 0 CA-C-O 121.382 0.611 . . . . 0.0 111.548 -174.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 47.7 m-20 . . . . . 0 CA--C 1.517 -0.307 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.601 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -79.13 137.74 19.64 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.791 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.549 HG21 ' HD3' ' A' ' 33' ' ' ARG . 48.3 mm -108.57 114.26 46.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.271 0.558 . . . . 0.0 110.778 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.46 ' HB2' HD11 ' A' ' 21' ' ' ILE . . . -109.54 112.4 24.47 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.805 176.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.657 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 0.6 OUTLIER -97.78 115.02 27.19 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.519 178.448 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 31.8 mt -93.81 107.96 19.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 172.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 55.42 21.92 4.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.701 -1.136 . . . . 0.0 111.921 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.64 -26.69 8.35 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.773 -0.727 . . . . 0.0 113.244 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.657 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 53.5 t80 -69.6 128.04 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.965 0.382 . . . . 0.0 110.715 -176.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.491 HG13 HG23 ' A' ' 31' ' ' ILE . 60.8 t -85.62 116.04 28.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.737 -174.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.464 HD11 HG12 ' A' ' 11' ' ' VAL . 54.0 mt -111.41 133.13 58.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.914 174.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -94.05 122.94 37.08 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.013 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.417 HG21 ' HB1' ' A' ' 64' ' ' ALA . 43.9 t -127.67 91.52 45.28 Favored Pre-proline 0 C--N 1.326 -0.434 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 38.4 Cg_exo -60.22 121.27 9.52 Favored 'Trans proline' 0 CA--C 1.528 0.192 0 C-N-CA 122.873 2.382 . . . . 0.0 113.033 -175.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.63 60.8 1.33 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.073 175.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.601 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 1.3 p -143.35 175.22 10.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 117.006 0.403 . . . . 0.0 110.72 176.701 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -129.86 150.09 51.31 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -178.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.416 HG21 HG12 ' A' ' 24' ' ' ILE . 67.4 t -58.82 116.62 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.881 0.372 . . . . 0.0 110.85 177.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.85 -9.27 14.32 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.227 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -71.98 105.4 3.86 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.821 0.343 . . . . 0.0 111.556 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 47.1 mt-10 -88.45 97.7 11.22 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 168.417 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.594 ' HA ' ' HG3' ' A' ' 68' ' ' GLU . 16.3 m -128.2 151.98 35.71 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.922 -0.581 . . . . 0.0 112.031 -172.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.412 ' H ' ' CG ' ' A' ' 68' ' ' GLU . 25.1 mmt180 -79.64 128.93 34.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.852 172.286 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 2.7 pp -134.57 147.16 29.94 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.706 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.586 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 47.6 tttp -102.66 111.74 24.19 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 173.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.2 t -67.75 112.91 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 175.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -92.06 -33.19 14.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.912 -169.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -156.45 130.12 8.31 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.997 -172.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.432 HG23 ' CG ' ' A' ' 13' ' ' GLU . 34.3 m -114.42 139.45 40.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.323 0.582 . . . . 0.0 111.198 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 96.9 mt -123.64 153.67 66.49 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 173.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.47 -16.6 14.47 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.722 2.282 . . . . 0.0 113.46 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 55.9 tptt -100.92 -34.7 9.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.553 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -170.18 173.52 5.8 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.453 -0.202 . . . . 0.0 110.453 -174.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -133.42 159.64 39.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.889 0.376 . . . . 0.0 111.633 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 39.1 m-85 -108.59 152.44 24.77 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.421 ' HB3' ' HB ' ' A' ' 52' ' ' ILE . . . -142.45 142.45 32.33 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.162 0.506 . . . . 0.0 111.742 177.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 42.2 m -94.34 139.3 31.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.477 174.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.6 t -81.64 118.25 29.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.653 0.263 . . . . 0.0 110.651 -178.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.8 m -118.17 20.16 6.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.172 0.511 . . . . 0.0 110.679 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.594 ' HG3' ' HA ' ' A' ' 50' ' ' VAL . 1.1 tm-20 . . . . . 0 C--O 1.244 0.783 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.212 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.418 ' HB2' HG23 ' A' ' 34' ' ' ILE . 73.0 Cg_endo . . . . . 0 C--O 1.234 0.315 0 N-CA-C 113.037 0.36 . . . . 0.0 113.037 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.449 ' HB ' HG23 ' A' ' 54' ' ' VAL . 19.4 m -131.33 143.7 39.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.745 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -121.58 148.9 43.92 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.681 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.475 ' CG ' HG23 ' A' ' 57' ' ' VAL . 44.1 mt-10 -66.31 129.46 39.89 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.315 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.65 27.17 30.3 Favored Glycine 0 N--CA 1.445 -0.767 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.917 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 72.0 mm-40 -124.05 156.44 36.54 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.256 0.55 . . . . 0.0 111.894 -177.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 57.0 t -113.83 130.65 67.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.149 -175.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -132.04 150.82 52.05 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.246 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.85 109.52 21.5 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.86 144.63 36.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.424 0.63 . . . . 0.0 112.15 -174.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.0 m -96.14 139.64 32.01 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 169.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.586 HG13 ' HB ' ' A' ' 44' ' ' THR . 45.8 mm -81.1 124.86 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.591 0.234 . . . . 0.0 110.972 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.443 ' OE1' ' HG2' ' A' ' 33' ' ' ARG . 2.3 mp0 -75.47 -56.33 4.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.979 -177.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -140.28 -179.41 5.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.15 -177.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.408 HD12 ' HA ' ' A' ' 45' ' ' LYS . 38.0 mm -123.7 127.45 73.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.315 -0.914 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.724 179.074 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 . . . . . 0 CA--C 1.517 -0.322 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.504 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -91.86 144.92 17.43 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.796 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 70.2 mt -100.87 109.84 26.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.952 0.406 . . . . 0.0 110.406 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -111.58 163.43 14.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.447 175.298 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.443 ' HG2' ' OE1' ' A' ' 22' ' ' GLN . 31.5 ptt180 -144.68 132.88 21.66 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.704 0.288 . . . . 0.0 110.822 -178.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.418 HG23 ' HB2' ' A' ' 10' ' ' PRO . 49.6 mt -129.06 117.82 44.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.29 26.82 14.41 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.953 0.882 . . . . 0.0 109.923 -175.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.36 -15.0 63.25 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.639 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.561 ' CE2' ' HB2' ' A' ' 62' ' ' ALA . 14.7 t80 -75.31 119.93 20.08 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.3 t -78.04 128.93 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.234 0.54 . . . . 0.0 111.382 -173.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.508 HG12 ' HB1' ' A' ' 62' ' ' ALA . 24.6 mt -120.11 129.72 75.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.797 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -101.54 125.24 48.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.857 0.36 . . . . 0.0 110.803 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.0 t -122.94 108.33 32.69 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.359 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.12 126.84 21.3 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 123.213 2.608 . . . . 0.0 113.184 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 64.39 2.25 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.066 -0.587 . . . . 0.0 113.384 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.586 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.4 p -134.88 -172.24 2.99 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 176.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 48' ' ' ASP . 36.7 ttpt -142.69 153.91 43.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.418 0.151 . . . . 0.0 110.871 -175.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.03 120.6 5.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.74 0.305 . . . . 0.0 111.113 179.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.7 4.35 90.27 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.602 177.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.442 ' HB2' ' HB3' ' A' ' 45' ' ' LYS . 40.3 t0 -75.87 122.67 24.47 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.3 106.49 18.26 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.087 0.47 . . . . 0.0 110.02 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.68 146.82 33.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.379 0.609 . . . . 0.0 111.333 -175.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -97.97 117.57 32.62 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 176.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 44.5 pt -116.27 155.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.475 -170.55 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.508 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 34.9 ttmt -105.37 118.09 35.67 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.449 HG23 ' HB ' ' A' ' 11' ' ' VAL . 90.2 t -69.19 118.35 13.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 174.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -92.84 -45.79 7.83 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.348 1.03 . . . . 0.0 111.217 -175.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 33.2 mtt180 -135.93 144.0 45.23 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.378 -172.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.475 HG23 ' CG ' ' A' ' 13' ' ' GLU . 27.6 m -124.7 116.05 46.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.698 0.761 . . . . 0.0 110.497 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.464 ' C ' ' H ' ' A' ' 60' ' ' LYS . 5.8 mp -112.94 152.22 44.72 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.619 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.13 11.0 0.28 Allowed 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 122.745 2.297 . . . . 0.0 112.481 177.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.464 ' H ' ' C ' ' A' ' 58' ' ' LEU . 56.9 mttm -118.51 -31.78 4.8 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.612 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -177.84 170.25 1.94 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.923 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.561 ' HB2' ' CE2' ' A' ' 37' ' ' PHE . . . -108.75 146.96 32.73 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.808 0.337 . . . . 0.0 110.533 176.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 53.4 t80 -122.0 123.68 42.21 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -134.85 152.02 51.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.873 -176.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 20.9 t -113.48 146.6 39.33 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.497 HG21 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -81.65 117.52 27.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.361 0.601 . . . . 0.0 111.126 -176.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.9 p -96.52 8.85 6.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.938 0.875 . . . . 0.0 108.993 178.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.497 ' H ' HG21 ' A' ' 66' ' ' VAL . 25.7 tt0 . . . . . 0 C--O 1.251 1.146 0 CA-C-N 113.334 -1.757 . . . . 0.0 111.268 177.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo . . . . . 0 C--O 1.231 0.149 0 CA-C-O 120.905 0.294 . . . . 0.0 112.177 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.5 162.06 37.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.48 -178.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.506 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.0 pt-20 -130.96 156.41 45.15 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.429 178.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 56.1 mt-10 -66.46 133.61 50.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.355 -174.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.91 31.08 33.27 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.688 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.506 ' HG3' ' HG3' ' A' ' 12' ' ' GLU . 58.8 mm-40 -127.17 155.86 42.72 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.556 -0.457 . . . . 0.0 110.912 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 7.1 p -118.66 128.23 75.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.09 -174.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.8 m-85 -125.95 132.43 52.08 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.793 -178.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.487 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 30.2 t70 -81.61 97.0 7.66 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 175.473 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.9 m -111.99 170.45 3.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.392 0.615 . . . . 0.0 111.663 -170.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 49' ' ' GLU . 26.0 m -120.51 128.73 53.39 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.111 171.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.573 HG13 ' HB ' ' A' ' 44' ' ' THR . 49.9 mm -68.48 116.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.168 0.508 . . . . 0.0 110.707 -175.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm-40 -84.29 -40.55 17.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.608 -173.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -143.33 179.55 7.02 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -177.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.529 HD13 ' HA2' ' A' ' 30' ' ' GLY . 32.0 mm -137.06 119.21 19.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.317 -0.838 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.943 178.172 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.831 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 6.6 m-20 . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.532 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -72.27 127.75 12.85 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.512 178.572 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.513 HG22 HG13 ' A' ' 38' ' ' VAL . 73.5 mt -95.52 106.49 18.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.339 0.59 . . . . 0.0 111.385 -176.047 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -96.69 94.65 7.43 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 170.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 9.9 ptm180 -93.91 98.46 11.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.57 0.7 . . . . 0.0 110.968 -174.465 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 45.1 mt -93.17 111.33 24.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.487 -179.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 56.64 26.33 11.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.941 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.53 -20.47 39.47 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.457 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.443 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 50.7 t80 -75.59 123.44 25.51 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.513 HG13 HG22 ' A' ' 31' ' ' ILE . 64.7 t -90.0 116.37 31.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.897 -173.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.425 HG12 ' HB2' ' A' ' 62' ' ' ALA . 55.4 mt -109.24 125.66 66.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.648 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -94.19 121.14 35.38 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.969 0.414 . . . . 0.0 111.359 -178.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.5 HG21 ' HB3' ' A' ' 64' ' ' ALA . 11.0 t -129.53 89.59 46.58 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.126 175.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . 0.831 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 32.8 Cg_endo -63.94 137.43 57.69 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.968 2.445 . . . . 0.0 113.239 -175.326 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.38 -10.15 30.87 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.032 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.573 ' HB ' HG13 ' A' ' 21' ' ' ILE . 35.3 p -95.59 -179.62 4.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.522 0.201 . . . . 0.0 110.962 -178.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HA ' HD12 ' A' ' 24' ' ' ILE . 34.3 ttmt -142.9 165.29 27.76 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 44.0 t -58.34 118.7 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 CA-C-O 120.664 0.268 . . . . 0.0 111.097 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.94 -5.74 59.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.761 178.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.423 ' O ' HG12 ' A' ' 21' ' ' ILE . 29.6 t0 -75.11 112.47 11.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 110.055 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.427 ' HA ' ' HA ' ' A' ' 20' ' ' THR . 8.4 pt-20 -100.29 108.09 20.06 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.743 -178.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.0 m -142.15 161.87 19.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.807 -176.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.487 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 66.0 mtm180 -82.95 124.23 30.18 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.796 174.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.6 pt -117.96 136.92 53.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.137 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.464 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 56.3 tttm -100.4 114.6 28.27 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.7 t -69.29 121.19 18.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -94.44 -45.73 7.31 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.209 0.943 . . . . 0.0 110.872 -174.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.8 tpm_? -140.68 137.91 33.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.143 -172.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 34.4 m -114.78 136.31 51.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.295 0.569 . . . . 0.0 110.858 176.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 5.6 mp -123.02 156.19 62.98 Favored Pre-proline 0 C--N 1.321 -0.652 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -58.47 -16.67 30.48 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.848 2.365 . . . . 0.0 113.518 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.2 ttmm -110.35 -22.52 11.67 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -176.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -172.47 172.14 4.44 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.682 0.277 . . . . 0.0 111.0 -174.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.425 ' HB2' HG12 ' A' ' 39' ' ' ILE . . . -128.13 157.47 40.69 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.688 0.28 . . . . 0.0 110.984 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -124.61 136.4 53.91 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.5 ' HB3' HG21 ' A' ' 41' ' ' VAL . . . -136.83 163.2 31.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.956 0.407 . . . . 0.0 111.423 -176.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.1 p -117.27 145.0 44.24 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.854 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 40.6 t -78.39 127.19 38.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.131 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.0 m -123.49 13.88 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.743 0.306 . . . . 0.0 110.465 176.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 . . . . . 0 C--O 1.25 1.119 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.504 -179.634 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 CA--C 1.531 0.368 0 N-CA-C 113.343 0.478 . . . . 0.0 113.343 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.79 130.7 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.706 0.289 . . . . 0.0 110.474 179.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -113.09 173.7 6.26 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.541 0.686 . . . . 0.0 111.773 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.503 ' OE1' ' HD3' ' A' ' 56' ' ' ARG . 33.5 mt-10 -67.28 126.63 29.84 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.806 -1.088 . . . . 0.0 112.152 -177.082 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.542 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 91.68 16.35 52.31 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.389 -0.823 . . . . 0.0 112.929 174.039 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.567 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 26.2 mt-10 -99.04 160.42 14.27 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.344 -0.542 . . . . 0.0 111.187 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.51 124.34 68.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.208 -179.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -128.54 141.05 51.49 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.858 -177.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -80.51 97.29 7.08 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.4 m -109.66 148.9 13.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.353 0.597 . . . . 0.0 111.764 -173.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.0 m -110.1 119.09 38.18 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.912 172.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.622 HG13 ' HB ' ' A' ' 44' ' ' THR . 41.3 mm -69.64 116.77 11.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.746 -175.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -87.17 -51.03 6.22 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.863 -174.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.408 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 15.2 m-20 -124.31 -179.26 4.38 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.892 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.545 HD12 ' HA2' ' A' ' 30' ' ' GLY . 39.6 mm -137.82 137.8 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.342 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.476 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . . . . . . 0 C--N 1.312 -1.038 0 CA-C-O 121.912 0.863 . . . . 0.0 109.201 177.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.476 ' HB2' ' HB3' ' A' ' 25' ' ' ALA . 5.1 m-20 . . . . . 0 CA--C 1.519 -0.229 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.545 ' HA2' HD12 ' A' ' 24' ' ' ILE . . . -80.21 144.07 25.59 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.294 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.419 HG22 HG11 ' A' ' 38' ' ' VAL . 50.2 mm -105.5 102.69 14.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.105 0.479 . . . . 0.0 110.166 179.607 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -98.18 147.51 24.52 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 174.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.463 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 8.9 ptp85 -138.95 109.43 6.55 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.297 0.57 . . . . 0.0 111.049 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.424 ' C ' ' H ' ' A' ' 36' ' ' GLY . 42.7 mt -101.65 118.32 48.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 173.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 67.78 -3.1 1.22 Allowed 'General case' 0 CA--C 1.535 0.371 0 O-C-N 124.186 0.929 . . . . 0.0 110.519 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 34' ' ' ILE . . . 117.86 -14.49 12.73 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.209 -176.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 34.8 t80 -74.87 127.76 33.96 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.419 HG11 HG22 ' A' ' 31' ' ' ILE . 46.9 t -81.04 130.49 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.715 -173.721 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.518 HG12 ' HB3' ' A' ' 62' ' ' ALA . 50.7 mt -123.12 125.28 71.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.594 176.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.67 133.54 34.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.624 0.249 . . . . 0.0 110.768 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.7 t -132.13 104.23 13.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.247 -179.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -69.5 104.21 1.24 Allowed 'Trans proline' 0 C--O 1.233 0.262 0 C-N-CA 122.947 2.432 . . . . 0.0 112.849 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.95 48.17 0.74 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.979 175.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' THR . . . . . 0.622 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.8 p -138.08 170.96 15.13 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.752 -0.264 . . . . 0.0 111.29 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.64 ' HE3' ' HA ' ' A' ' 45' ' ' LYS . 0.2 OUTLIER -132.97 166.84 21.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.087 -177.044 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 43.8 t -65.47 116.42 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 178.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 95.62 1.76 61.87 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.407 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -75.12 123.66 25.64 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -103.19 108.57 19.83 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.385 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.5 m -138.18 161.58 31.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.366 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -96.34 123.67 40.06 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.267 172.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.455 HG23 ' HA ' ' A' ' 66' ' ' VAL . 46.9 pt -117.46 143.37 28.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.625 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . 0.567 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 49.1 tttp -98.82 109.8 22.51 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 173.073 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.5 t -68.92 107.48 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 176.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -88.71 -40.84 12.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.653 0.596 . . . . 0.0 111.21 -172.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.503 ' HD3' ' OE1' ' A' ' 13' ' ' GLU . 19.6 mmt180 -139.71 129.59 24.78 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.004 -175.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.1 m -97.1 117.96 42.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 172.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.483 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 80.1 mt -101.37 162.08 21.61 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.922 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PRO . . . . . 0.483 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 91.1 Cg_exo -43.89 -38.49 10.03 Favored 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 123.57 2.847 . . . . 0.0 114.666 -175.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 17.6 tptp -120.29 -3.72 9.98 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -172.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.404 ' CE1' HD12 ' A' ' 58' ' ' LEU . 54.2 p90 -170.74 167.8 7.59 Favored 'General case' 0 C--O 1.222 -0.361 0 CA-C-O 120.613 0.244 . . . . 0.0 110.909 -177.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.518 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -108.47 147.35 31.8 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.031 0.443 . . . . 0.0 111.05 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -112.52 126.62 55.53 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.187 176.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -130.26 156.11 45.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.122 0.487 . . . . 0.0 111.468 -176.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 6.6 t -105.73 130.46 53.73 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.733 178.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.455 ' HA ' HG23 ' A' ' 52' ' ' ILE . 6.3 p -79.95 122.99 36.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.135 0.493 . . . . 0.0 111.067 -177.713 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 6.2 t -105.11 0.48 10.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.698 0.761 . . . . 0.0 109.639 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 . . . . . 0 C--O 1.247 0.952 0 CA-C-N 114.259 -1.337 . . . . 0.0 110.819 -175.234 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.481 1.079 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -82.19 -18.96 40.83 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 175.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -97.62 132.66 43.07 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.728 176.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -64.34 144.08 57.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.226 177.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -80.82 124.1 28.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.9 p -74.06 -9.65 58.84 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.993 0.425 . . . . 0.0 110.489 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.456 ' HD2' ' HA ' ' A' ' 7' ' ' ARG . 0.8 OUTLIER 64.55 23.76 12.93 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 115.47 -0.787 . . . . 0.0 111.559 -178.416 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.8 m -68.12 94.68 0.52 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.991 -0.549 . . . . 0.0 109.689 175.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 15.3 m -111.07 157.23 39.36 Favored Pre-proline 0 N--CA 1.448 -0.546 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.915 -176.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -67.07 -42.86 7.32 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.792 2.328 . . . . 0.0 112.78 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.5 m -126.29 146.62 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.225 0.536 . . . . 0.0 112.268 -172.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -121.07 171.51 8.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 174.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.559 ' HG2' ' HA ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -66.54 125.12 24.74 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.239 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 23.06 17.37 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 116.203 -0.453 . . . . 0.0 113.633 173.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.438 ' O ' ' HD2' ' A' ' 53' ' ' LYS . 45.0 mt-10 -105.28 171.65 7.21 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.278 0.539 . . . . 0.0 110.924 -177.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 7.1 p -141.97 129.28 20.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.857 0.361 . . . . 0.0 110.59 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 87.8 m-85 -134.84 142.47 46.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.388 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -82.03 94.3 7.15 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.423 HG23 HD13 ' A' ' 52' ' ' ILE . 32.9 m -111.54 159.11 11.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.304 0.573 . . . . 0.0 111.477 -173.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 m -112.69 125.97 54.88 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.292 -0.867 . . . . 0.0 108.809 172.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.562 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.0 mm -69.59 100.55 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.047 0.451 . . . . 0.0 110.257 -179.356 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -81.51 -34.72 31.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.283 -175.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.512 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 31.2 t0 -138.57 170.36 16.15 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.264 -178.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.415 HG12 ' HA2' ' A' ' 30' ' ' GLY . 27.8 mt -145.37 131.68 14.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.63 144.23 29.57 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.407 ' O ' ' HB2' ' A' ' 27' ' ' GLN . 48.8 mtm180 -64.62 92.94 0.1 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.361 0.6 . . . . 0.0 112.086 -173.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.407 ' HB2' ' O ' ' A' ' 26' ' ' ARG . 8.0 tp-100 166.27 -27.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 114.202 -1.363 . . . . 0.0 108.44 -177.184 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 120.29 7.38 9.21 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.351 -0.84 . . . . 0.0 112.402 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.594 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 5.5 m-20 -83.27 114.67 21.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.664 0.268 . . . . 0.0 110.309 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.415 ' HA2' HG12 ' A' ' 24' ' ' ILE . . . -71.73 126.42 12.39 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.632 177.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.545 HG22 HG13 ' A' ' 38' ' ' VAL . 75.5 mt -94.42 107.19 19.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.192 0.52 . . . . 0.0 110.649 -178.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.412 ' HB1' ' HB ' ' A' ' 39' ' ' ILE . . . -99.81 96.32 7.5 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.157 -0.928 . . . . 0.0 109.183 173.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.413 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 14.6 ptm180 -93.26 93.54 8.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.433 -176.276 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 52.5 mt -89.11 109.88 20.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.259 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 57.56 12.89 1.68 Allowed 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.953 -1.022 . . . . 0.0 112.302 -176.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.37 -19.73 12.87 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.313 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.413 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 70.4 t80 -73.72 125.66 28.58 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.545 HG13 HG22 ' A' ' 31' ' ' ILE . 98.0 t -93.18 112.58 26.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.346 0.593 . . . . 0.0 111.652 -173.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.412 ' HB ' ' HB1' ' A' ' 32' ' ' ALA . 57.2 mt -103.21 126.78 57.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.474 173.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -95.17 121.8 37.19 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.011 0.434 . . . . 0.0 111.002 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.511 HG22 ' HB1' ' A' ' 64' ' ' ALA . 21.6 t -120.33 89.9 44.32 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.498 176.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . 0.594 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 17.3 Cg_exo -66.15 127.48 17.65 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.899 2.399 . . . . 0.0 112.536 -175.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.79 43.21 3.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.815 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.562 ' HB ' HG13 ' A' ' 21' ' ' ILE . 6.6 p -128.06 -171.7 2.51 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.588 0.232 . . . . 0.0 111.254 179.033 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -140.06 152.94 46.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.237 -176.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 38.9 t -63.01 118.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.74 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.24 1.85 64.42 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.382 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -76.18 119.43 20.08 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.774 0.321 . . . . 0.0 110.621 -178.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -98.67 108.11 20.72 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.577 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.3 m -139.79 160.25 27.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -174.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -86.14 110.36 19.51 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 44.8 pt -97.55 132.44 42.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.719 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.438 ' HD2' ' O ' ' A' ' 15' ' ' GLU . 51.0 tptt -92.95 104.86 17.05 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 174.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 99.5 t -69.29 97.24 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -65.36 -48.55 72.59 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.559 ' HA ' ' HG2' ' A' ' 13' ' ' GLU . 75.0 mtp180 -150.97 161.77 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.536 -177.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 27.7 m -128.98 135.64 61.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.106 0.479 . . . . 0.0 110.576 179.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -111.61 157.55 39.0 Favored Pre-proline 0 C--N 1.32 -0.682 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.28 -16.42 22.33 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.965 2.443 . . . . 0.0 113.805 -176.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.4 mmtm -117.32 -18.23 9.95 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -176.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -169.88 161.06 8.81 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.425 0.155 . . . . 0.0 110.66 -175.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -120.08 156.63 30.6 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.263 -178.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -114.43 134.2 55.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.346 176.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.511 ' HB1' HG22 ' A' ' 41' ' ' VAL . . . -145.75 154.9 42.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.699 178.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.3 t -128.47 157.14 41.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.041 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 99.1 t -84.25 119.64 33.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.823 -177.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.7 m -104.59 15.88 6.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.083 0.468 . . . . 0.0 110.813 178.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 . . . . . 0 C--O 1.247 0.948 0 CA-C-N 114.547 -1.206 . . . . 0.0 111.307 178.984 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.694 0.283 . . . . 0.0 110.758 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.01 -173.45 2.25 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 63.31 42.4 6.96 Favored 'General case' 0 C--O 1.236 0.356 0 O-C-N 123.615 0.572 . . . . 0.0 110.184 -177.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -60.34 134.21 56.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.555 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . 0.407 ' C ' ' HG ' ' A' ' 6' ' ' SER . 21.7 tt0 -56.77 118.02 4.49 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.31 -173.31 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.407 ' HG ' ' C ' ' A' ' 5' ' ' GLU . 88.4 p 57.81 13.07 1.9 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.504 1.122 . . . . 0.0 112.594 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 68.8 mtt-85 66.36 -57.68 0.37 Allowed 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.74 0.816 . . . . 0.0 112.635 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 40.6 m 70.82 14.05 7.05 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.624 0.77 . . . . 0.0 111.066 -175.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 3.3 m -148.38 100.02 3.6 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.284 178.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -83.7 -14.25 7.83 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.529 2.153 . . . . 0.0 112.82 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 m -113.33 151.22 15.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.806 -178.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 -92.31 148.74 21.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.499 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.454 ' CG ' HG21 ' A' ' 57' ' ' VAL . 37.5 mt-10 -68.42 109.56 3.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.243 0.544 . . . . 0.0 110.856 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.438 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 105.33 28.87 5.32 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.001 -178.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -87.04 160.03 18.75 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 175.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.513 HG21 ' HG3' ' A' ' 53' ' ' LYS . 46.5 t -139.02 115.48 10.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.673 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -151.25 142.92 23.69 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.404 178.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.573 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 3.7 p-10 -84.47 137.04 33.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.26 0.552 . . . . 0.0 110.446 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 18.2 m -134.63 160.55 41.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.026 -176.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.5 m -103.52 125.92 50.36 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 169.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.547 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.4 mm -67.41 114.38 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -95.75 -32.67 12.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.122 -170.296 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -140.62 165.9 26.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.639 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.693 HG22 ' H ' ' A' ' 26' ' ' ARG . 43.5 mm -129.79 133.75 64.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.509 ' HB2' HD13 ' A' ' 31' ' ' ILE . . . -80.88 11.43 3.96 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -175.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.693 ' H ' HG22 ' A' ' 24' ' ' ILE . 17.2 tpt180 57.88 85.63 0.09 Allowed 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.256 -179.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 171.56 -24.85 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.732 -1.122 . . . . 0.0 108.928 -169.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 118.34 -11.44 12.78 Favored Glycine 0 N--CA 1.451 -0.334 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.693 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.522 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 38.9 m-20 -99.01 143.25 29.5 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.692 0.282 . . . . 0.0 110.523 -179.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.524 ' HA2' HD11 ' A' ' 24' ' ' ILE . . . -89.97 150.64 21.13 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.813 -176.073 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.509 HD13 ' HB2' ' A' ' 25' ' ' ALA . 43.0 mm -111.0 117.3 54.69 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.161 0.505 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -119.28 102.94 9.06 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.369 -0.832 . . . . 0.0 108.815 172.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 25.0 ptt85 -107.07 114.84 29.16 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.98 0.419 . . . . 0.0 111.444 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.498 HG21 ' HG3' ' A' ' 35' ' ' GLU . 41.6 mt -99.36 119.51 47.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.996 177.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.498 ' HG3' HG21 ' A' ' 34' ' ' ILE . 32.9 mt-10 62.23 26.06 15.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.994 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.65 -19.82 53.1 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.197 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.419 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 58.8 t80 -72.06 108.84 5.48 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.47 HG13 HG23 ' A' ' 31' ' ' ILE . 59.3 t -76.14 124.18 33.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.106 0.479 . . . . 0.0 111.526 -175.32 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.52 HG12 ' HB2' ' A' ' 62' ' ' ALA . 63.7 mt -118.77 129.77 74.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.187 -0.46 . . . . 0.0 109.885 176.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -92.38 124.66 36.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.736 -177.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.406 ' HA ' ' HD2' ' A' ' 42' ' ' PRO . 38.8 t -111.13 109.15 57.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.819 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . 0.522 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 13.6 Cg_endo -57.24 119.62 6.99 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 122.953 2.435 . . . . 0.0 113.191 -175.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 63.58 74.13 0.47 Allowed Glycine 0 CA--C 1.519 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.862 175.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.547 ' HB ' HG13 ' A' ' 21' ' ' ILE . 1.2 p -143.33 161.52 38.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.802 0.334 . . . . 0.0 110.918 176.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 tptm -120.09 151.95 38.3 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.058 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.44 HG22 HG12 ' A' ' 24' ' ' ILE . 80.6 t -60.11 126.17 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 176.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 103.51 -5.07 47.8 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.893 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.81 107.83 4.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.915 0.388 . . . . 0.0 110.601 174.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -87.94 96.17 10.39 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 173.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.542 ' HB ' HG21 ' A' ' 66' ' ' VAL . 19.1 m -134.48 147.79 29.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -169.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.573 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 0.2 OUTLIER -79.38 120.15 23.41 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.595 174.76 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 2.7 pp -116.88 141.16 36.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.552 178.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.513 ' HG3' HG21 ' A' ' 16' ' ' VAL . 78.4 tttt -101.57 114.72 29.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 172.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.6 t -69.25 99.13 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 173.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -88.52 -37.53 15.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.085 -169.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -150.47 130.99 13.87 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -174.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.454 HG21 ' CG ' ' A' ' 13' ' ' GLU . 26.9 m -112.69 139.24 38.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.17 0.509 . . . . 0.0 111.662 -177.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -118.28 154.31 51.9 Favored Pre-proline 0 C--N 1.322 -0.627 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 170.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.03 -19.57 26.91 Favored 'Trans proline' 0 CA--C 1.533 0.45 0 C-N-CA 122.634 2.222 . . . . 0.0 113.654 -177.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -105.99 -26.32 11.71 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -168.71 163.75 12.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.426 0.155 . . . . 0.0 110.59 -172.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.52 ' HB2' HG12 ' A' ' 39' ' ' ILE . . . -129.88 159.39 36.76 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.117 0.484 . . . . 0.0 111.755 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -105.92 127.82 53.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.565 174.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -141.23 126.89 19.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 11.6 t -100.55 145.92 27.74 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.261 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.542 HG21 ' HB ' ' A' ' 50' ' ' VAL . 4.0 p -82.38 116.67 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.681 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 25.5 m -101.79 4.61 10.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.621 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.527 ' OXT' ' HB2' ' A' ' 51' ' ' ARG . 43.6 mt-10 . . . . . 0 C--O 1.247 0.922 0 CA-C-N 114.254 -1.339 . . . . 0.0 112.361 177.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.422 ' O ' ' HB2' ' A' ' 2' ' ' PHE . 24.9 ttt . . . . . 0 N--CA 1.479 0.989 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.647 ' HD1' ' HG2' ' A' ' 3' ' ' ARG . 22.6 t80 176.37 -77.84 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 175.212 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.647 ' HG2' ' HD1' ' A' ' 2' ' ' PHE . 32.9 ptt180 -175.12 22.92 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.58 174.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -95.37 122.59 38.25 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.805 -170.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 67.61 -170.47 0.19 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.464 -178.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.1 m 66.01 26.92 10.8 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.12 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.4 mtp85 -106.57 155.8 19.25 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.417 -178.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.4 m -82.39 33.86 0.41 Allowed 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -170.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 2.1 m -130.19 101.36 17.88 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-O 120.958 0.409 . . . . 0.0 110.579 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -71.74 -30.3 14.61 Favored 'Trans proline' 0 CA--C 1.53 0.29 0 C-N-CA 123.083 2.522 . . . . 0.0 113.535 -175.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.2 m -122.23 148.23 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.91 0.386 . . . . 0.0 111.459 -175.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.8 mm-40 -102.33 161.88 13.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.327 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.448 ' HG3' HG21 ' A' ' 57' ' ' VAL . 3.5 mp0 -65.98 119.64 11.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.266 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.3 18.7 27.89 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 116.029 -0.532 . . . . 0.0 113.153 173.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.471 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 33.0 mt-10 -92.61 166.59 12.42 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.036 -176.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.14 127.11 60.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.954 0.407 . . . . 0.0 110.216 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -129.98 140.81 50.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.764 -176.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -79.97 90.38 5.36 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 171.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.3 m -104.73 148.77 8.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.395 0.616 . . . . 0.0 111.72 -172.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.544 HG22 ' HG2' ' A' ' 49' ' ' GLU . 24.6 m -101.72 124.91 48.15 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.318 173.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.526 HG13 ' HB ' ' A' ' 44' ' ' THR . 43.6 mm -70.33 89.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.3 mt-30 -81.93 -33.1 30.51 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.859 -175.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -128.84 170.67 13.09 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.655 179.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.45 ' HB ' ' CG2' ' A' ' 46' ' ' VAL . 8.4 tt -147.73 150.46 14.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.602 ' HB1' ' OE1' ' A' ' 27' ' ' GLN . . . -97.25 175.13 6.39 Favored 'General case' 0 C--N 1.314 -0.936 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.557 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 29.2 mtm180 -71.18 -22.13 62.07 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -171.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.602 ' OE1' ' HB1' ' A' ' 25' ' ' ALA . 0.1 OUTLIER -80.6 -17.28 51.84 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.297 -0.561 . . . . 0.0 110.048 177.536 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.91 19.83 11.39 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.919 -0.582 . . . . 0.0 113.342 174.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.6 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 56.7 m-20 -99.75 144.86 28.33 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 175.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.53 ' HA3' ' HG1' ' A' ' 44' ' ' THR . . . -74.21 141.37 28.89 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.901 -0.591 . . . . 0.0 113.003 -171.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.526 HG22 HG13 ' A' ' 38' ' ' VAL . 47.9 mm -107.73 104.52 17.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.137 0.494 . . . . 0.0 110.154 178.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -97.53 97.02 8.71 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.636 175.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 29.7 ptt85 -96.05 94.51 7.6 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.289 0.566 . . . . 0.0 111.394 -175.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 55.1 mt -86.51 113.47 24.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.99 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.2 mm-40 54.98 24.34 5.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.729 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.52 -17.99 51.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -75.95 121.74 23.15 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.526 HG13 HG22 ' A' ' 31' ' ' ILE . 57.9 t -83.35 121.66 36.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.197 0.523 . . . . 0.0 112.079 -173.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.548 HG12 ' HB2' ' A' ' 62' ' ' ALA . 48.2 mt -116.61 126.92 74.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.548 174.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -91.22 125.22 35.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.825 0.345 . . . . 0.0 111.136 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.4 t -119.45 111.79 36.19 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.669 176.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . 0.6 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 45.8 Cg_endo -68.65 114.72 3.61 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 122.631 2.22 . . . . 0.0 113.659 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.53 0.35 58.0 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.805 -0.712 . . . . 0.0 114.738 170.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.53 ' HG1' ' HA3' ' A' ' 30' ' ' GLY . 16.7 p -89.12 138.41 31.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 118.09 0.945 . . . . 0.0 111.936 -177.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.4 ' HG2' ' N ' ' A' ' 46' ' ' VAL . 2.5 tmtp? -92.28 155.5 17.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.967 -179.171 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.45 ' CG2' ' HB ' ' A' ' 24' ' ' ILE . 96.9 t -64.4 128.56 27.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-O 121.069 0.461 . . . . 0.0 110.962 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.66 -17.72 42.11 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.214 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.09 115.08 9.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.952 0.406 . . . . 0.0 110.446 178.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.544 ' HG2' HG22 ' A' ' 20' ' ' THR . 37.2 mt-10 -97.6 97.83 9.38 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.315 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.9 167.29 23.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.799 -173.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 60.3 mtt180 -100.25 120.81 40.48 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.13 0.491 . . . . 0.0 109.885 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.7 pt -113.25 144.6 20.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.394 -178.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 46.0 tttp -99.21 108.71 21.36 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.8 t -68.94 98.4 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -86.38 -35.3 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.478 -171.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -141.56 139.5 33.2 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.802 -174.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.448 HG21 ' HG3' ' A' ' 13' ' ' GLU . 15.4 m -123.23 115.51 45.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.4 0.619 . . . . 0.0 110.54 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.4 ' N ' HD22 ' A' ' 58' ' ' LEU . 3.1 mm? -97.65 155.05 37.65 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.234 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.63 -6.96 8.05 Favored 'Trans proline' 0 CA--C 1.531 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 113.304 -178.054 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.788 ' HZ2' ' HB2' ' A' ' 60' ' ' LYS . 5.0 ttmp? -111.25 -30.72 7.33 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.056 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -170.86 167.48 7.48 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.365 -175.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.548 ' HB2' HG12 ' A' ' 39' ' ' ILE . . . -110.28 156.21 21.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.913 0.387 . . . . 0.0 110.946 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -123.87 136.43 54.36 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 178.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.99 148.61 43.7 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.064 0.459 . . . . 0.0 111.461 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 p -105.82 130.17 53.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.745 174.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.692 HG21 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -77.06 130.51 36.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.056 0.455 . . . . 0.0 110.764 -176.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.5 m -108.24 22.25 4.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.099 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.692 ' H ' HG21 ' A' ' 66' ' ' VAL . 26.5 mm-40 . . . . . 0 C--O 1.246 0.909 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.543 -177.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.0 mmt . . . . . 0 N--CA 1.481 1.077 0 CA-C-O 120.637 0.255 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -86.75 163.27 17.39 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 178.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 7.7 mtt180 66.66 -165.87 0.22 Allowed 'General case' 0 C--O 1.233 0.222 0 O-C-N 123.4 0.437 . . . . 0.0 110.15 -176.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -78.83 82.41 5.04 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.447 0.641 . . . . 0.0 111.052 -178.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 55.3 mt-10 63.62 16.45 9.68 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 114.67 -1.15 . . . . 0.0 111.652 177.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.5 m 59.77 14.37 4.09 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.253 -0.885 . . . . 0.0 112.205 178.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.6 mtp180 62.6 -76.97 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.1 t 66.51 -161.31 0.25 Allowed 'General case' 0 C--O 1.235 0.309 0 CA-C-N 114.978 -1.01 . . . . 0.0 108.494 -164.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 17.1 m 35.33 70.65 0.94 Allowed Pre-proline 0 N--CA 1.473 0.679 0 C-N-CA 123.917 0.887 . . . . 0.0 113.028 -178.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -90.16 -7.74 4.26 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.506 2.138 . . . . 0.0 113.316 -177.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.1 m -116.67 156.38 17.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.667 0.27 . . . . 0.0 111.001 -175.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -129.1 157.69 41.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.231 -0.441 . . . . 0.0 109.933 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.401 ' HB3' ' HA ' ' A' ' 56' ' ' ARG . 8.8 pt-20 -67.03 127.67 33.47 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.135 0.493 . . . . 0.0 110.978 176.206 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.68 29.45 7.35 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.988 -178.042 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -115.04 170.43 8.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.47 125.35 16.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.182 0.515 . . . . 0.0 110.48 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -136.15 151.51 49.84 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.432 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -91.86 126.52 36.97 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 170.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.9 m -140.48 153.79 21.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.003 0.43 . . . . 0.0 111.552 -174.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -106.75 121.82 45.14 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 171.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.539 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.3 mm -68.95 116.02 8.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 120.886 0.374 . . . . 0.0 110.566 -177.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.86 -54.53 5.52 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.227 -175.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.509 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 47.0 t0 -128.4 176.27 7.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.957 -176.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.512 HD12 ' HA2' ' A' ' 30' ' ' GLY . 43.6 mm -134.36 139.05 48.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.028 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.45 26.87 0.53 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -175.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 52.4 mtm180 60.85 35.45 19.35 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 175.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -158.6 -36.06 0.07 Allowed 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.436 0.636 . . . . 0.0 109.652 -177.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 150.06 -29.43 1.11 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.243 -0.979 . . . . 0.0 112.381 178.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.652 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 1.8 m-20 -64.13 118.11 8.09 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 176.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.512 ' HA2' HD12 ' A' ' 24' ' ' ILE . . . -78.75 146.48 29.85 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.25 179.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.509 ' HB ' ' HB3' ' A' ' 23' ' ' ASP . 50.9 mm -104.52 99.7 8.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.993 0.425 . . . . 0.0 110.457 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -127.22 110.74 13.19 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.591 175.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.551 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 23.7 ptt180 -108.64 139.49 43.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.216 0.531 . . . . 0.0 111.295 -176.452 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 61.6 mt -122.03 119.04 57.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.714 175.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.6 mm-40 58.24 32.54 22.17 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.822 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.14 -31.72 7.4 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.739 179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -76.14 110.16 10.4 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.93 0.395 . . . . 0.0 110.058 -177.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 33' ' ' ARG . 7.2 p -84.7 134.64 26.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.182 0.515 . . . . 0.0 111.753 -174.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.514 HG12 ' HB3' ' A' ' 62' ' ' ALA . 51.5 mt -107.99 126.43 64.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.754 176.331 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -92.95 122.35 35.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.524 178.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.524 HG22 HG23 ' A' ' 52' ' ' ILE . 28.2 t -124.41 95.27 43.52 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.176 -0.466 . . . . 0.0 109.808 178.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 43.3 Cg_endo -68.15 122.19 9.24 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.851 2.367 . . . . 0.0 112.989 -177.279 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.21 27.9 4.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.34 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.539 ' HB ' HG13 ' A' ' 21' ' ' ILE . 17.3 p -118.99 164.34 15.62 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.991 0.424 . . . . 0.0 111.197 -179.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.512 ' O ' ' HB2' ' A' ' 48' ' ' ASP . 17.7 tptp -116.21 164.03 15.1 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.785 177.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 61.9 t -65.08 120.5 12.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 177.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.91 62.13 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.01 -178.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.512 ' HB2' ' O ' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -69.25 107.92 3.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.754 0.311 . . . . 0.0 110.604 176.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -92.56 100.45 12.98 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 175.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.4 m -135.89 160.07 39.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.256 0.551 . . . . 0.0 112.131 -172.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -91.66 119.48 31.58 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.524 172.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.524 HG23 HG22 ' A' ' 41' ' ' VAL . 47.6 pt -108.74 139.53 30.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.296 0.569 . . . . 0.0 111.566 -175.492 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 50.3 tptt -99.26 106.04 18.13 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.435 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 58.1 t -68.9 113.42 4.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -90.57 -37.23 13.97 Favored 'General case' 0 C--N 1.323 -0.552 0 O-C-N 123.609 0.568 . . . . 0.0 110.911 -174.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.401 ' HA ' ' HB3' ' A' ' 13' ' ' GLU . 73.0 mtp180 -143.07 155.75 44.68 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.976 0.417 . . . . 0.0 111.371 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 54.6 t -126.17 125.71 68.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.973 174.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.561 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 5.8 mp -114.01 162.16 24.34 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.561 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 40.4 Cg_exo -36.77 -44.35 1.05 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.347 3.365 . . . . 0.0 115.686 -174.188 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.578 ' HG3' ' HD1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.74 14.47 5.37 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -175.299 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.578 ' HD1' ' HG3' ' A' ' 60' ' ' LYS . 46.9 p90 -169.25 149.47 4.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.938 0.399 . . . . 0.0 111.19 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.514 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -107.16 165.52 11.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.655 179.204 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -128.17 122.33 31.65 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.463 ' HB1' HG21 ' A' ' 41' ' ' VAL . . . -139.79 164.38 30.12 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.824 0.345 . . . . 0.0 111.508 -176.02 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 9.5 p -133.98 158.82 42.53 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.371 176.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.9 t -83.86 115.51 26.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.786 0.327 . . . . 0.0 110.424 -177.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.7 m -118.24 3.34 7.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.016 0.436 . . . . 0.0 110.937 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 . . . . . 0 C--O 1.245 0.85 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.581 -174.027 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 mpt? . . . . . 0 N--CA 1.483 1.219 0 CA-C-O 120.86 0.362 . . . . 0.0 110.224 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -137.1 151.82 49.3 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.619 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 20.2 ttm-85 -145.78 143.06 29.45 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.582 175.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -77.69 171.87 14.28 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.184 0.516 . . . . 0.0 111.412 -178.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -90.37 159.88 16.37 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.962 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.7 m -137.88 -51.49 0.61 Allowed 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.498 -178.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.6 mmt180 64.55 120.25 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.546 0 O-C-N 123.676 0.61 . . . . 0.0 111.291 -172.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.657 ' O ' HG22 ' A' ' 9' ' ' VAL . 2.8 m -77.35 80.36 3.85 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 174.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.657 HG22 ' O ' ' A' ' 8' ' ' SER . 1.5 m 60.39 170.26 0.07 OUTLIER Pre-proline 0 CA--C 1.549 0.935 0 O-C-N 124.395 1.059 . . . . 0.0 109.804 -169.527 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.616 ' HD2' ' HB ' ' A' ' 9' ' ' VAL . 30.0 Cg_endo -63.65 -11.15 25.0 Favored 'Trans proline' 0 C--N 1.353 0.812 0 C-N-CA 121.983 1.789 . . . . 0.0 113.999 -173.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.544 ' HB ' HG22 ' A' ' 54' ' ' VAL . 24.5 m -135.13 132.5 52.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.496 ' HG2' ' HB2' ' A' ' 8' ' ' SER . 43.8 mt-10 -118.77 170.75 8.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.245 0.545 . . . . 0.0 111.748 -177.114 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.424 ' HG3' HG22 ' A' ' 57' ' ' VAL . 28.2 mt-10 -65.6 116.98 7.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.196 -0.911 . . . . 0.0 112.355 -172.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.514 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 94.17 31.69 7.89 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.389 171.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -122.77 153.71 39.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.209 -0.597 . . . . 0.0 110.771 178.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.402 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 3.9 p -110.45 133.1 56.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.403 -178.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -132.38 150.79 52.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.046 -177.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -94.29 107.58 19.52 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 176.258 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.425 HG11 HD11 ' A' ' 34' ' ' ILE . 29.4 m -118.47 166.65 12.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.531 0.681 . . . . 0.0 111.834 -171.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.9 m -131.38 127.52 37.74 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.358 174.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.513 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.5 mm -69.0 125.07 26.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.78 -174.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 mm-40 -98.83 -41.52 7.6 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.398 -175.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 26.3 m-20 -133.77 173.66 11.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.771 0.319 . . . . 0.0 111.144 -177.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.442 HG12 HG22 ' A' ' 46' ' ' VAL . 45.5 mm -122.36 134.11 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.53 ' HB1' ' HB3' ' A' ' 29' ' ' ASP . . . -101.2 175.13 5.69 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.363 -179.117 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 56.8 mtp85 -68.01 -31.45 71.14 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -174.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.601 HE21 ' HA ' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -78.31 12.92 1.7 Allowed 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 178.778 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 69.62 27.78 72.99 Favored Glycine 0 N--CA 1.451 -0.338 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 -174.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.53 ' HB3' ' HB1' ' A' ' 25' ' ' ALA . 13.5 t70 -91.24 144.8 25.23 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.82 -0.69 . . . . 0.0 110.053 -176.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.576 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -96.19 112.63 4.47 Favored Glycine 0 N--CA 1.439 -1.158 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 177.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.498 HG22 HG12 ' A' ' 38' ' ' VAL . 74.7 mt -79.14 103.39 6.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.283 0.563 . . . . 0.0 110.71 -175.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.48 ' HB1' HD13 ' A' ' 21' ' ' ILE . . . -105.48 116.43 31.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.221 175.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 25.1 ptt180 -107.5 136.59 47.01 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.476 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.425 HD11 HG11 ' A' ' 19' ' ' VAL . 56.7 mt -124.48 118.25 52.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.608 174.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 59.42 26.94 15.94 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.743 -179.438 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.08 -22.63 39.88 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.762 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -75.55 130.65 39.18 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.498 HG12 HG22 ' A' ' 31' ' ' ILE . 61.9 t -86.26 122.11 38.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.171 0.51 . . . . 0.0 111.689 -175.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.421 HD13 HG12 ' A' ' 11' ' ' VAL . 46.1 mt -115.1 133.4 61.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.182 174.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.449 ' HB3' ' OD2' ' A' ' 29' ' ' ASP . 98.1 m-85 -98.14 130.05 44.91 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.974 0.416 . . . . 0.0 111.206 -177.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 41.6 t -130.34 93.5 32.64 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.862 178.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 26.1 Cg_exo -62.66 129.16 25.45 Favored 'Trans proline' 0 CA--C 1.528 0.221 0 C-N-CA 123.095 2.53 . . . . 0.0 113.333 -174.35 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.44 50.53 3.36 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.609 174.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.576 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 11.1 p -139.72 -178.57 5.48 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.643 -0.327 . . . . 0.0 110.768 177.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.754 ' HZ1' ' HB3' ' A' ' 45' ' ' LYS . 4.9 ttpm? -133.93 153.69 51.59 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.442 HG22 HG12 ' A' ' 24' ' ' ILE . 38.5 t -58.37 117.0 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 175.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.97 -16.44 18.22 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.379 -177.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.535 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.1 m-20 -67.7 115.82 7.7 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.95 178.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.23 90.87 4.49 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.69 174.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.4 m -120.86 169.14 12.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.153 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 64.0 mtp180 -102.07 128.36 48.56 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.474 HG21 ' HA ' ' A' ' 66' ' ' VAL . 2.8 pp -127.02 150.29 32.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.204 -176.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.514 ' HE2' ' HA2' ' A' ' 14' ' ' GLY . 69.6 tttt -106.07 118.78 37.52 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 172.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.544 HG22 ' HB ' ' A' ' 11' ' ' VAL . 87.1 t -69.27 106.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 171.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 13.5 tp10 -84.87 -36.19 21.71 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.294 -170.178 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 56' ' ' ARG . 7.4 ptp85 -156.44 150.07 24.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.293 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.424 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.1 m -121.25 138.92 50.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.098 0.475 . . . . 0.0 110.925 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.7 mp -110.57 157.89 37.04 Favored Pre-proline 0 C--N 1.319 -0.76 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 174.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -58.89 -1.46 0.8 Allowed 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.162 2.575 . . . . 0.0 114.68 -176.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.4 -16.8 2.36 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -169.03 161.08 10.38 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.605 0.241 . . . . 0.0 110.838 -176.026 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -115.04 152.18 32.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.89 0.376 . . . . 0.0 111.515 -177.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.4 t80 -112.14 129.02 56.38 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.416 178.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -128.58 149.52 50.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.313 0.578 . . . . 0.0 111.889 -177.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.3 t -109.74 136.02 49.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.166 175.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.512 HG21 ' H ' ' A' ' 68' ' ' GLU . 6.9 p -82.47 123.23 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.333 0.587 . . . . 0.0 111.063 -176.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.5 m -107.45 28.43 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.512 ' H ' HG21 ' A' ' 66' ' ' VAL . 41.8 mt-10 . . . . . 0 C--O 1.251 1.152 0 CA-C-N 115.073 -0.967 . . . . 0.0 111.256 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.1 ttt . . . . . 0 N--CA 1.475 0.8 0 CA-C-O 120.895 0.379 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -155.27 102.18 2.27 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.42 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 44.2 mtm105 -145.72 110.01 4.98 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.023 176.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 61.6 71.0 0.56 Allowed 'General case' 0 C--N 1.33 -0.261 0 O-C-N 123.517 0.511 . . . . 0.0 110.993 174.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 42.46 -156.71 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.54 1.136 . . . . 0.0 112.984 -178.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.4 m -133.79 -55.51 0.88 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.408 176.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.422 HH11 ' HD2' ' A' ' 7' ' ' ARG . 5.1 ptp180 -175.8 67.8 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.451 178.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 12.9 m -84.82 23.04 1.24 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.739 -173.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 4.3 m -134.99 112.64 11.36 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-O 121.098 0.475 . . . . 0.0 111.065 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -67.15 -31.01 37.23 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.593 2.195 . . . . 0.0 111.234 175.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.9 m -132.42 151.75 35.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.24 177.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.21 155.66 41.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.036 0.446 . . . . 0.0 110.95 -177.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -66.42 122.52 17.72 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.355 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.71 21.46 33.92 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.957 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -113.76 164.1 14.17 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.755 0.312 . . . . 0.0 110.369 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.67 ' HB ' ' HE3' ' A' ' 53' ' ' LYS . 14.9 p -129.92 131.85 66.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 120.92 0.39 . . . . 0.0 110.373 -176.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -135.96 154.66 51.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.389 -176.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -93.36 123.61 36.77 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 31.9 m -133.37 156.64 42.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.177 0.513 . . . . 0.0 111.709 -173.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.505 HG22 ' HG2' ' A' ' 49' ' ' GLU . 61.0 m -113.16 124.62 52.99 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.248 -0.887 . . . . 0.0 109.622 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.545 HG13 ' HB ' ' A' ' 44' ' ' THR . 48.7 mm -70.41 95.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -86.61 -33.91 20.02 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.315 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.428 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 20.3 t70 -126.73 163.73 22.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.537 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.484 HG13 ' HA2' ' A' ' 30' ' ' GLY . 7.5 tt -141.48 132.19 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 174.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.06 162.63 27.35 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.428 -175.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.3 ttm105 -68.74 -12.89 61.98 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.566 0.698 . . . . 0.0 109.463 178.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -72.16 -16.77 61.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.807 172.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.52 17.13 59.12 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.662 -0.699 . . . . 0.0 113.087 176.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 -105.68 143.07 34.35 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 177.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.484 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -68.29 133.83 28.59 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.156 -175.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.479 HG23 HG21 ' A' ' 38' ' ' VAL . 48.0 mm -106.68 109.97 29.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.325 0.584 . . . . 0.0 110.583 -178.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.476 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -101.4 149.77 23.72 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.381 175.124 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 1.2 ptm180 -138.37 113.79 9.57 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.98 0.419 . . . . 0.0 110.929 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.0 mt -104.48 105.75 19.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.991 176.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 51.57 27.67 4.09 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.686 -1.143 . . . . 0.0 112.131 -178.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 118.45 -31.81 5.45 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.756 -0.735 . . . . 0.0 113.025 177.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -75.51 125.42 28.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.843 0.354 . . . . 0.0 110.252 -177.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.479 HG21 HG23 ' A' ' 31' ' ' ILE . 7.0 p -88.75 135.38 25.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.287 0.565 . . . . 0.0 111.551 -176.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.534 HG12 ' HB1' ' A' ' 62' ' ' ALA . 42.7 mt -124.29 132.13 71.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.943 178.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -93.17 119.63 32.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.81 0.338 . . . . 0.0 110.576 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.39 100.09 45.06 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.963 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.48 127.36 17.95 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 123.226 2.618 . . . . 0.0 113.118 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.85 -9.13 55.04 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.83 173.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.545 ' HB ' HG13 ' A' ' 21' ' ' ILE . 25.8 p -89.12 156.13 19.01 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 117.355 0.578 . . . . 0.0 111.669 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -111.4 157.61 20.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.764 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 88.1 t -58.99 124.12 12.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.281 177.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 108.44 -13.1 36.31 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.512 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -68.84 117.32 10.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.119 0.485 . . . . 0.0 110.966 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.505 ' HG2' HG22 ' A' ' 20' ' ' THR . 44.3 mt-10 -106.64 97.03 6.87 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.636 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.86 173.74 14.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.063 -173.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.9 mtp85 -103.23 126.49 50.43 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.75 177.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.1 pt -116.17 143.35 26.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.326 -175.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.67 ' HE3' ' HB ' ' A' ' 16' ' ' VAL . 0.9 OUTLIER -97.87 102.84 14.7 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.122 175.824 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.475 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 55.9 t -69.35 108.45 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.56 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.22 -26.41 17.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.738 -173.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 37.8 ttt180 -154.92 144.91 21.72 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.823 0.344 . . . . 0.0 110.731 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 35.7 m -110.19 141.7 24.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.122 175.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.538 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 3.1 mm? -115.59 160.45 34.68 Favored Pre-proline 0 C--N 1.32 -0.687 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.538 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 9.8 Cg_endo -52.69 -28.41 37.5 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.122 2.548 . . . . 0.0 114.177 -175.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -121.79 -2.96 9.24 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -175.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -169.58 162.62 10.01 Favored 'General case' 0 C--O 1.222 -0.382 0 CA-C-N 117.76 0.254 . . . . 0.0 110.941 -175.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB1' HG12 ' A' ' 39' ' ' ILE . . . -113.87 157.47 22.31 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.685 0.279 . . . . 0.0 110.569 177.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -123.2 129.0 50.8 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -146.69 158.5 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.353 . . . . 0.0 111.677 -176.018 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.2 p -115.73 160.08 20.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.551 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 41.4 t -81.62 123.98 38.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.329 -176.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.45 33.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.15 0.5 . . . . 0.0 110.539 179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 45.9 tt0 . . . . . 0 C--O 1.25 1.116 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.419 177.698 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.0 mmt . . . . . 0 N--CA 1.478 0.942 0 CA-C-O 120.646 0.26 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.515 ' CD2' ' HG2' ' A' ' 3' ' ' ARG . 53.2 p90 -81.39 157.47 24.99 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.515 ' HG2' ' CD2' ' A' ' 2' ' ' PHE . 32.4 mmt180 73.67 152.45 0.13 Allowed 'General case' 0 N--CA 1.469 0.492 0 O-C-N 123.823 0.702 . . . . 0.0 109.321 -170.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -85.7 59.81 5.86 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.414 0.626 . . . . 0.0 109.984 177.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -89.81 131.19 35.88 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 121.54 0.686 . . . . 0.0 110.726 -175.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.462 ' C ' ' H ' ' A' ' 8' ' ' SER . 40.7 p -114.48 -53.91 2.62 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 171.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.2 mtt-85 67.38 -36.97 0.3 Allowed 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 114.851 -1.068 . . . . 0.0 112.625 177.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.462 ' H ' ' C ' ' A' ' 6' ' ' SER . 49.9 m 62.2 70.79 0.56 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.533 0.682 . . . . 0.0 110.73 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.2 m -95.86 142.36 24.46 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.63 178.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -69.24 -31.21 23.32 Favored 'Trans proline' 0 N--CA 1.463 -0.29 0 C-N-CA 122.427 2.084 . . . . 0.0 112.338 179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.464 HG12 HD11 ' A' ' 39' ' ' ILE . 30.3 m -136.63 156.25 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.786 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.548 ' CG ' ' HG3' ' A' ' 15' ' ' GLU . 10.8 pt-20 -133.24 160.45 37.25 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.42 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.432 ' CG ' HG23 ' A' ' 57' ' ' VAL . 39.3 mt-10 -66.83 132.87 48.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.13 0.49 . . . . 0.0 112.15 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.475 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 77.75 36.14 33.82 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.205 -0.907 . . . . 0.0 112.997 174.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.586 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 19.6 mm-40 -125.03 164.62 19.78 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-O 120.791 0.329 . . . . 0.0 111.011 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 55.0 t -121.81 122.99 68.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.719 -174.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 41.9 m-85 -125.89 145.87 50.07 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.86 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -90.92 95.75 10.28 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.517 0.675 . . . . 0.0 109.244 171.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 49' ' ' GLU . 28.5 m -104.76 161.29 4.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.514 -171.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.8 m -110.58 119.57 39.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.041 175.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.464 HG13 ' HB ' ' A' ' 44' ' ' THR . 47.7 mm -69.7 106.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 175.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.804 ' HA ' HE21 ' A' ' 22' ' ' GLN . 0.0 OUTLIER -97.84 -22.13 16.54 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.286 -173.634 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 29.3 t70 -142.88 164.28 30.53 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.895 -0.322 . . . . 0.0 111.263 -174.131 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.416 HG12 HG21 ' A' ' 46' ' ' VAL . 48.5 mm -124.49 131.94 72.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.44 ' HB3' HD13 ' A' ' 31' ' ' ILE . . . -98.55 -150.79 0.37 Allowed 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.382 0.611 . . . . 0.0 111.548 -174.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 8.3 ttp180 -47.68 117.37 1.81 Allowed 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.654 -1.157 . . . . 0.0 110.893 173.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.5 tt0 72.65 -74.84 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 O-C-N 123.892 0.745 . . . . 0.0 112.123 169.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -160.75 19.06 0.21 Allowed Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.572 -177.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 47.7 m-20 -78.01 123.23 26.57 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 176.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.601 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -79.13 137.74 19.64 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.791 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.549 HG21 ' HD3' ' A' ' 33' ' ' ARG . 48.3 mm -108.57 114.26 46.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.271 0.558 . . . . 0.0 110.778 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.46 ' HB2' HD11 ' A' ' 21' ' ' ILE . . . -109.54 112.4 24.47 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.805 176.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.657 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 0.6 OUTLIER -97.78 115.02 27.19 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.519 178.448 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 31.8 mt -93.81 107.96 19.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 172.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 55.42 21.92 4.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.701 -1.136 . . . . 0.0 111.921 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.64 -26.69 8.35 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.773 -0.727 . . . . 0.0 113.244 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.657 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 53.5 t80 -69.6 128.04 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.965 0.382 . . . . 0.0 110.715 -176.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.491 HG13 HG23 ' A' ' 31' ' ' ILE . 60.8 t -85.62 116.04 28.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.737 -174.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.464 HD11 HG12 ' A' ' 11' ' ' VAL . 54.0 mt -111.41 133.13 58.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.914 174.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -94.05 122.94 37.08 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.013 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.417 HG21 ' HB1' ' A' ' 64' ' ' ALA . 43.9 t -127.67 91.52 45.28 Favored Pre-proline 0 C--N 1.326 -0.434 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 38.4 Cg_exo -60.22 121.27 9.52 Favored 'Trans proline' 0 CA--C 1.528 0.192 0 C-N-CA 122.873 2.382 . . . . 0.0 113.033 -175.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.63 60.8 1.33 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.073 175.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.601 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 1.3 p -143.35 175.22 10.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 117.006 0.403 . . . . 0.0 110.72 176.701 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -129.86 150.09 51.31 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -178.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.416 HG21 HG12 ' A' ' 24' ' ' ILE . 67.4 t -58.82 116.62 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.881 0.372 . . . . 0.0 110.85 177.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.85 -9.27 14.32 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.227 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -71.98 105.4 3.86 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.821 0.343 . . . . 0.0 111.556 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 47.1 mt-10 -88.45 97.7 11.22 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 168.417 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.594 ' HA ' ' HG3' ' A' ' 68' ' ' GLU . 16.3 m -128.2 151.98 35.71 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.922 -0.581 . . . . 0.0 112.031 -172.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.412 ' H ' ' CG ' ' A' ' 68' ' ' GLU . 25.1 mmt180 -79.64 128.93 34.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.852 172.286 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 2.7 pp -134.57 147.16 29.94 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.706 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.586 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 47.6 tttp -102.66 111.74 24.19 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 173.77 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.2 t -67.75 112.91 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 175.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -92.06 -33.19 14.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.912 -169.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -156.45 130.12 8.31 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.997 -172.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.432 HG23 ' CG ' ' A' ' 13' ' ' GLU . 34.3 m -114.42 139.45 40.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.323 0.582 . . . . 0.0 111.198 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 96.9 mt -123.64 153.67 66.49 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 173.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.47 -16.6 14.47 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.722 2.282 . . . . 0.0 113.46 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 55.9 tptt -100.92 -34.7 9.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.553 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -170.18 173.52 5.8 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.453 -0.202 . . . . 0.0 110.453 -174.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -133.42 159.64 39.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.889 0.376 . . . . 0.0 111.633 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 39.1 m-85 -108.59 152.44 24.77 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.421 ' HB3' ' HB ' ' A' ' 52' ' ' ILE . . . -142.45 142.45 32.33 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.162 0.506 . . . . 0.0 111.742 177.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 42.2 m -94.34 139.3 31.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.477 174.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.6 t -81.64 118.25 29.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.653 0.263 . . . . 0.0 110.651 -178.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.8 m -118.17 20.16 6.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.172 0.511 . . . . 0.0 110.679 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.594 ' HG3' ' HA ' ' A' ' 50' ' ' VAL . 1.1 tm-20 . . . . . 0 C--O 1.244 0.783 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.212 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.402 ' SD ' ' N ' ' A' ' 1' ' ' MET . 1.5 mpt? . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 121.09 0.471 . . . . 0.0 109.854 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -112.93 -20.89 11.39 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.934 -174.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 6.8 mmt180 -150.07 -53.87 0.16 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.636 0.731 . . . . 0.0 110.559 -177.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 177.96 -19.63 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 -172.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 74.3 -158.72 0.07 Allowed 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 113.167 -1.833 . . . . 0.0 110.313 175.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 80.7 p 54.76 31.96 16.53 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 122.254 1.026 . . . . 0.0 108.255 -164.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 48.4 mtm180 -88.92 -159.37 0.56 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 114.062 -1.426 . . . . 0.0 110.327 -178.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.2 t -63.78 102.05 0.42 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.216 0.531 . . . . 0.0 111.613 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 2.7 m -138.49 88.04 14.84 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.365 173.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.418 ' HB2' HG23 ' A' ' 34' ' ' ILE . 73.0 Cg_endo -75.49 -15.96 19.4 Favored 'Trans proline' 0 C--O 1.234 0.315 0 C-N-CA 122.728 2.285 . . . . 0.0 113.037 -174.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.449 ' HB ' HG23 ' A' ' 54' ' ' VAL . 19.4 m -131.33 143.7 39.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.745 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -121.58 148.9 43.92 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.681 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.475 ' CG ' HG23 ' A' ' 57' ' ' VAL . 44.1 mt-10 -66.31 129.46 39.89 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.315 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.65 27.17 30.3 Favored Glycine 0 N--CA 1.445 -0.767 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.917 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 72.0 mm-40 -124.05 156.44 36.54 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.256 0.55 . . . . 0.0 111.894 -177.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 57.0 t -113.83 130.65 67.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.149 -175.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -132.04 150.82 52.05 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.246 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.85 109.52 21.5 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.86 144.63 36.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.424 0.63 . . . . 0.0 112.15 -174.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.0 m -96.14 139.64 32.01 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 169.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.586 HG13 ' HB ' ' A' ' 44' ' ' THR . 45.8 mm -81.1 124.86 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.591 0.234 . . . . 0.0 110.972 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.443 ' OE1' ' HG2' ' A' ' 33' ' ' ARG . 2.3 mp0 -75.47 -56.33 4.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.979 -177.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -140.28 -179.41 5.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.15 -177.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.408 HD12 ' HA ' ' A' ' 45' ' ' LYS . 38.0 mm -123.7 127.45 73.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.81 146.69 26.65 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.724 179.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 37.2 ttt180 -61.44 -16.65 48.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.833 -173.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -70.19 -23.99 63.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.82 0.343 . . . . 0.0 110.987 177.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.97 17.52 10.89 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.729 -0.748 . . . . 0.0 111.728 -175.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -113.41 153.07 29.2 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.504 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -91.86 144.92 17.43 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.796 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 70.2 mt -100.87 109.84 26.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.952 0.406 . . . . 0.0 110.406 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -111.58 163.43 14.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.447 175.298 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.443 ' HG2' ' OE1' ' A' ' 22' ' ' GLN . 31.5 ptt180 -144.68 132.88 21.66 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.704 0.288 . . . . 0.0 110.822 -178.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.418 HG23 ' HB2' ' A' ' 10' ' ' PRO . 49.6 mt -129.06 117.82 44.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.29 26.82 14.41 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.953 0.882 . . . . 0.0 109.923 -175.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.36 -15.0 63.25 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.639 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.561 ' CE2' ' HB2' ' A' ' 62' ' ' ALA . 14.7 t80 -75.31 119.93 20.08 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.3 t -78.04 128.93 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.234 0.54 . . . . 0.0 111.382 -173.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.508 HG12 ' HB1' ' A' ' 62' ' ' ALA . 24.6 mt -120.11 129.72 75.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.797 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -101.54 125.24 48.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.857 0.36 . . . . 0.0 110.803 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.0 t -122.94 108.33 32.69 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.359 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.12 126.84 21.3 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 123.213 2.608 . . . . 0.0 113.184 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 64.39 2.25 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.066 -0.587 . . . . 0.0 113.384 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.586 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.4 p -134.88 -172.24 2.99 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 176.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 48' ' ' ASP . 36.7 ttpt -142.69 153.91 43.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.418 0.151 . . . . 0.0 110.871 -175.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.03 120.6 5.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.74 0.305 . . . . 0.0 111.113 179.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.7 4.35 90.27 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.602 177.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.442 ' HB2' ' HB3' ' A' ' 45' ' ' LYS . 40.3 t0 -75.87 122.67 24.47 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.3 106.49 18.26 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.087 0.47 . . . . 0.0 110.02 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.68 146.82 33.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.379 0.609 . . . . 0.0 111.333 -175.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -97.97 117.57 32.62 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 176.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 44.5 pt -116.27 155.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.475 -170.55 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.508 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 34.9 ttmt -105.37 118.09 35.67 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.449 HG23 ' HB ' ' A' ' 11' ' ' VAL . 90.2 t -69.19 118.35 13.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 174.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -92.84 -45.79 7.83 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.348 1.03 . . . . 0.0 111.217 -175.398 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 33.2 mtt180 -135.93 144.0 45.23 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.378 -172.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.475 HG23 ' CG ' ' A' ' 13' ' ' GLU . 27.6 m -124.7 116.05 46.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.698 0.761 . . . . 0.0 110.497 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.464 ' C ' ' H ' ' A' ' 60' ' ' LYS . 5.8 mp -112.94 152.22 44.72 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.619 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.13 11.0 0.28 Allowed 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 122.745 2.297 . . . . 0.0 112.481 177.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.464 ' H ' ' C ' ' A' ' 58' ' ' LEU . 56.9 mttm -118.51 -31.78 4.8 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.612 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -177.84 170.25 1.94 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.923 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.561 ' HB2' ' CE2' ' A' ' 37' ' ' PHE . . . -108.75 146.96 32.73 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.808 0.337 . . . . 0.0 110.533 176.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 53.4 t80 -122.0 123.68 42.21 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -134.85 152.02 51.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.873 -176.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 20.9 t -113.48 146.6 39.33 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.497 HG21 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -81.65 117.52 27.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.361 0.601 . . . . 0.0 111.126 -176.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.9 p -96.52 8.85 6.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.938 0.875 . . . . 0.0 108.993 178.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.497 ' H ' HG21 ' A' ' 66' ' ' VAL . 25.7 tt0 . . . . . 0 C--O 1.251 1.146 0 CA-C-N 113.334 -1.757 . . . . 0.0 111.268 177.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.412 ' H1 ' ' HA ' ' A' ' 4' ' ' GLU . 4.2 mpp? . . . . . 0 N--CA 1.481 1.116 0 CA-C-O 120.403 0.144 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.525 ' C ' ' H ' ' A' ' 4' ' ' GLU . 86.7 m-85 64.86 95.98 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.117 0.567 . . . . 0.0 110.995 176.037 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.452 ' HB2' ' O ' ' A' ' 2' ' ' PHE . 66.2 mtt180 71.89 -9.69 0.95 Allowed 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 115.344 -0.843 . . . . 0.0 110.38 -171.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.525 ' H ' ' C ' ' A' ' 2' ' ' PHE . 33.8 mm-40 66.14 10.91 7.46 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 114.932 -1.031 . . . . 0.0 113.638 169.541 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 56.44 -154.45 0.33 Allowed 'General case' 0 CA--C 1.529 0.155 0 O-C-N 123.354 0.409 . . . . 0.0 111.078 168.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.5 t -87.73 -42.02 12.92 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.01 0.434 . . . . 0.0 109.846 175.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.606 ' C ' ' H ' ' A' ' 9' ' ' VAL . 17.0 mmt180 -116.85 -64.71 1.27 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.19 -0.459 . . . . 0.0 112.053 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 82.1 p 66.62 -20.85 0.1 Allowed 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 125.256 1.423 . . . . 0.0 112.327 -174.499 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.606 ' H ' ' C ' ' A' ' 7' ' ' ARG . 0.4 OUTLIER -158.06 105.22 1.73 Allowed Pre-proline 0 C--N 1.31 -1.132 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.178 177.26 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -62.82 -41.41 30.33 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.775 2.317 . . . . 0.0 112.177 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.5 162.06 37.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.48 -178.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.506 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.0 pt-20 -130.96 156.41 45.15 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.429 178.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 56.1 mt-10 -66.46 133.61 50.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.355 -174.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.91 31.08 33.27 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.688 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.506 ' HG3' ' HG3' ' A' ' 12' ' ' GLU . 58.8 mm-40 -127.17 155.86 42.72 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.556 -0.457 . . . . 0.0 110.912 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 7.1 p -118.66 128.23 75.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.09 -174.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.8 m-85 -125.95 132.43 52.08 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.793 -178.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.487 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 30.2 t70 -81.61 97.0 7.66 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 175.473 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.9 m -111.99 170.45 3.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.392 0.615 . . . . 0.0 111.663 -170.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.427 ' HA ' ' HA ' ' A' ' 49' ' ' GLU . 26.0 m -120.51 128.73 53.39 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.111 171.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.573 HG13 ' HB ' ' A' ' 44' ' ' THR . 49.9 mm -68.48 116.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.168 0.508 . . . . 0.0 110.707 -175.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm-40 -84.29 -40.55 17.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.608 -173.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -143.33 179.55 7.02 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -177.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.529 HD13 ' HA2' ' A' ' 30' ' ' GLY . 32.0 mm -137.06 119.21 19.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -71.69 150.57 44.41 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.943 178.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 55.2 ttp180 -47.81 -35.71 10.57 Favored 'General case' 0 C--N 1.329 -0.316 0 O-C-N 123.478 0.486 . . . . 0.0 112.051 -177.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.565 ' HB2' ' OD1' ' A' ' 29' ' ' ASP . 15.5 mt-30 -73.09 -14.19 61.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.767 -175.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.41 7.92 41.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.666 -175.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.831 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 6.6 m-20 -80.95 122.82 27.73 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 177.281 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.532 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -72.27 127.75 12.85 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.512 178.572 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.513 HG22 HG13 ' A' ' 38' ' ' VAL . 73.5 mt -95.52 106.49 18.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.339 0.59 . . . . 0.0 111.385 -176.047 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -96.69 94.65 7.43 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 170.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 9.9 ptm180 -93.91 98.46 11.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.57 0.7 . . . . 0.0 110.968 -174.465 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 45.1 mt -93.17 111.33 24.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.487 -179.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 56.64 26.33 11.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.941 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.53 -20.47 39.47 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.457 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.443 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 50.7 t80 -75.59 123.44 25.51 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.513 HG13 HG22 ' A' ' 31' ' ' ILE . 64.7 t -90.0 116.37 31.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.897 -173.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.425 HG12 ' HB2' ' A' ' 62' ' ' ALA . 55.4 mt -109.24 125.66 66.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.648 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -94.19 121.14 35.38 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.969 0.414 . . . . 0.0 111.359 -178.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.5 HG21 ' HB3' ' A' ' 64' ' ' ALA . 11.0 t -129.53 89.59 46.58 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.126 175.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . 0.831 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 32.8 Cg_endo -63.94 137.43 57.69 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.968 2.445 . . . . 0.0 113.239 -175.326 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.38 -10.15 30.87 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.032 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.573 ' HB ' HG13 ' A' ' 21' ' ' ILE . 35.3 p -95.59 -179.62 4.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.522 0.201 . . . . 0.0 110.962 -178.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HA ' HD12 ' A' ' 24' ' ' ILE . 34.3 ttmt -142.9 165.29 27.76 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 44.0 t -58.34 118.7 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 CA-C-O 120.664 0.268 . . . . 0.0 111.097 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.94 -5.74 59.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.761 178.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.423 ' O ' HG12 ' A' ' 21' ' ' ILE . 29.6 t0 -75.11 112.47 11.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 110.055 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.427 ' HA ' ' HA ' ' A' ' 20' ' ' THR . 8.4 pt-20 -100.29 108.09 20.06 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.743 -178.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.0 m -142.15 161.87 19.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.807 -176.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.487 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 66.0 mtm180 -82.95 124.23 30.18 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.796 174.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.6 pt -117.96 136.92 53.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.137 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.464 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 56.3 tttm -100.4 114.6 28.27 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.7 t -69.29 121.19 18.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -94.44 -45.73 7.31 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.209 0.943 . . . . 0.0 110.872 -174.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.8 tpm_? -140.68 137.91 33.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.143 -172.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 34.4 m -114.78 136.31 51.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.295 0.569 . . . . 0.0 110.858 176.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 5.6 mp -123.02 156.19 62.98 Favored Pre-proline 0 C--N 1.321 -0.652 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -58.47 -16.67 30.48 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.848 2.365 . . . . 0.0 113.518 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.2 ttmm -110.35 -22.52 11.67 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -176.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -172.47 172.14 4.44 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.682 0.277 . . . . 0.0 111.0 -174.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.425 ' HB2' HG12 ' A' ' 39' ' ' ILE . . . -128.13 157.47 40.69 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.688 0.28 . . . . 0.0 110.984 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -124.61 136.4 53.91 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.5 ' HB3' HG21 ' A' ' 41' ' ' VAL . . . -136.83 163.2 31.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.956 0.407 . . . . 0.0 111.423 -176.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.1 p -117.27 145.0 44.24 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.854 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 40.6 t -78.39 127.19 38.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.131 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.0 m -123.49 13.88 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.743 0.306 . . . . 0.0 110.465 176.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 . . . . . 0 C--O 1.25 1.119 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.504 -179.634 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.2 mpt? . . . . . 0 N--CA 1.481 1.12 0 CA-C-O 120.488 0.185 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 62.74 -169.28 0.19 Allowed 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.04 -176.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 62.0 ttt180 -156.54 -35.99 0.08 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.467 -178.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 75.18 96.52 0.07 Allowed 'General case' 0 N--CA 1.462 0.175 0 O-C-N 124.118 0.886 . . . . 0.0 109.191 -173.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . 0.402 ' O ' ' HB2' ' A' ' 6' ' ' SER . 2.8 mm-40 -75.7 -163.47 0.27 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.835 -175.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . 0.402 ' HB2' ' O ' ' A' ' 5' ' ' GLU . 50.0 m 73.62 76.64 0.13 Allowed 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.25 -173.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 19.1 mmt85 -52.38 138.83 26.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.699 -179.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 17.6 m -67.93 96.55 0.6 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.404 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 8.4 t 69.97 115.95 0.03 OUTLIER Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.673 173.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.07 -7.33 21.17 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 122.944 2.429 . . . . 0.0 113.343 -177.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.79 130.7 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.706 0.289 . . . . 0.0 110.474 179.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -113.09 173.7 6.26 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.541 0.686 . . . . 0.0 111.773 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.503 ' OE1' ' HD3' ' A' ' 56' ' ' ARG . 33.5 mt-10 -67.28 126.63 29.84 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.806 -1.088 . . . . 0.0 112.152 -177.082 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.542 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 91.68 16.35 52.31 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.389 -0.823 . . . . 0.0 112.929 174.039 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.567 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 26.2 mt-10 -99.04 160.42 14.27 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.344 -0.542 . . . . 0.0 111.187 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.51 124.34 68.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.208 -179.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -128.54 141.05 51.49 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.858 -177.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -80.51 97.29 7.08 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.4 m -109.66 148.9 13.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.353 0.597 . . . . 0.0 111.764 -173.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.0 m -110.1 119.09 38.18 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.912 172.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.622 HG13 ' HB ' ' A' ' 44' ' ' THR . 41.3 mm -69.64 116.77 11.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.746 -175.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -87.17 -51.03 6.22 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.863 -174.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.408 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 15.2 m-20 -124.31 -179.26 4.38 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.892 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.545 HD12 ' HA2' ' A' ' 30' ' ' GLY . 39.6 mm -137.82 137.8 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.342 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.476 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . -68.54 -65.75 0.66 Allowed 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 121.912 0.863 . . . . 0.0 109.201 177.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 37.2 ptt180 -172.64 127.46 0.51 Allowed 'General case' 0 N--CA 1.439 -0.987 0 CA-C-N 113.514 -1.676 . . . . 0.0 108.178 172.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 61.7 tt0 79.55 -63.29 0.26 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.402 -0.817 . . . . 0.0 112.099 172.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.22 -21.65 0.12 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 119.587 -1.292 . . . . 0.0 114.687 -170.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.476 ' HB2' ' HB3' ' A' ' 25' ' ' ALA . 5.1 m-20 -73.62 108.24 6.35 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 117.799 0.8 . . . . 0.0 109.587 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.545 ' HA2' HD12 ' A' ' 24' ' ' ILE . . . -80.21 144.07 25.59 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.294 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.419 HG22 HG11 ' A' ' 38' ' ' VAL . 50.2 mm -105.5 102.69 14.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.105 0.479 . . . . 0.0 110.166 179.607 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -98.18 147.51 24.52 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 174.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.463 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 8.9 ptp85 -138.95 109.43 6.55 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.297 0.57 . . . . 0.0 111.049 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.424 ' C ' ' H ' ' A' ' 36' ' ' GLY . 42.7 mt -101.65 118.32 48.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 173.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 67.78 -3.1 1.22 Allowed 'General case' 0 CA--C 1.535 0.371 0 O-C-N 124.186 0.929 . . . . 0.0 110.519 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 34' ' ' ILE . . . 117.86 -14.49 12.73 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.209 -176.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 34.8 t80 -74.87 127.76 33.96 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.419 HG11 HG22 ' A' ' 31' ' ' ILE . 46.9 t -81.04 130.49 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.715 -173.721 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.518 HG12 ' HB3' ' A' ' 62' ' ' ALA . 50.7 mt -123.12 125.28 71.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.594 176.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.67 133.54 34.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.624 0.249 . . . . 0.0 110.768 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.7 t -132.13 104.23 13.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.247 -179.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -69.5 104.21 1.24 Allowed 'Trans proline' 0 C--O 1.233 0.262 0 C-N-CA 122.947 2.432 . . . . 0.0 112.849 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.95 48.17 0.74 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.979 175.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' THR . . . . . 0.622 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.8 p -138.08 170.96 15.13 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.752 -0.264 . . . . 0.0 111.29 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.64 ' HE3' ' HA ' ' A' ' 45' ' ' LYS . 0.2 OUTLIER -132.97 166.84 21.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.087 -177.044 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 43.8 t -65.47 116.42 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 178.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 95.62 1.76 61.87 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.407 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -75.12 123.66 25.64 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -103.19 108.57 19.83 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.385 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.5 m -138.18 161.58 31.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.366 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -96.34 123.67 40.06 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.267 172.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.455 HG23 ' HA ' ' A' ' 66' ' ' VAL . 46.9 pt -117.46 143.37 28.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.625 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.567 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 49.1 tttp -98.82 109.8 22.51 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 173.073 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.5 t -68.92 107.48 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 176.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -88.71 -40.84 12.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.653 0.596 . . . . 0.0 111.21 -172.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.503 ' HD3' ' OE1' ' A' ' 13' ' ' GLU . 19.6 mmt180 -139.71 129.59 24.78 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.004 -175.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.1 m -97.1 117.96 42.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 172.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.483 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 80.1 mt -101.37 162.08 21.61 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.922 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PRO . . . . . 0.483 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 91.1 Cg_exo -43.89 -38.49 10.03 Favored 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 123.57 2.847 . . . . 0.0 114.666 -175.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 17.6 tptp -120.29 -3.72 9.98 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -172.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.404 ' CE1' HD12 ' A' ' 58' ' ' LEU . 54.2 p90 -170.74 167.8 7.59 Favored 'General case' 0 C--O 1.222 -0.361 0 CA-C-O 120.613 0.244 . . . . 0.0 110.909 -177.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.518 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -108.47 147.35 31.8 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.031 0.443 . . . . 0.0 111.05 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -112.52 126.62 55.53 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.187 176.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -130.26 156.11 45.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.122 0.487 . . . . 0.0 111.468 -176.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 6.6 t -105.73 130.46 53.73 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.733 178.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.455 ' HA ' HG23 ' A' ' 52' ' ' ILE . 6.3 p -79.95 122.99 36.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.135 0.493 . . . . 0.0 111.067 -177.713 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 6.2 t -105.11 0.48 10.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.698 0.761 . . . . 0.0 109.639 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 . . . . . 0 C--O 1.247 0.952 0 CA-C-N 114.259 -1.337 . . . . 0.0 110.819 -175.234 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo . . . . . 0 N--CA 1.463 -0.306 0 N-CA-C 112.78 0.261 . . . . 0.0 112.78 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.5 m -126.29 146.62 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.225 0.536 . . . . 0.0 112.268 -172.557 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -121.07 171.51 8.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 174.608 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.549 ' HG2' ' HA ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -66.54 125.12 24.74 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.239 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 23.06 17.37 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 116.203 -0.453 . . . . 0.0 113.633 173.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.45 ' O ' ' HD2' ' A' ' 53' ' ' LYS . 45.0 mt-10 -105.28 171.65 7.21 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.278 0.539 . . . . 0.0 110.924 -177.825 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 7.1 p -141.97 129.28 20.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.857 0.361 . . . . 0.0 110.59 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 87.8 m-85 -134.84 142.47 46.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.388 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -82.03 94.3 7.15 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 32.9 m -111.54 159.11 11.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.304 0.573 . . . . 0.0 111.477 -173.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 m -112.69 125.97 54.88 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.292 -0.867 . . . . 0.0 108.809 172.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.578 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.0 mm -69.59 100.55 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.047 0.451 . . . . 0.0 110.257 -179.356 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -81.51 -34.72 31.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.283 -175.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.517 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 31.2 t0 -138.57 170.36 16.15 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.264 -178.817 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.44 HG12 ' HA2' ' A' ' 30' ' ' GLY . 27.8 mt -145.37 131.68 14.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.67 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.784 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.606 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 5.5 m-20 . . . . . 0 CA--C 1.516 -0.333 0 CA-C-O 120.664 0.268 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.44 ' HA2' HG12 ' A' ' 24' ' ' ILE . . . -71.73 126.42 12.39 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.632 177.265 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.571 HG23 HG13 ' A' ' 38' ' ' VAL . 75.5 mt -94.42 107.19 19.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.192 0.52 . . . . 0.0 110.649 -178.305 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.409 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -99.81 96.32 7.5 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.157 -0.928 . . . . 0.0 109.183 173.05 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 14.6 ptm180 -93.26 93.54 8.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.433 -176.276 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 52.5 mt -89.11 109.88 20.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.259 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 57.56 12.89 1.68 Allowed 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.953 -1.022 . . . . 0.0 112.302 -176.654 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.37 -19.73 12.87 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.313 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.427 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 70.4 t80 -73.72 125.66 28.58 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.571 HG13 HG23 ' A' ' 31' ' ' ILE . 98.0 t -93.18 112.58 26.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.346 0.593 . . . . 0.0 111.652 -173.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.409 ' HB ' ' HB3' ' A' ' 32' ' ' ALA . 57.2 mt -103.21 126.78 57.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.474 173.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -95.17 121.8 37.19 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.011 0.434 . . . . 0.0 111.002 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.526 HG22 ' HB3' ' A' ' 64' ' ' ALA . 21.6 t -120.33 89.9 44.32 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.498 176.029 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 17.3 Cg_exo -66.15 127.48 17.65 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.899 2.399 . . . . 0.0 112.536 -175.047 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.79 43.21 3.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.815 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.578 ' HB ' HG13 ' A' ' 21' ' ' ILE . 6.6 p -128.06 -171.7 2.51 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.588 0.232 . . . . 0.0 111.254 179.033 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -140.06 152.94 46.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.237 -176.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 38.9 t -63.01 118.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.74 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.24 1.85 64.42 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.382 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -76.18 119.43 20.08 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.774 0.321 . . . . 0.0 110.621 -178.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -98.67 108.11 20.72 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.577 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.419 ' HB ' HG13 ' A' ' 66' ' ' VAL . 15.3 m -139.79 160.25 27.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -174.195 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -86.14 110.36 19.51 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.32 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 44.8 pt -97.55 132.44 42.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.719 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.45 ' HD2' ' O ' ' A' ' 15' ' ' GLU . 51.0 tptt -92.95 104.86 17.05 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 174.177 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 99.5 t -69.29 97.24 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -65.36 -48.55 72.59 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.549 ' HA ' ' HG2' ' A' ' 13' ' ' GLU . 75.0 mtp180 -150.97 161.77 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.536 -177.108 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.427 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.7 m -128.98 135.64 61.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.106 0.479 . . . . 0.0 110.576 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -111.61 157.55 39.0 Favored Pre-proline 0 C--N 1.32 -0.682 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.28 -16.42 22.33 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.965 2.443 . . . . 0.0 113.805 -176.119 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.4 mmtm -117.32 -18.23 9.95 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -176.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -169.88 161.06 8.81 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.425 0.155 . . . . 0.0 110.66 -175.014 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -120.08 156.63 30.6 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.263 -178.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -114.43 134.2 55.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.346 176.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.526 ' HB3' HG22 ' A' ' 41' ' ' VAL . . . -145.75 154.9 42.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.699 178.178 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.3 t -128.47 157.14 41.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.041 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.454 HG12 ' H ' ' A' ' 68' ' ' GLU . 99.1 t -84.25 119.64 33.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.823 -177.03 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.7 m -104.59 15.88 6.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.083 0.468 . . . . 0.0 110.813 178.472 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.454 ' H ' HG12 ' A' ' 66' ' ' VAL . 41.9 mt-10 . . . . . 0 C--O 1.247 0.948 0 CA-C-N 114.547 -1.206 . . . . 0.0 111.307 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo . . . . . 0 N--CA 1.462 -0.343 0 CA-C-O 120.867 0.278 . . . . 0.0 112.82 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 m -113.33 151.22 15.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.806 -178.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.416 ' HB2' ' HG2' ' A' ' 15' ' ' GLU . 43.3 mm-40 -92.31 148.74 21.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.499 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.454 ' CG ' HG22 ' A' ' 57' ' ' VAL . 37.5 mt-10 -68.42 109.56 3.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.243 0.544 . . . . 0.0 110.856 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.474 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 105.33 28.87 5.32 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.001 -178.306 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 12' ' ' GLU . 8.4 mm-40 -87.04 160.03 18.75 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 175.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.516 HG22 ' HG3' ' A' ' 53' ' ' LYS . 46.5 t -139.02 115.48 10.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.673 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.406 ' CE2' HD11 ' A' ' 52' ' ' ILE . 37.4 p90 -151.25 142.92 23.69 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.404 178.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.608 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 3.7 p-10 -84.47 137.04 33.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.26 0.552 . . . . 0.0 110.446 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 18.2 m -134.63 160.55 41.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.026 -176.128 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.5 m -103.52 125.92 50.36 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 169.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.558 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.4 mm -67.41 114.38 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -95.75 -32.67 12.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.122 -170.296 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -140.62 165.9 26.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.639 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.552 HD13 ' HA2' ' A' ' 30' ' ' GLY . 43.5 mm -129.79 133.75 64.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.535 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . . . . . . 0 C--N 1.319 -0.756 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -175.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.551 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 38.9 m-20 . . . . . 0 C--O 1.236 0.376 0 CA-C-O 120.692 0.282 . . . . 0.0 110.523 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.552 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -89.97 150.64 21.13 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.813 -176.073 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.535 HD11 ' HB2' ' A' ' 25' ' ' ALA . 43.0 mm -111.0 117.3 54.69 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.161 0.505 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -119.28 102.94 9.06 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.369 -0.832 . . . . 0.0 108.815 172.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 25.0 ptt85 -107.07 114.84 29.16 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.98 0.419 . . . . 0.0 111.444 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.521 HG22 ' HG3' ' A' ' 35' ' ' GLU . 41.6 mt -99.36 119.51 47.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.996 177.172 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.521 ' HG3' HG22 ' A' ' 34' ' ' ILE . 32.9 mt-10 62.23 26.06 15.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.994 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.65 -19.82 53.1 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.197 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.426 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 58.8 t80 -72.06 108.84 5.48 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 HG23 ' A' ' 31' ' ' ILE . 59.3 t -76.14 124.18 33.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.106 0.479 . . . . 0.0 111.526 -175.32 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.572 HG12 ' HB3' ' A' ' 62' ' ' ALA . 63.7 mt -118.77 129.77 74.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.187 -0.46 . . . . 0.0 109.885 176.725 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -92.38 124.66 36.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.736 -177.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.414 ' HA ' ' HD2' ' A' ' 42' ' ' PRO . 38.8 t -111.13 109.15 57.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.819 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.551 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 13.6 Cg_endo -57.24 119.62 6.99 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 122.953 2.435 . . . . 0.0 113.191 -175.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 63.58 74.13 0.47 Allowed Glycine 0 CA--C 1.519 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.862 175.121 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.558 ' HB ' HG13 ' A' ' 21' ' ' ILE . 1.2 p -143.33 161.52 38.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.802 0.334 . . . . 0.0 110.918 176.824 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 tptm -120.09 151.95 38.3 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.058 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.456 HG23 HG12 ' A' ' 24' ' ' ILE . 80.6 t -60.11 126.17 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 176.753 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 103.51 -5.07 47.8 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.893 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.81 107.83 4.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.915 0.388 . . . . 0.0 110.601 174.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -87.94 96.17 10.39 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 173.087 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.519 ' HB ' HG23 ' A' ' 66' ' ' VAL . 19.1 m -134.48 147.79 29.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -169.587 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.608 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 0.2 OUTLIER -79.38 120.15 23.41 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.595 174.76 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.406 HD11 ' CE2' ' A' ' 17' ' ' TYR . 2.7 pp -116.88 141.16 36.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.552 178.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.516 ' HG3' HG22 ' A' ' 16' ' ' VAL . 78.4 tttt -101.57 114.72 29.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 172.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.6 t -69.25 99.13 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 173.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -88.52 -37.53 15.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.085 -169.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -150.47 130.99 13.87 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -174.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.454 HG22 ' CG ' ' A' ' 13' ' ' GLU . 26.9 m -112.69 139.24 38.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.17 0.509 . . . . 0.0 111.662 -177.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -118.28 154.31 51.9 Favored Pre-proline 0 C--N 1.322 -0.627 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 170.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.03 -19.57 26.91 Favored 'Trans proline' 0 CA--C 1.533 0.45 0 C-N-CA 122.634 2.222 . . . . 0.0 113.654 -177.142 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -105.99 -26.32 11.71 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -168.71 163.75 12.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.426 0.155 . . . . 0.0 110.59 -172.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.572 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -129.88 159.39 36.76 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.117 0.484 . . . . 0.0 111.755 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -105.92 127.82 53.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.565 174.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -141.23 126.89 19.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 11.6 t -100.55 145.92 27.74 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.261 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.519 HG23 ' HB ' ' A' ' 50' ' ' VAL . 4.0 p -82.38 116.67 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.681 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 25.5 m -101.79 4.61 10.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.621 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.542 ' OXT' ' HB2' ' A' ' 51' ' ' ARG . 43.6 mt-10 . . . . . 0 C--O 1.247 0.922 0 CA-C-N 114.254 -1.339 . . . . 0.0 112.361 177.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 CA--C 1.53 0.29 0 N-CA-C 113.535 0.552 . . . . 0.0 113.535 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.2 m -122.23 148.23 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.91 0.386 . . . . 0.0 111.459 -175.213 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.8 mm-40 -102.33 161.88 13.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.327 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.458 ' HG3' HG22 ' A' ' 57' ' ' VAL . 3.5 mp0 -65.98 119.64 11.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.266 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.3 18.7 27.89 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 116.029 -0.532 . . . . 0.0 113.153 173.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 33.0 mt-10 -92.61 166.59 12.42 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.036 -176.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.14 127.11 60.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.954 0.407 . . . . 0.0 110.216 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -129.98 140.81 50.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.764 -176.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -79.97 90.38 5.36 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 171.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.3 m -104.73 148.77 8.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.395 0.616 . . . . 0.0 111.72 -172.073 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.63 HG23 ' HG2' ' A' ' 49' ' ' GLU . 24.6 m -101.72 124.91 48.15 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.318 173.56 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.538 HG13 ' HB ' ' A' ' 44' ' ' THR . 43.6 mm -70.33 89.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.3 mt-30 -81.93 -33.1 30.51 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.859 -175.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -128.84 170.67 13.09 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.655 179.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.455 ' HB ' ' CG2' ' A' ' 46' ' ' VAL . 8.4 tt -147.73 150.46 14.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.838 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.936 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.557 -178.903 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.616 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 56.7 m-20 . . . . . 0 C--O 1.236 0.387 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.416 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -74.21 141.37 28.89 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.901 -0.591 . . . . 0.0 113.003 -171.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.539 HG23 HG13 ' A' ' 38' ' ' VAL . 47.9 mm -107.73 104.52 17.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.137 0.494 . . . . 0.0 110.154 178.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -97.53 97.02 8.71 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.636 175.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 29.7 ptt85 -96.05 94.51 7.6 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.289 0.566 . . . . 0.0 111.394 -175.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 55.1 mt -86.51 113.47 24.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.99 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.2 mm-40 54.98 24.34 5.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.729 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.52 -17.99 51.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 35.1 t80 -75.95 121.74 23.15 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.539 HG13 HG23 ' A' ' 31' ' ' ILE . 57.9 t -83.35 121.66 36.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.197 0.523 . . . . 0.0 112.079 -173.308 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.571 HG12 ' HB3' ' A' ' 62' ' ' ALA . 48.2 mt -116.61 126.92 74.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.548 174.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -91.22 125.22 35.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.825 0.345 . . . . 0.0 111.136 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.4 t -119.45 111.79 36.19 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.669 176.108 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.616 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 45.8 Cg_endo -68.65 114.72 3.61 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 122.631 2.22 . . . . 0.0 113.659 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.53 0.35 58.0 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.805 -0.712 . . . . 0.0 114.738 170.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.538 ' HB ' HG13 ' A' ' 21' ' ' ILE . 16.7 p -89.12 138.41 31.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 118.09 0.945 . . . . 0.0 111.936 -177.257 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -92.28 155.5 17.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.967 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.455 ' CG2' ' HB ' ' A' ' 24' ' ' ILE . 96.9 t -64.4 128.56 27.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-O 121.069 0.461 . . . . 0.0 110.962 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.66 -17.72 42.11 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.214 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.09 115.08 9.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.952 0.406 . . . . 0.0 110.446 178.366 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.63 ' HG2' HG23 ' A' ' 20' ' ' THR . 37.2 mt-10 -97.6 97.83 9.38 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.315 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.9 167.29 23.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.799 -173.04 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 60.3 mtt180 -100.25 120.81 40.48 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.13 0.491 . . . . 0.0 109.885 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 47.7 pt -113.25 144.6 20.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.394 -178.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 46.0 tttp -99.21 108.71 21.36 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.023 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.8 t -68.94 98.4 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.06 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -86.38 -35.3 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.478 -171.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -141.56 139.5 33.2 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.802 -174.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.458 HG22 ' HG3' ' A' ' 13' ' ' GLU . 15.4 m -123.23 115.51 45.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.4 0.619 . . . . 0.0 110.54 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -97.65 155.05 37.65 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.63 -6.96 8.05 Favored 'Trans proline' 0 CA--C 1.531 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 113.304 -178.054 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.446 ' NZ ' ' HB2' ' A' ' 60' ' ' LYS . 5.0 ttmp? -111.25 -30.72 7.33 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.056 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -170.86 167.48 7.48 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.365 -175.461 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.571 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -110.28 156.21 21.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.913 0.387 . . . . 0.0 110.946 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -123.87 136.43 54.36 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 178.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.99 148.61 43.7 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.064 0.459 . . . . 0.0 111.461 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 p -105.82 130.17 53.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.745 174.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.769 HG22 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -77.06 130.51 36.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.056 0.455 . . . . 0.0 110.764 -176.67 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.5 m -108.24 22.25 4.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.099 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.769 ' H ' HG22 ' A' ' 66' ' ' VAL . 26.5 mm-40 . . . . . 0 C--O 1.246 0.909 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.543 -177.351 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo . . . . . 0 N--CA 1.456 -0.7 0 N-CA-C 113.316 0.468 . . . . 0.0 113.316 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.1 m -116.67 156.38 17.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.667 0.27 . . . . 0.0 111.001 -175.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -129.1 157.69 41.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.231 -0.441 . . . . 0.0 109.933 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.43 ' HB3' ' HA ' ' A' ' 56' ' ' ARG . 8.8 pt-20 -67.03 127.67 33.47 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.135 0.493 . . . . 0.0 110.978 176.206 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.68 29.45 7.35 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.988 -178.042 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -115.04 170.43 8.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.47 125.35 16.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.182 0.515 . . . . 0.0 110.48 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -136.15 151.51 49.84 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.432 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -91.86 126.52 36.97 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 170.869 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.9 m -140.48 153.79 21.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.003 0.43 . . . . 0.0 111.552 -174.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -106.75 121.82 45.14 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 171.031 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.558 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.3 mm -68.95 116.02 8.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 120.886 0.374 . . . . 0.0 110.566 -177.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.86 -54.53 5.52 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.227 -175.263 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 47.0 t0 -128.4 176.27 7.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.957 -176.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.554 HD13 ' HA2' ' A' ' 30' ' ' GLY . 43.6 mm -134.36 139.05 48.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.028 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.741 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -175.41 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.634 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 1.8 m-20 . . . . . 0 CA--C 1.517 -0.313 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.554 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -78.75 146.48 29.85 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.25 179.164 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 23' ' ' ASP . 50.9 mm -104.52 99.7 8.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.993 0.425 . . . . 0.0 110.457 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -127.22 110.74 13.19 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.591 175.359 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.573 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 23.7 ptt180 -108.64 139.49 43.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.216 0.531 . . . . 0.0 111.295 -176.452 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 61.6 mt -122.03 119.04 57.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.714 175.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.6 mm-40 58.24 32.54 22.17 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.822 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.14 -31.72 7.4 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.739 179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.404 ' HE2' ' HB2' ' A' ' 62' ' ' ALA . 20.0 t80 -76.14 110.16 10.4 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.93 0.395 . . . . 0.0 110.058 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' A' ' 33' ' ' ARG . 7.2 p -84.7 134.64 26.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.182 0.515 . . . . 0.0 111.753 -174.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.537 HG12 ' HB3' ' A' ' 62' ' ' ALA . 51.5 mt -107.99 126.43 64.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.754 176.331 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -92.95 122.35 35.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.524 178.219 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.537 HG21 HG21 ' A' ' 52' ' ' ILE . 28.2 t -124.41 95.27 43.52 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.176 -0.466 . . . . 0.0 109.808 178.349 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.634 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 43.3 Cg_endo -68.15 122.19 9.24 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.851 2.367 . . . . 0.0 112.989 -177.279 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.21 27.9 4.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.34 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.558 ' HB ' HG13 ' A' ' 21' ' ' ILE . 17.3 p -118.99 164.34 15.62 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.991 0.424 . . . . 0.0 111.197 -179.522 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 48' ' ' ASP . 17.7 tptp -116.21 164.03 15.1 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.785 177.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 61.9 t -65.08 120.5 12.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 177.169 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.91 62.13 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.01 -178.285 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.513 ' HB2' ' O ' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -69.25 107.92 3.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.754 0.311 . . . . 0.0 110.604 176.943 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -92.56 100.45 12.98 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 175.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.4 m -135.89 160.07 39.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.256 0.551 . . . . 0.0 112.131 -172.598 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -91.66 119.48 31.58 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.524 172.1 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.537 HG21 HG21 ' A' ' 41' ' ' VAL . 47.6 pt -108.74 139.53 30.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.296 0.569 . . . . 0.0 111.566 -175.492 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 50.3 tptt -99.26 106.04 18.13 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.516 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 58.1 t -68.9 113.42 4.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -90.57 -37.23 13.97 Favored 'General case' 0 C--N 1.323 -0.552 0 O-C-N 123.609 0.568 . . . . 0.0 110.911 -174.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.43 ' HA ' ' HB3' ' A' ' 13' ' ' GLU . 73.0 mtp180 -143.07 155.75 44.68 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.976 0.417 . . . . 0.0 111.371 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 54.6 t -126.17 125.71 68.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.973 174.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.575 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 5.8 mp -114.01 162.16 24.34 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.575 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 40.4 Cg_exo -36.77 -44.35 1.05 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.347 3.365 . . . . 0.0 115.686 -174.188 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.601 ' HG3' ' HD1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.74 14.47 5.37 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -175.299 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.601 ' HD1' ' HG3' ' A' ' 60' ' ' LYS . 46.9 p90 -169.25 149.47 4.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.938 0.399 . . . . 0.0 111.19 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.537 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -107.16 165.52 11.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.655 179.204 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -128.17 122.33 31.65 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.516 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -139.79 164.38 30.12 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.824 0.345 . . . . 0.0 111.508 -176.02 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 9.5 p -133.98 158.82 42.53 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.371 176.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.9 t -83.86 115.51 26.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.786 0.327 . . . . 0.0 110.424 -177.725 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.7 m -118.24 3.34 7.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.016 0.436 . . . . 0.0 110.937 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 . . . . . 0 C--O 1.245 0.85 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.581 -174.027 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo . . . . . 0 N--CA 1.476 0.463 0 N-CA-C 113.999 0.73 . . . . 0.0 113.999 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.557 ' HB ' HG21 ' A' ' 54' ' ' VAL . 24.5 m -135.13 132.5 52.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -118.77 170.75 8.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.245 0.545 . . . . 0.0 111.748 -177.114 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.47 ' HG3' HG22 ' A' ' 57' ' ' VAL . 28.2 mt-10 -65.6 116.98 7.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.196 -0.911 . . . . 0.0 112.355 -172.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.551 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 94.17 31.69 7.89 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.389 171.236 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -122.77 153.71 39.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.209 -0.597 . . . . 0.0 110.771 178.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 3.9 p -110.45 133.1 56.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.403 -178.106 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -132.38 150.79 52.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.046 -177.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -94.29 107.58 19.52 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 176.258 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.436 HG12 HD11 ' A' ' 34' ' ' ILE . 29.4 m -118.47 166.65 12.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.531 0.681 . . . . 0.0 111.834 -171.582 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.9 m -131.38 127.52 37.74 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.358 174.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.517 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.5 mm -69.0 125.07 26.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.78 -174.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 mm-40 -98.83 -41.52 7.6 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.398 -175.523 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.405 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 26.3 m-20 -133.77 173.66 11.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.771 0.319 . . . . 0.0 111.144 -177.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.453 HG12 HG23 ' A' ' 46' ' ' VAL . 45.5 mm -122.36 134.11 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.327 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.616 ' HB3' ' HB3' ' A' ' 29' ' ' ASP . . . . . . . . 0 C--N 1.323 -0.562 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.363 -179.117 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.616 ' HB3' ' HB3' ' A' ' 25' ' ' ALA . 13.5 t70 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.583 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -96.19 112.63 4.47 Favored Glycine 0 N--CA 1.439 -1.158 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 177.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.518 HG23 HG13 ' A' ' 38' ' ' VAL . 74.7 mt -79.14 103.39 6.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.283 0.563 . . . . 0.0 110.71 -175.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.508 ' HB2' HD13 ' A' ' 21' ' ' ILE . . . -105.48 116.43 31.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.221 175.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 25.1 ptt180 -107.5 136.59 47.01 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.476 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.436 HD11 HG12 ' A' ' 19' ' ' VAL . 56.7 mt -124.48 118.25 52.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.608 174.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 59.42 26.94 15.94 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.743 -179.438 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.08 -22.63 39.88 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.762 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -75.55 130.65 39.18 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.518 HG13 HG23 ' A' ' 31' ' ' ILE . 61.9 t -86.26 122.11 38.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.171 0.51 . . . . 0.0 111.689 -175.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.45 HD11 HG11 ' A' ' 11' ' ' VAL . 46.1 mt -115.1 133.4 61.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.182 174.749 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.455 ' HB3' ' OD2' ' A' ' 29' ' ' ASP . 98.1 m-85 -98.14 130.05 44.91 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.974 0.416 . . . . 0.0 111.206 -177.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 41.6 t -130.34 93.5 32.64 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.862 178.723 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.521 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 26.1 Cg_exo -62.66 129.16 25.45 Favored 'Trans proline' 0 CA--C 1.528 0.221 0 C-N-CA 123.095 2.53 . . . . 0.0 113.333 -174.35 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.44 50.53 3.36 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.609 174.44 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.583 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 11.1 p -139.72 -178.57 5.48 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.643 -0.327 . . . . 0.0 110.768 177.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.543 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 4.9 ttpm? -133.93 153.69 51.59 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.453 HG23 HG12 ' A' ' 24' ' ' ILE . 38.5 t -58.37 117.0 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 175.048 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.97 -16.44 18.22 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.379 -177.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.543 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.1 m-20 -67.7 115.82 7.7 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.95 178.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.23 90.87 4.49 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.69 174.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.4 m -120.86 169.14 12.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.153 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 64.0 mtp180 -102.07 128.36 48.56 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.035 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.478 HG22 ' HA ' ' A' ' 66' ' ' VAL . 2.8 pp -127.02 150.29 32.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.204 -176.513 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.551 ' HE2' ' HA2' ' A' ' 14' ' ' GLY . 69.6 tttt -106.07 118.78 37.52 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 172.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.557 HG21 ' HB ' ' A' ' 11' ' ' VAL . 87.1 t -69.27 106.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 171.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 13.5 tp10 -84.87 -36.19 21.71 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.294 -170.178 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 56' ' ' ARG . 7.4 ptp85 -156.44 150.07 24.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.293 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.47 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.1 m -121.25 138.92 50.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.098 0.475 . . . . 0.0 110.925 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.7 mp -110.57 157.89 37.04 Favored Pre-proline 0 C--N 1.319 -0.76 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 174.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -58.89 -1.46 0.8 Allowed 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.162 2.575 . . . . 0.0 114.68 -176.654 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.4 -16.8 2.36 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -169.03 161.08 10.38 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.605 0.241 . . . . 0.0 110.838 -176.026 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -115.04 152.18 32.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.89 0.376 . . . . 0.0 111.515 -177.33 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.4 t80 -112.14 129.02 56.38 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.416 178.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -128.58 149.52 50.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.313 0.578 . . . . 0.0 111.889 -177.062 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.3 t -109.74 136.02 49.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.166 175.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.567 HG22 ' H ' ' A' ' 68' ' ' GLU . 6.9 p -82.47 123.23 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.333 0.587 . . . . 0.0 111.063 -176.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.5 m -107.45 28.43 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.567 ' H ' HG22 ' A' ' 66' ' ' VAL . 41.8 mt-10 . . . . . 0 C--O 1.251 1.152 0 CA-C-N 115.073 -0.967 . . . . 0.0 111.256 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo . . . . . 0 N--CA 1.465 -0.169 0 CA-C-O 121.21 0.421 . . . . 0.0 111.234 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.9 m -132.42 151.75 35.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.24 177.478 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.21 155.66 41.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.036 0.446 . . . . 0.0 110.95 -177.302 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -66.42 122.52 17.72 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.355 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.71 21.46 33.92 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.957 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -113.76 164.1 14.17 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.755 0.312 . . . . 0.0 110.369 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.694 ' HB ' ' HE3' ' A' ' 53' ' ' LYS . 14.9 p -129.92 131.85 66.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 120.92 0.39 . . . . 0.0 110.373 -176.176 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -135.96 154.66 51.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.389 -176.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -93.36 123.61 36.77 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 31.9 m -133.37 156.64 42.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.177 0.513 . . . . 0.0 111.709 -173.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.553 HG23 ' HG2' ' A' ' 49' ' ' GLU . 61.0 m -113.16 124.62 52.99 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.248 -0.887 . . . . 0.0 109.622 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.557 HG13 ' HB ' ' A' ' 44' ' ' THR . 48.7 mm -70.41 95.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -86.61 -33.91 20.02 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.315 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.429 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 20.3 t70 -126.73 163.73 22.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.537 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.493 HG13 ' HA2' ' A' ' 30' ' ' GLY . 7.5 tt -141.48 132.19 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 174.235 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.957 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.428 -175.949 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 . . . . . 0 C--O 1.235 0.318 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.493 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -68.29 133.83 28.59 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.156 -175.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.49 HG23 HG23 ' A' ' 38' ' ' VAL . 48.0 mm -106.68 109.97 29.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.325 0.584 . . . . 0.0 110.583 -178.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.499 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -101.4 149.77 23.72 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.381 175.124 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 33' ' ' ARG . 1.2 ptm180 -138.37 113.79 9.57 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.98 0.419 . . . . 0.0 110.929 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.0 mt -104.48 105.75 19.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.991 176.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 51.57 27.67 4.09 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.686 -1.143 . . . . 0.0 112.131 -178.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 118.45 -31.81 5.45 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.756 -0.735 . . . . 0.0 113.025 177.076 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.402 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 12.5 t80 -75.51 125.42 28.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.843 0.354 . . . . 0.0 110.252 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.49 HG23 HG23 ' A' ' 31' ' ' ILE . 7.0 p -88.75 135.38 25.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.287 0.565 . . . . 0.0 111.551 -176.213 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.558 HG12 ' HB3' ' A' ' 62' ' ' ALA . 42.7 mt -124.29 132.13 71.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.943 178.852 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -93.17 119.63 32.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.81 0.338 . . . . 0.0 110.576 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.39 100.09 45.06 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.963 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.48 127.36 17.95 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 123.226 2.618 . . . . 0.0 113.118 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.85 -9.13 55.04 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.83 173.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.557 ' HB ' HG13 ' A' ' 21' ' ' ILE . 25.8 p -89.12 156.13 19.01 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 117.355 0.578 . . . . 0.0 111.669 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -111.4 157.61 20.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.764 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 88.1 t -58.99 124.12 12.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.281 177.856 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 108.44 -13.1 36.31 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.512 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -68.84 117.32 10.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.119 0.485 . . . . 0.0 110.966 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.553 ' HG2' HG23 ' A' ' 20' ' ' THR . 44.3 mt-10 -106.64 97.03 6.87 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.636 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.86 173.74 14.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.063 -173.213 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.9 mtp85 -103.23 126.49 50.43 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.75 177.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.1 pt -116.17 143.35 26.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.326 -175.469 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.694 ' HE3' ' HB ' ' A' ' 16' ' ' VAL . 0.9 OUTLIER -97.87 102.84 14.7 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.122 175.824 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.524 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 55.9 t -69.35 108.45 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.56 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.22 -26.41 17.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.738 -173.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 37.8 ttt180 -154.92 144.91 21.72 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.823 0.344 . . . . 0.0 110.731 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 35.7 m -110.19 141.7 24.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.122 175.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.532 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 3.1 mm? -115.59 160.45 34.68 Favored Pre-proline 0 C--N 1.32 -0.687 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.532 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 9.8 Cg_endo -52.69 -28.41 37.5 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.122 2.548 . . . . 0.0 114.177 -175.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -121.79 -2.96 9.24 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -175.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -169.58 162.62 10.01 Favored 'General case' 0 C--O 1.222 -0.382 0 CA-C-N 117.76 0.254 . . . . 0.0 110.941 -175.721 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.558 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -113.87 157.47 22.31 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.685 0.279 . . . . 0.0 110.569 177.726 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -123.2 129.0 50.8 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.524 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -146.69 158.5 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.353 . . . . 0.0 111.677 -176.018 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.2 p -115.73 160.08 20.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.551 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 68' ' ' GLU . 41.4 t -81.62 123.98 38.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.329 -176.771 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.45 33.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.15 0.5 . . . . 0.0 110.539 179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.435 ' H ' HG12 ' A' ' 66' ' ' VAL . 45.9 tt0 . . . . . 0 C--O 1.25 1.116 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.419 177.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo . . . . . 0 N--CA 1.463 -0.29 0 CA-C-O 120.554 0.148 . . . . 0.0 112.338 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.475 HG11 HD11 ' A' ' 39' ' ' ILE . 30.3 m -136.63 156.25 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.786 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.576 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.8 pt-20 -133.24 160.45 37.25 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.42 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.44 ' CG ' HG22 ' A' ' 57' ' ' VAL . 39.3 mt-10 -66.83 132.87 48.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.13 0.49 . . . . 0.0 112.15 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.489 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 77.75 36.14 33.82 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.205 -0.907 . . . . 0.0 112.997 174.387 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.589 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 19.6 mm-40 -125.03 164.62 19.78 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-O 120.791 0.329 . . . . 0.0 111.011 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 55.0 t -121.81 122.99 68.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.719 -174.774 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 41.9 m-85 -125.89 145.87 50.07 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.86 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -90.92 95.75 10.28 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.517 0.675 . . . . 0.0 109.244 171.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 49' ' ' GLU . 28.5 m -104.76 161.29 4.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.514 -171.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.8 m -110.58 119.57 39.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.041 175.405 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.478 HD13 ' HB2' ' A' ' 32' ' ' ALA . 47.7 mm -69.7 106.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 175.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -97.84 -22.13 16.54 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.286 -173.634 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.541 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 29.3 t70 -142.88 164.28 30.53 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.895 -0.322 . . . . 0.0 111.263 -174.131 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.431 HG12 HG23 ' A' ' 46' ' ' VAL . 48.5 mm -124.49 131.94 72.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.473 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . . . . . . 0 C--N 1.319 -0.752 0 CA-C-O 121.382 0.611 . . . . 0.0 111.548 -174.229 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.562 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 47.7 m-20 . . . . . 0 CA--C 1.517 -0.307 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.605 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -79.13 137.74 19.64 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.791 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.578 HG22 ' HD3' ' A' ' 33' ' ' ARG . 48.3 mm -108.57 114.26 46.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.271 0.558 . . . . 0.0 110.778 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.478 ' HB2' HD13 ' A' ' 21' ' ' ILE . . . -109.54 112.4 24.47 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.805 176.397 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.661 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 0.6 OUTLIER -97.78 115.02 27.19 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.519 178.448 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 31.8 mt -93.81 107.96 19.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 172.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 55.42 21.92 4.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.701 -1.136 . . . . 0.0 111.921 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.64 -26.69 8.35 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.773 -0.727 . . . . 0.0 113.244 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.661 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 53.5 t80 -69.6 128.04 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.965 0.382 . . . . 0.0 110.715 -176.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.519 HG13 HG23 ' A' ' 31' ' ' ILE . 60.8 t -85.62 116.04 28.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.737 -174.226 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.475 HD11 HG11 ' A' ' 11' ' ' VAL . 54.0 mt -111.41 133.13 58.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.914 174.228 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -94.05 122.94 37.08 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.013 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' A' ' 64' ' ' ALA . 43.9 t -127.67 91.52 45.28 Favored Pre-proline 0 C--N 1.326 -0.434 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 38.4 Cg_exo -60.22 121.27 9.52 Favored 'Trans proline' 0 CA--C 1.528 0.192 0 C-N-CA 122.873 2.382 . . . . 0.0 113.033 -175.092 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.63 60.8 1.33 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.073 175.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.605 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 1.3 p -143.35 175.22 10.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 117.006 0.403 . . . . 0.0 110.72 176.701 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -129.86 150.09 51.31 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -178.282 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.431 HG23 HG12 ' A' ' 24' ' ' ILE . 67.4 t -58.82 116.62 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.881 0.372 . . . . 0.0 110.85 177.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.85 -9.27 14.32 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.227 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -71.98 105.4 3.86 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.821 0.343 . . . . 0.0 111.556 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 47.1 mt-10 -88.45 97.7 11.22 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 168.417 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.595 ' HA ' ' HG3' ' A' ' 68' ' ' GLU . 16.3 m -128.2 151.98 35.71 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.922 -0.581 . . . . 0.0 112.031 -172.605 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.428 ' H ' ' CG ' ' A' ' 68' ' ' GLU . 25.1 mmt180 -79.64 128.93 34.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.852 172.286 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 2.7 pp -134.57 147.16 29.94 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.706 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 47.6 tttp -102.66 111.74 24.19 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 173.77 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.2 t -67.75 112.91 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 175.414 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -92.06 -33.19 14.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.912 -169.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -156.45 130.12 8.31 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.997 -172.59 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.44 HG22 ' CG ' ' A' ' 13' ' ' GLU . 34.3 m -114.42 139.45 40.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.323 0.582 . . . . 0.0 111.198 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 96.9 mt -123.64 153.67 66.49 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 173.242 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.47 -16.6 14.47 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.722 2.282 . . . . 0.0 113.46 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 55.9 tptt -100.92 -34.7 9.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.553 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -170.18 173.52 5.8 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.453 -0.202 . . . . 0.0 110.453 -174.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -133.42 159.64 39.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.889 0.376 . . . . 0.0 111.633 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 39.1 m-85 -108.59 152.44 24.77 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.398 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.456 ' HB1' ' HB ' ' A' ' 52' ' ' ILE . . . -142.45 142.45 32.33 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.162 0.506 . . . . 0.0 111.742 177.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 42.2 m -94.34 139.3 31.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.477 174.454 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.6 t -81.64 118.25 29.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.653 0.263 . . . . 0.0 110.651 -178.041 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.8 m -118.17 20.16 6.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.172 0.511 . . . . 0.0 110.679 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.595 ' HG3' ' HA ' ' A' ' 50' ' ' VAL . 1.1 tm-20 . . . . . 0 C--O 1.244 0.783 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.212 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.473 ' HB2' HG22 ' A' ' 34' ' ' ILE . 73.0 Cg_endo . . . . . 0 C--O 1.234 0.315 0 N-CA-C 113.037 0.36 . . . . 0.0 113.037 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' HG21 ' A' ' 54' ' ' VAL . 19.4 m -131.33 143.7 39.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.745 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -121.58 148.9 43.92 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.681 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.481 ' CG ' HG22 ' A' ' 57' ' ' VAL . 44.1 mt-10 -66.31 129.46 39.89 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.315 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.65 27.17 30.3 Favored Glycine 0 N--CA 1.445 -0.767 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.917 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 72.0 mm-40 -124.05 156.44 36.54 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.256 0.55 . . . . 0.0 111.894 -177.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 57.0 t -113.83 130.65 67.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.149 -175.435 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -132.04 150.82 52.05 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.246 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.85 109.52 21.5 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.526 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.86 144.63 36.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.424 0.63 . . . . 0.0 112.15 -174.34 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.0 m -96.14 139.64 32.01 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 169.527 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.603 HG13 ' HB ' ' A' ' 44' ' ' THR . 45.8 mm -81.1 124.86 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.591 0.234 . . . . 0.0 110.972 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.464 ' OE1' ' HG2' ' A' ' 33' ' ' ARG . 2.3 mp0 -75.47 -56.33 4.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.979 -177.602 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -140.28 -179.41 5.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.15 -177.46 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.0 mm -123.7 127.45 73.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.315 -0.914 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.724 179.074 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 . . . . . 0 CA--C 1.517 -0.322 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.51 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -91.86 144.92 17.43 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.796 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 70.2 mt -100.87 109.84 26.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.952 0.406 . . . . 0.0 110.406 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -111.58 163.43 14.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.447 175.298 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.464 ' HG2' ' OE1' ' A' ' 22' ' ' GLN . 31.5 ptt180 -144.68 132.88 21.66 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.704 0.288 . . . . 0.0 110.822 -178.638 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.473 HG22 ' HB2' ' A' ' 10' ' ' PRO . 49.6 mt -129.06 117.82 44.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.18 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.29 26.82 14.41 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.953 0.882 . . . . 0.0 109.923 -175.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.36 -15.0 63.25 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.639 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.55 ' CE2' ' HB2' ' A' ' 62' ' ' ALA . 14.7 t80 -75.31 119.93 20.08 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.3 t -78.04 128.93 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.234 0.54 . . . . 0.0 111.382 -173.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.534 HG12 ' HB3' ' A' ' 62' ' ' ALA . 24.6 mt -120.11 129.72 75.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.797 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -101.54 125.24 48.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.857 0.36 . . . . 0.0 110.803 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.0 t -122.94 108.33 32.69 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.359 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.12 126.84 21.3 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 123.213 2.608 . . . . 0.0 113.184 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 64.39 2.25 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.066 -0.587 . . . . 0.0 113.384 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.603 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.4 p -134.88 -172.24 2.99 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 176.448 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.459 ' HB3' ' HB2' ' A' ' 48' ' ' ASP . 36.7 ttpt -142.69 153.91 43.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.418 0.151 . . . . 0.0 110.871 -175.801 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.03 120.6 5.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.74 0.305 . . . . 0.0 111.113 179.176 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.7 4.35 90.27 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.602 177.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.459 ' HB2' ' HB3' ' A' ' 45' ' ' LYS . 40.3 t0 -75.87 122.67 24.47 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.3 106.49 18.26 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.087 0.47 . . . . 0.0 110.02 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.68 146.82 33.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.379 0.609 . . . . 0.0 111.333 -175.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -97.97 117.57 32.62 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 176.325 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.488 HG22 ' HA ' ' A' ' 66' ' ' VAL . 44.5 pt -116.27 155.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.475 -170.55 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.504 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 34.9 ttmt -105.37 118.09 35.67 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.459 HG21 ' HB ' ' A' ' 11' ' ' VAL . 90.2 t -69.19 118.35 13.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 174.34 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -92.84 -45.79 7.83 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.348 1.03 . . . . 0.0 111.217 -175.398 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 33.2 mtt180 -135.93 144.0 45.23 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.378 -172.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.481 HG22 ' CG ' ' A' ' 13' ' ' GLU . 27.6 m -124.7 116.05 46.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.698 0.761 . . . . 0.0 110.497 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.432 ' C ' ' H ' ' A' ' 60' ' ' LYS . 5.8 mp -112.94 152.22 44.72 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.619 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.13 11.0 0.28 Allowed 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 122.745 2.297 . . . . 0.0 112.481 177.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.432 ' H ' ' C ' ' A' ' 58' ' ' LEU . 56.9 mttm -118.51 -31.78 4.8 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.612 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -177.84 170.25 1.94 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.923 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.55 ' HB2' ' CE2' ' A' ' 37' ' ' PHE . . . -108.75 146.96 32.73 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.808 0.337 . . . . 0.0 110.533 176.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 53.4 t80 -122.0 123.68 42.21 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -134.85 152.02 51.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.873 -176.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 20.9 t -113.48 146.6 39.33 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.52 HG22 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -81.65 117.52 27.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.361 0.601 . . . . 0.0 111.126 -176.361 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.9 p -96.52 8.85 6.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.938 0.875 . . . . 0.0 108.993 178.304 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.52 ' H ' HG22 ' A' ' 66' ' ' VAL . 25.7 tt0 . . . . . 0 C--O 1.251 1.146 0 CA-C-N 113.334 -1.757 . . . . 0.0 111.268 177.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo . . . . . 0 C--O 1.231 0.149 0 CA-C-O 120.905 0.294 . . . . 0.0 112.177 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.5 162.06 37.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.48 -178.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.545 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.0 pt-20 -130.96 156.41 45.15 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.429 178.445 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.4 ' CD ' HH21 ' A' ' 56' ' ' ARG . 56.1 mt-10 -66.46 133.61 50.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.355 -174.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.91 31.08 33.27 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.688 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.545 ' HG3' ' HG3' ' A' ' 12' ' ' GLU . 58.8 mm-40 -127.17 155.86 42.72 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.556 -0.457 . . . . 0.0 110.912 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 7.1 p -118.66 128.23 75.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.09 -174.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.8 m-85 -125.95 132.43 52.08 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.793 -178.579 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 30.2 t70 -81.61 97.0 7.66 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 175.473 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.9 m -111.99 170.45 3.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.392 0.615 . . . . 0.0 111.663 -170.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 49' ' ' GLU . 26.0 m -120.51 128.73 53.39 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.111 171.508 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.587 HG13 ' HB ' ' A' ' 44' ' ' THR . 49.9 mm -68.48 116.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.168 0.508 . . . . 0.0 110.707 -175.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm-40 -84.29 -40.55 17.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.608 -173.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -143.33 179.55 7.02 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -177.332 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.551 HD13 ' HA2' ' A' ' 30' ' ' GLY . 32.0 mm -137.06 119.21 19.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.42 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . . . . . . 0 C--N 1.317 -0.838 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.943 178.172 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.813 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 6.6 m-20 . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.551 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -72.27 127.75 12.85 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.512 178.572 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.57 HG23 HG13 ' A' ' 38' ' ' VAL . 73.5 mt -95.52 106.49 18.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.339 0.59 . . . . 0.0 111.385 -176.047 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -96.69 94.65 7.43 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 170.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.463 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 9.9 ptm180 -93.91 98.46 11.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.57 0.7 . . . . 0.0 110.968 -174.465 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 45.1 mt -93.17 111.33 24.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.487 -179.329 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 56.64 26.33 11.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.941 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.53 -20.47 39.47 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.457 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 50.7 t80 -75.59 123.44 25.51 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.57 HG13 HG23 ' A' ' 31' ' ' ILE . 64.7 t -90.0 116.37 31.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.897 -173.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.445 HG12 ' HB3' ' A' ' 62' ' ' ALA . 55.4 mt -109.24 125.66 66.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.648 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -94.19 121.14 35.38 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.969 0.414 . . . . 0.0 111.359 -178.293 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 64' ' ' ALA . 11.0 t -129.53 89.59 46.58 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.126 175.857 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.813 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 32.8 Cg_endo -63.94 137.43 57.69 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.968 2.445 . . . . 0.0 113.239 -175.326 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.38 -10.15 30.87 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.032 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.587 ' HB ' HG13 ' A' ' 21' ' ' ILE . 35.3 p -95.59 -179.62 4.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.522 0.201 . . . . 0.0 110.962 -178.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.533 ' HA ' HD11 ' A' ' 24' ' ' ILE . 34.3 ttmt -142.9 165.29 27.76 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 44.0 t -58.34 118.7 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 CA-C-O 120.664 0.268 . . . . 0.0 111.097 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.94 -5.74 59.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.761 178.323 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.444 ' O ' HG12 ' A' ' 21' ' ' ILE . 29.6 t0 -75.11 112.47 11.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 110.055 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 20' ' ' THR . 8.4 pt-20 -100.29 108.09 20.06 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.743 -178.799 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.0 m -142.15 161.87 19.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.807 -176.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.492 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 66.0 mtm180 -82.95 124.23 30.18 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.796 174.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.6 pt -117.96 136.92 53.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.137 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 56.3 tttm -100.4 114.6 28.27 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.443 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.7 t -69.29 121.19 18.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -94.44 -45.73 7.31 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.209 0.943 . . . . 0.0 110.872 -174.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.4 HH21 ' CD ' ' A' ' 13' ' ' GLU . 1.8 tpm_? -140.68 137.91 33.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.143 -172.336 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 34.4 m -114.78 136.31 51.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.295 0.569 . . . . 0.0 110.858 176.144 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 5.6 mp -123.02 156.19 62.98 Favored Pre-proline 0 C--N 1.321 -0.652 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -58.47 -16.67 30.48 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.848 2.365 . . . . 0.0 113.518 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.2 ttmm -110.35 -22.52 11.67 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -176.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -172.47 172.14 4.44 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.682 0.277 . . . . 0.0 111.0 -174.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.445 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -128.13 157.47 40.69 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.688 0.28 . . . . 0.0 110.984 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -124.61 136.4 53.91 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.518 ' HB3' HG22 ' A' ' 41' ' ' VAL . . . -136.83 163.2 31.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.956 0.407 . . . . 0.0 111.423 -176.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.1 p -117.27 145.0 44.24 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.854 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 40.6 t -78.39 127.19 38.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.131 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.0 m -123.49 13.88 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.743 0.306 . . . . 0.0 110.465 176.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 . . . . . 0 C--O 1.25 1.119 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.504 -179.634 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 CA--C 1.531 0.368 0 N-CA-C 113.343 0.478 . . . . 0.0 113.343 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.79 130.7 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.706 0.289 . . . . 0.0 110.474 179.14 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -113.09 173.7 6.26 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.541 0.686 . . . . 0.0 111.773 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.525 ' OE1' ' HD3' ' A' ' 56' ' ' ARG . 33.5 mt-10 -67.28 126.63 29.84 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.806 -1.088 . . . . 0.0 112.152 -177.082 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.555 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 91.68 16.35 52.31 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.389 -0.823 . . . . 0.0 112.929 174.039 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.569 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 26.2 mt-10 -99.04 160.42 14.27 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.344 -0.542 . . . . 0.0 111.187 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.51 124.34 68.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.208 -179.244 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -128.54 141.05 51.49 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.858 -177.563 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -80.51 97.29 7.08 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.4 m -109.66 148.9 13.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.353 0.597 . . . . 0.0 111.764 -173.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.0 m -110.1 119.09 38.18 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.912 172.405 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.64 HG13 ' HB ' ' A' ' 44' ' ' THR . 41.3 mm -69.64 116.77 11.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.746 -175.502 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -87.17 -51.03 6.22 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.863 -174.538 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.433 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 15.2 m-20 -124.31 -179.26 4.38 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.892 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.603 HD13 ' HA2' ' A' ' 30' ' ' GLY . 39.6 mm -137.82 137.8 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.342 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.584 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . . . . . . 0 C--N 1.312 -1.038 0 CA-C-O 121.912 0.863 . . . . 0.0 109.201 177.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.584 ' HB2' ' HB3' ' A' ' 25' ' ' ALA . 5.1 m-20 . . . . . 0 CA--C 1.519 -0.229 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.603 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -80.21 144.07 25.59 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.294 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.434 HG23 HG13 ' A' ' 38' ' ' VAL . 50.2 mm -105.5 102.69 14.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.105 0.479 . . . . 0.0 110.166 179.607 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.406 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -98.18 147.51 24.52 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 174.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 8.9 ptp85 -138.95 109.43 6.55 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.297 0.57 . . . . 0.0 111.049 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.7 mt -101.65 118.32 48.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 173.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 67.78 -3.1 1.22 Allowed 'General case' 0 CA--C 1.535 0.371 0 O-C-N 124.186 0.929 . . . . 0.0 110.519 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 117.86 -14.49 12.73 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.209 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.474 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 34.8 t80 -74.87 127.76 33.96 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.434 HG13 HG23 ' A' ' 31' ' ' ILE . 46.9 t -81.04 130.49 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.715 -173.721 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.536 HG12 ' HB3' ' A' ' 62' ' ' ALA . 50.7 mt -123.12 125.28 71.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.594 176.449 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.67 133.54 34.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.624 0.249 . . . . 0.0 110.768 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.7 t -132.13 104.23 13.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.247 -179.055 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -69.5 104.21 1.24 Allowed 'Trans proline' 0 C--O 1.233 0.262 0 C-N-CA 122.947 2.432 . . . . 0.0 112.849 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.95 48.17 0.74 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.979 175.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.64 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.8 p -138.08 170.96 15.13 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.752 -0.264 . . . . 0.0 111.29 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.663 ' HE3' ' HA ' ' A' ' 45' ' ' LYS . 0.2 OUTLIER -132.97 166.84 21.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.087 -177.044 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 43.8 t -65.47 116.42 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 178.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 95.62 1.76 61.87 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.407 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -75.12 123.66 25.64 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -103.19 108.57 19.83 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.385 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.5 m -138.18 161.58 31.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.366 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -96.34 123.67 40.06 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.267 172.337 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.472 HG22 ' HA ' ' A' ' 66' ' ' VAL . 46.9 pt -117.46 143.37 28.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.625 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.569 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 49.1 tttp -98.82 109.8 22.51 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 173.073 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.5 t -68.92 107.48 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 176.008 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -88.71 -40.84 12.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.653 0.596 . . . . 0.0 111.21 -172.373 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.525 ' HD3' ' OE1' ' A' ' 13' ' ' GLU . 19.6 mmt180 -139.71 129.59 24.78 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.004 -175.085 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.1 m -97.1 117.96 42.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 172.469 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.506 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 80.1 mt -101.37 162.08 21.61 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.922 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PRO . . . . . 0.506 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 91.1 Cg_exo -43.89 -38.49 10.03 Favored 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 123.57 2.847 . . . . 0.0 114.666 -175.501 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 17.6 tptp -120.29 -3.72 9.98 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -172.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.416 ' CE1' HD12 ' A' ' 58' ' ' LEU . 54.2 p90 -170.74 167.8 7.59 Favored 'General case' 0 C--O 1.222 -0.361 0 CA-C-O 120.613 0.244 . . . . 0.0 110.909 -177.591 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.536 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -108.47 147.35 31.8 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.031 0.443 . . . . 0.0 111.05 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -112.52 126.62 55.53 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.187 176.081 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -130.26 156.11 45.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.122 0.487 . . . . 0.0 111.468 -176.354 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 6.6 t -105.73 130.46 53.73 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.733 178.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.472 ' HA ' HG22 ' A' ' 52' ' ' ILE . 6.3 p -79.95 122.99 36.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.135 0.493 . . . . 0.0 111.067 -177.713 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 6.2 t -105.11 0.48 10.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.698 0.761 . . . . 0.0 109.639 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 . . . . . 0 C--O 1.247 0.952 0 CA-C-N 114.259 -1.337 . . . . 0.0 110.819 -175.234 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.481 1.079 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -82.19 -18.96 40.83 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 175.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -97.62 132.66 43.07 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.728 176.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -64.34 144.08 57.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.226 177.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -80.82 124.1 28.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.9 p -74.06 -9.65 58.84 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.993 0.425 . . . . 0.0 110.489 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.466 ' HD2' ' HA ' ' A' ' 7' ' ' ARG . 0.8 OUTLIER 64.55 23.76 12.93 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 115.47 -0.787 . . . . 0.0 111.559 -178.416 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.8 m -68.12 94.68 0.52 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.991 -0.549 . . . . 0.0 109.689 175.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 15.3 m -111.07 157.23 39.36 Favored Pre-proline 0 N--CA 1.448 -0.546 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.915 -176.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -67.07 -42.86 7.32 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.792 2.328 . . . . 0.0 112.78 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.5 m -126.29 146.62 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.225 0.536 . . . . 0.0 112.268 -172.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -121.07 171.51 8.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 174.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.549 ' HG2' ' HA ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -66.54 125.12 24.74 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.239 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 23.06 17.37 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 116.203 -0.453 . . . . 0.0 113.633 173.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.45 ' O ' ' HD2' ' A' ' 53' ' ' LYS . 45.0 mt-10 -105.28 171.65 7.21 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.278 0.539 . . . . 0.0 110.924 -177.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 7.1 p -141.97 129.28 20.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.857 0.361 . . . . 0.0 110.59 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 87.8 m-85 -134.84 142.47 46.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.388 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -82.03 94.3 7.15 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 32.9 m -111.54 159.11 11.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.304 0.573 . . . . 0.0 111.477 -173.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 m -112.69 125.97 54.88 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.292 -0.867 . . . . 0.0 108.809 172.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.578 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.0 mm -69.59 100.55 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.047 0.451 . . . . 0.0 110.257 -179.356 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -81.51 -34.72 31.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.283 -175.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.517 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 31.2 t0 -138.57 170.36 16.15 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.264 -178.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.44 HG12 ' HA2' ' A' ' 30' ' ' GLY . 27.8 mt -145.37 131.68 14.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.63 144.23 29.57 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.416 ' O ' ' HB2' ' A' ' 27' ' ' GLN . 48.8 mtm180 -64.62 92.94 0.1 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.361 0.6 . . . . 0.0 112.086 -173.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.416 ' HB2' ' O ' ' A' ' 26' ' ' ARG . 57.7 tp60 166.27 -27.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 114.202 -1.363 . . . . 0.0 108.44 -177.184 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 120.29 7.38 9.21 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.351 -0.84 . . . . 0.0 112.402 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.606 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 5.5 m-20 -83.27 114.67 21.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.664 0.268 . . . . 0.0 110.309 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.44 ' HA2' HG12 ' A' ' 24' ' ' ILE . . . -71.73 126.42 12.39 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.632 177.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.571 HG23 HG13 ' A' ' 38' ' ' VAL . 75.5 mt -94.42 107.19 19.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.192 0.52 . . . . 0.0 110.649 -178.305 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.409 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -99.81 96.32 7.5 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.157 -0.928 . . . . 0.0 109.183 173.05 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 14.6 ptm180 -93.26 93.54 8.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.433 -176.276 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 52.5 mt -89.11 109.88 20.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.259 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 57.56 12.89 1.68 Allowed 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.953 -1.022 . . . . 0.0 112.302 -176.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.37 -19.73 12.87 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.313 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.427 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 70.4 t80 -73.72 125.66 28.58 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.571 HG13 HG23 ' A' ' 31' ' ' ILE . 98.0 t -93.18 112.58 26.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.346 0.593 . . . . 0.0 111.652 -173.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.409 ' HB ' ' HB3' ' A' ' 32' ' ' ALA . 57.2 mt -103.21 126.78 57.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.474 173.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -95.17 121.8 37.19 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.011 0.434 . . . . 0.0 111.002 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.526 HG22 ' HB3' ' A' ' 64' ' ' ALA . 21.6 t -120.33 89.9 44.32 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.498 176.029 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 17.3 Cg_exo -66.15 127.48 17.65 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.899 2.399 . . . . 0.0 112.536 -175.047 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.79 43.21 3.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.815 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.578 ' HB ' HG13 ' A' ' 21' ' ' ILE . 6.6 p -128.06 -171.7 2.51 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.588 0.232 . . . . 0.0 111.254 179.033 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -140.06 152.94 46.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.237 -176.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 38.9 t -63.01 118.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.74 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.24 1.85 64.42 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.382 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -76.18 119.43 20.08 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.774 0.321 . . . . 0.0 110.621 -178.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -98.67 108.11 20.72 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.577 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.419 ' HB ' HG13 ' A' ' 66' ' ' VAL . 15.3 m -139.79 160.25 27.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -174.195 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -86.14 110.36 19.51 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 44.8 pt -97.55 132.44 42.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.719 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.45 ' HD2' ' O ' ' A' ' 15' ' ' GLU . 51.0 tptt -92.95 104.86 17.05 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 174.177 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 99.5 t -69.29 97.24 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -65.36 -48.55 72.59 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.549 ' HA ' ' HG2' ' A' ' 13' ' ' GLU . 75.0 mtp180 -150.97 161.77 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.536 -177.108 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.427 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.7 m -128.98 135.64 61.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.106 0.479 . . . . 0.0 110.576 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -111.61 157.55 39.0 Favored Pre-proline 0 C--N 1.32 -0.682 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.28 -16.42 22.33 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.965 2.443 . . . . 0.0 113.805 -176.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.4 mmtm -117.32 -18.23 9.95 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -176.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -169.88 161.06 8.81 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.425 0.155 . . . . 0.0 110.66 -175.014 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -120.08 156.63 30.6 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.263 -178.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -114.43 134.2 55.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.346 176.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.526 ' HB3' HG22 ' A' ' 41' ' ' VAL . . . -145.75 154.9 42.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.699 178.178 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.3 t -128.47 157.14 41.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.041 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.454 HG12 ' H ' ' A' ' 68' ' ' GLU . 99.1 t -84.25 119.64 33.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.823 -177.03 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.7 m -104.59 15.88 6.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.083 0.468 . . . . 0.0 110.813 178.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.454 ' H ' HG12 ' A' ' 66' ' ' VAL . 41.9 mt-10 . . . . . 0 C--O 1.247 0.948 0 CA-C-N 114.547 -1.206 . . . . 0.0 111.307 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.694 0.283 . . . . 0.0 110.758 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.01 -173.45 2.25 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 63.31 42.4 6.96 Favored 'General case' 0 C--O 1.236 0.356 0 O-C-N 123.615 0.572 . . . . 0.0 110.184 -177.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.454 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 1.8 pm0 -60.34 134.21 56.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.555 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 -56.77 118.02 4.49 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.31 -173.31 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.4 p 57.81 13.07 1.9 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.504 1.122 . . . . 0.0 112.594 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 68.8 mtt-85 66.36 -57.68 0.37 Allowed 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.74 0.816 . . . . 0.0 112.635 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 40.6 m 70.82 14.05 7.05 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.624 0.77 . . . . 0.0 111.066 -175.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 3.3 m -148.38 100.02 3.6 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.284 178.287 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -83.7 -14.25 7.83 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.529 2.153 . . . . 0.0 112.82 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 m -113.33 151.22 15.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.806 -178.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.416 ' HB2' ' HG2' ' A' ' 15' ' ' GLU . 43.3 mm-40 -92.31 148.74 21.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.499 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.454 ' CG ' HG22 ' A' ' 57' ' ' VAL . 37.5 mt-10 -68.42 109.56 3.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.243 0.544 . . . . 0.0 110.856 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.474 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 105.33 28.87 5.32 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.001 -178.306 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 12' ' ' GLU . 8.4 mm-40 -87.04 160.03 18.75 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 175.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.516 HG22 ' HG3' ' A' ' 53' ' ' LYS . 46.5 t -139.02 115.48 10.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.673 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.406 ' CE2' HD11 ' A' ' 52' ' ' ILE . 37.4 p90 -151.25 142.92 23.69 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.404 178.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.608 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 3.7 p-10 -84.47 137.04 33.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.26 0.552 . . . . 0.0 110.446 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 18.2 m -134.63 160.55 41.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.026 -176.128 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.5 m -103.52 125.92 50.36 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 169.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.558 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.4 mm -67.41 114.38 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -95.75 -32.67 12.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.122 -170.296 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -140.62 165.9 26.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.639 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.758 HG22 ' H ' ' A' ' 26' ' ' ARG . 43.5 mm -129.79 133.75 64.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.535 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -80.88 11.43 3.96 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -175.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.758 ' H ' HG22 ' A' ' 24' ' ' ILE . 17.2 tpt180 57.88 85.63 0.09 Allowed 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.256 -179.204 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 171.56 -24.85 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.732 -1.122 . . . . 0.0 108.928 -169.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 118.34 -11.44 12.78 Favored Glycine 0 N--CA 1.451 -0.334 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.693 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.551 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 38.9 m-20 -99.01 143.25 29.5 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.692 0.282 . . . . 0.0 110.523 -179.181 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.552 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -89.97 150.64 21.13 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.813 -176.073 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.535 HD11 ' HB2' ' A' ' 25' ' ' ALA . 43.0 mm -111.0 117.3 54.69 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.161 0.505 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -119.28 102.94 9.06 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.369 -0.832 . . . . 0.0 108.815 172.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 25.0 ptt85 -107.07 114.84 29.16 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.98 0.419 . . . . 0.0 111.444 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.521 HG22 ' HG3' ' A' ' 35' ' ' GLU . 41.6 mt -99.36 119.51 47.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.996 177.172 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.521 ' HG3' HG22 ' A' ' 34' ' ' ILE . 32.9 mt-10 62.23 26.06 15.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.994 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.65 -19.82 53.1 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.197 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.426 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 58.8 t80 -72.06 108.84 5.48 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 HG23 ' A' ' 31' ' ' ILE . 59.3 t -76.14 124.18 33.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.106 0.479 . . . . 0.0 111.526 -175.32 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.572 HG12 ' HB3' ' A' ' 62' ' ' ALA . 63.7 mt -118.77 129.77 74.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.187 -0.46 . . . . 0.0 109.885 176.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -92.38 124.66 36.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.736 -177.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.414 ' HA ' ' HD2' ' A' ' 42' ' ' PRO . 38.8 t -111.13 109.15 57.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.819 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.551 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 13.6 Cg_endo -57.24 119.62 6.99 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 122.953 2.435 . . . . 0.0 113.191 -175.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 63.58 74.13 0.47 Allowed Glycine 0 CA--C 1.519 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.862 175.121 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.558 ' HB ' HG13 ' A' ' 21' ' ' ILE . 1.2 p -143.33 161.52 38.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.802 0.334 . . . . 0.0 110.918 176.824 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 tptm -120.09 151.95 38.3 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.058 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.456 HG23 HG12 ' A' ' 24' ' ' ILE . 80.6 t -60.11 126.17 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 176.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 103.51 -5.07 47.8 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.893 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.81 107.83 4.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.915 0.388 . . . . 0.0 110.601 174.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -87.94 96.17 10.39 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 173.087 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.519 ' HB ' HG23 ' A' ' 66' ' ' VAL . 19.1 m -134.48 147.79 29.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -169.587 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.608 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 0.2 OUTLIER -79.38 120.15 23.41 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.595 174.76 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.406 HD11 ' CE2' ' A' ' 17' ' ' TYR . 2.7 pp -116.88 141.16 36.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.552 178.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.516 ' HG3' HG22 ' A' ' 16' ' ' VAL . 78.4 tttt -101.57 114.72 29.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 172.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.6 t -69.25 99.13 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 173.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -88.52 -37.53 15.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.085 -169.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -150.47 130.99 13.87 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -174.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.454 HG22 ' CG ' ' A' ' 13' ' ' GLU . 26.9 m -112.69 139.24 38.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.17 0.509 . . . . 0.0 111.662 -177.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -118.28 154.31 51.9 Favored Pre-proline 0 C--N 1.322 -0.627 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 170.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.03 -19.57 26.91 Favored 'Trans proline' 0 CA--C 1.533 0.45 0 C-N-CA 122.634 2.222 . . . . 0.0 113.654 -177.142 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -105.99 -26.32 11.71 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -168.71 163.75 12.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.426 0.155 . . . . 0.0 110.59 -172.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.572 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -129.88 159.39 36.76 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.117 0.484 . . . . 0.0 111.755 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -105.92 127.82 53.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.565 174.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -141.23 126.89 19.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 11.6 t -100.55 145.92 27.74 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.261 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.519 HG23 ' HB ' ' A' ' 50' ' ' VAL . 4.0 p -82.38 116.67 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.681 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 25.5 m -101.79 4.61 10.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.621 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.542 ' OXT' ' HB2' ' A' ' 51' ' ' ARG . 43.6 mt-10 . . . . . 0 C--O 1.247 0.922 0 CA-C-N 114.254 -1.339 . . . . 0.0 112.361 177.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.431 ' O ' ' HB2' ' A' ' 2' ' ' PHE . 24.9 ttt . . . . . 0 N--CA 1.479 0.989 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.652 ' HD1' ' HG2' ' A' ' 3' ' ' ARG . 22.6 t80 176.37 -77.84 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 175.212 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.652 ' HG2' ' HD1' ' A' ' 2' ' ' PHE . 32.9 ptt180 -175.12 22.92 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.58 174.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -95.37 122.59 38.25 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.805 -170.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 67.61 -170.47 0.19 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.464 -178.327 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.1 m 66.01 26.92 10.8 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.12 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.4 mtp85 -106.57 155.8 19.25 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.417 -178.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.4 m -82.39 33.86 0.41 Allowed 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -170.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 2.1 m -130.19 101.36 17.88 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-O 120.958 0.409 . . . . 0.0 110.579 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -71.74 -30.3 14.61 Favored 'Trans proline' 0 CA--C 1.53 0.29 0 C-N-CA 123.083 2.522 . . . . 0.0 113.535 -175.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.2 m -122.23 148.23 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.91 0.386 . . . . 0.0 111.459 -175.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.8 mm-40 -102.33 161.88 13.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.327 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.458 ' HG3' HG22 ' A' ' 57' ' ' VAL . 3.5 mp0 -65.98 119.64 11.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.266 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.3 18.7 27.89 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 116.029 -0.532 . . . . 0.0 113.153 173.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 33.0 mt-10 -92.61 166.59 12.42 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.036 -176.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.14 127.11 60.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.954 0.407 . . . . 0.0 110.216 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -129.98 140.81 50.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.764 -176.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -79.97 90.38 5.36 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 171.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.3 m -104.73 148.77 8.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.395 0.616 . . . . 0.0 111.72 -172.073 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.63 HG23 ' HG2' ' A' ' 49' ' ' GLU . 24.6 m -101.72 124.91 48.15 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.318 173.56 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.538 HG13 ' HB ' ' A' ' 44' ' ' THR . 43.6 mm -70.33 89.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.3 mt-30 -81.93 -33.1 30.51 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.859 -175.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -128.84 170.67 13.09 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.655 179.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.455 ' HB ' ' CG2' ' A' ' 46' ' ' VAL . 8.4 tt -147.73 150.46 14.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.838 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.571 ' HB3' ' OE1' ' A' ' 27' ' ' GLN . . . -97.25 175.13 6.39 Favored 'General case' 0 C--N 1.314 -0.936 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.557 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 29.2 mtm180 -71.18 -22.13 62.07 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -171.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.571 ' OE1' ' HB3' ' A' ' 25' ' ' ALA . 0.1 OUTLIER -80.6 -17.28 51.84 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.297 -0.561 . . . . 0.0 110.048 177.536 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.91 19.83 11.39 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.919 -0.582 . . . . 0.0 113.342 174.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.616 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 56.7 m-20 -99.75 144.86 28.33 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 175.632 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.416 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -74.21 141.37 28.89 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.901 -0.591 . . . . 0.0 113.003 -171.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.539 HG23 HG13 ' A' ' 38' ' ' VAL . 47.9 mm -107.73 104.52 17.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.137 0.494 . . . . 0.0 110.154 178.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -97.53 97.02 8.71 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.636 175.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 29.7 ptt85 -96.05 94.51 7.6 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.289 0.566 . . . . 0.0 111.394 -175.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 55.1 mt -86.51 113.47 24.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.99 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.2 mm-40 54.98 24.34 5.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.729 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.52 -17.99 51.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 35.1 t80 -75.95 121.74 23.15 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.539 HG13 HG23 ' A' ' 31' ' ' ILE . 57.9 t -83.35 121.66 36.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.197 0.523 . . . . 0.0 112.079 -173.308 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.571 HG12 ' HB3' ' A' ' 62' ' ' ALA . 48.2 mt -116.61 126.92 74.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.548 174.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -91.22 125.22 35.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.825 0.345 . . . . 0.0 111.136 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.4 t -119.45 111.79 36.19 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.669 176.108 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.616 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 45.8 Cg_endo -68.65 114.72 3.61 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 122.631 2.22 . . . . 0.0 113.659 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.53 0.35 58.0 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.805 -0.712 . . . . 0.0 114.738 170.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.538 ' HB ' HG13 ' A' ' 21' ' ' ILE . 16.7 p -89.12 138.41 31.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 118.09 0.945 . . . . 0.0 111.936 -177.257 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -92.28 155.5 17.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.967 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.455 ' CG2' ' HB ' ' A' ' 24' ' ' ILE . 96.9 t -64.4 128.56 27.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-O 121.069 0.461 . . . . 0.0 110.962 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.66 -17.72 42.11 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.214 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.09 115.08 9.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.952 0.406 . . . . 0.0 110.446 178.366 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.63 ' HG2' HG23 ' A' ' 20' ' ' THR . 37.2 mt-10 -97.6 97.83 9.38 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.315 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.9 167.29 23.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.799 -173.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 60.3 mtt180 -100.25 120.81 40.48 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.13 0.491 . . . . 0.0 109.885 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 47.7 pt -113.25 144.6 20.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.394 -178.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 46.0 tttp -99.21 108.71 21.36 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.023 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.8 t -68.94 98.4 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.06 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -86.38 -35.3 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.478 -171.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -141.56 139.5 33.2 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.802 -174.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.458 HG22 ' HG3' ' A' ' 13' ' ' GLU . 15.4 m -123.23 115.51 45.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.4 0.619 . . . . 0.0 110.54 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -97.65 155.05 37.65 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.63 -6.96 8.05 Favored 'Trans proline' 0 CA--C 1.531 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 113.304 -178.054 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.446 ' NZ ' ' HB2' ' A' ' 60' ' ' LYS . 5.0 ttmp? -111.25 -30.72 7.33 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.056 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -170.86 167.48 7.48 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.365 -175.461 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.571 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -110.28 156.21 21.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.913 0.387 . . . . 0.0 110.946 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -123.87 136.43 54.36 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 178.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.99 148.61 43.7 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.064 0.459 . . . . 0.0 111.461 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 p -105.82 130.17 53.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.745 174.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.769 HG22 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -77.06 130.51 36.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.056 0.455 . . . . 0.0 110.764 -176.67 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.5 m -108.24 22.25 4.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.099 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.769 ' H ' HG22 ' A' ' 66' ' ' VAL . 26.5 mm-40 . . . . . 0 C--O 1.246 0.909 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.543 -177.351 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.0 mmt . . . . . 0 N--CA 1.481 1.077 0 CA-C-O 120.637 0.255 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -86.75 163.27 17.39 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 178.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 7.7 mtt180 66.66 -165.87 0.22 Allowed 'General case' 0 C--O 1.233 0.222 0 O-C-N 123.4 0.437 . . . . 0.0 110.15 -176.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -78.83 82.41 5.04 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.447 0.641 . . . . 0.0 111.052 -178.247 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 55.3 mt-10 63.62 16.45 9.68 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 114.67 -1.15 . . . . 0.0 111.652 177.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.5 m 59.77 14.37 4.09 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.253 -0.885 . . . . 0.0 112.205 178.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.6 mtp180 62.6 -76.97 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.1 t 66.51 -161.31 0.25 Allowed 'General case' 0 C--O 1.235 0.309 0 CA-C-N 114.978 -1.01 . . . . 0.0 108.494 -164.543 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 17.1 m 35.33 70.65 0.94 Allowed Pre-proline 0 N--CA 1.473 0.679 0 C-N-CA 123.917 0.887 . . . . 0.0 113.028 -178.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -90.16 -7.74 4.26 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.506 2.138 . . . . 0.0 113.316 -177.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.1 m -116.67 156.38 17.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.667 0.27 . . . . 0.0 111.001 -175.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -129.1 157.69 41.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.231 -0.441 . . . . 0.0 109.933 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.43 ' HB3' ' HA ' ' A' ' 56' ' ' ARG . 8.8 pt-20 -67.03 127.67 33.47 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.135 0.493 . . . . 0.0 110.978 176.206 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.68 29.45 7.35 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.988 -178.042 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -115.04 170.43 8.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.47 125.35 16.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.182 0.515 . . . . 0.0 110.48 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -136.15 151.51 49.84 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.432 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -91.86 126.52 36.97 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 170.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.9 m -140.48 153.79 21.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.003 0.43 . . . . 0.0 111.552 -174.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -106.75 121.82 45.14 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 171.031 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.558 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.3 mm -68.95 116.02 8.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 120.886 0.374 . . . . 0.0 110.566 -177.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.86 -54.53 5.52 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.227 -175.263 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 47.0 t0 -128.4 176.27 7.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.957 -176.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.554 HD13 ' HA2' ' A' ' 30' ' ' GLY . 43.6 mm -134.36 139.05 48.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.028 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.45 26.87 0.53 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -175.41 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.42 ' H ' HG22 ' A' ' 24' ' ' ILE . 52.4 mtm180 60.85 35.45 19.35 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 175.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -158.6 -36.06 0.07 Allowed 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.436 0.636 . . . . 0.0 109.652 -177.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 150.06 -29.43 1.11 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.243 -0.979 . . . . 0.0 112.381 178.005 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.634 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 1.8 m-20 -64.13 118.11 8.09 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 176.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.554 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -78.75 146.48 29.85 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.25 179.164 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 23' ' ' ASP . 50.9 mm -104.52 99.7 8.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.993 0.425 . . . . 0.0 110.457 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -127.22 110.74 13.19 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.591 175.359 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.573 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 23.7 ptt180 -108.64 139.49 43.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.216 0.531 . . . . 0.0 111.295 -176.452 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 61.6 mt -122.03 119.04 57.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.714 175.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.6 mm-40 58.24 32.54 22.17 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.822 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.14 -31.72 7.4 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.739 179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.404 ' HE2' ' HB2' ' A' ' 62' ' ' ALA . 20.0 t80 -76.14 110.16 10.4 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.93 0.395 . . . . 0.0 110.058 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' A' ' 33' ' ' ARG . 7.2 p -84.7 134.64 26.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.182 0.515 . . . . 0.0 111.753 -174.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.537 HG12 ' HB3' ' A' ' 62' ' ' ALA . 51.5 mt -107.99 126.43 64.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.754 176.331 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -92.95 122.35 35.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.524 178.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.537 HG21 HG21 ' A' ' 52' ' ' ILE . 28.2 t -124.41 95.27 43.52 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.176 -0.466 . . . . 0.0 109.808 178.349 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.634 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 43.3 Cg_endo -68.15 122.19 9.24 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.851 2.367 . . . . 0.0 112.989 -177.279 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.21 27.9 4.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.34 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.558 ' HB ' HG13 ' A' ' 21' ' ' ILE . 17.3 p -118.99 164.34 15.62 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.991 0.424 . . . . 0.0 111.197 -179.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 48' ' ' ASP . 17.7 tptp -116.21 164.03 15.1 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.785 177.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 61.9 t -65.08 120.5 12.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 177.169 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.91 62.13 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.01 -178.285 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.513 ' HB2' ' O ' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -69.25 107.92 3.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.754 0.311 . . . . 0.0 110.604 176.943 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -92.56 100.45 12.98 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 175.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.4 m -135.89 160.07 39.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.256 0.551 . . . . 0.0 112.131 -172.598 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -91.66 119.48 31.58 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.524 172.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.537 HG21 HG21 ' A' ' 41' ' ' VAL . 47.6 pt -108.74 139.53 30.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.296 0.569 . . . . 0.0 111.566 -175.492 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 50.3 tptt -99.26 106.04 18.13 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.516 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 58.1 t -68.9 113.42 4.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -90.57 -37.23 13.97 Favored 'General case' 0 C--N 1.323 -0.552 0 O-C-N 123.609 0.568 . . . . 0.0 110.911 -174.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.43 ' HA ' ' HB3' ' A' ' 13' ' ' GLU . 73.0 mtp180 -143.07 155.75 44.68 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.976 0.417 . . . . 0.0 111.371 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 54.6 t -126.17 125.71 68.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.973 174.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.575 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 5.8 mp -114.01 162.16 24.34 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.575 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 40.4 Cg_exo -36.77 -44.35 1.05 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.347 3.365 . . . . 0.0 115.686 -174.188 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.601 ' HG3' ' HD1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.74 14.47 5.37 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -175.299 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.601 ' HD1' ' HG3' ' A' ' 60' ' ' LYS . 46.9 p90 -169.25 149.47 4.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.938 0.399 . . . . 0.0 111.19 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.537 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -107.16 165.52 11.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.655 179.204 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -128.17 122.33 31.65 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.516 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -139.79 164.38 30.12 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.824 0.345 . . . . 0.0 111.508 -176.02 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 9.5 p -133.98 158.82 42.53 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.371 176.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.9 t -83.86 115.51 26.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.786 0.327 . . . . 0.0 110.424 -177.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.7 m -118.24 3.34 7.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.016 0.436 . . . . 0.0 110.937 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 . . . . . 0 C--O 1.245 0.85 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.581 -174.027 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 mpt? . . . . . 0 N--CA 1.483 1.219 0 CA-C-O 120.86 0.362 . . . . 0.0 110.224 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -137.1 151.82 49.3 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.619 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.402 ' HD3' HH11 ' A' ' 3' ' ' ARG . 20.2 ttm-85 -145.78 143.06 29.45 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.582 175.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -77.69 171.87 14.28 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.184 0.516 . . . . 0.0 111.412 -178.154 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -90.37 159.88 16.37 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.962 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.7 m -137.88 -51.49 0.61 Allowed 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.498 -178.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.6 mmt180 64.55 120.25 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.546 0 O-C-N 123.676 0.61 . . . . 0.0 111.291 -172.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.624 ' O ' HG22 ' A' ' 9' ' ' VAL . 2.8 m -77.35 80.36 3.85 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 174.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.685 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 1.5 m 60.39 170.26 0.07 OUTLIER Pre-proline 0 CA--C 1.549 0.935 0 O-C-N 124.395 1.059 . . . . 0.0 109.804 -169.527 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.685 ' HD2' ' HB ' ' A' ' 9' ' ' VAL . 30.0 Cg_endo -63.65 -11.15 25.0 Favored 'Trans proline' 0 C--N 1.353 0.812 0 C-N-CA 121.983 1.789 . . . . 0.0 113.999 -173.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.557 ' HB ' HG21 ' A' ' 54' ' ' VAL . 24.5 m -135.13 132.5 52.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.494 ' HG2' ' HB2' ' A' ' 8' ' ' SER . 43.8 mt-10 -118.77 170.75 8.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.245 0.545 . . . . 0.0 111.748 -177.114 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.47 ' HG3' HG22 ' A' ' 57' ' ' VAL . 28.2 mt-10 -65.6 116.98 7.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.196 -0.911 . . . . 0.0 112.355 -172.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.551 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 94.17 31.69 7.89 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.389 171.236 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -122.77 153.71 39.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.209 -0.597 . . . . 0.0 110.771 178.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 3.9 p -110.45 133.1 56.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.403 -178.106 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -132.38 150.79 52.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.046 -177.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -94.29 107.58 19.52 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 176.258 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.436 HG12 HD11 ' A' ' 34' ' ' ILE . 29.4 m -118.47 166.65 12.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.531 0.681 . . . . 0.0 111.834 -171.582 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.9 m -131.38 127.52 37.74 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.358 174.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.517 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.5 mm -69.0 125.07 26.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.78 -174.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 mm-40 -98.83 -41.52 7.6 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.398 -175.523 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.405 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 26.3 m-20 -133.77 173.66 11.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.771 0.319 . . . . 0.0 111.144 -177.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.453 HG12 HG23 ' A' ' 46' ' ' VAL . 45.5 mm -122.36 134.11 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.327 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.616 ' HB3' ' HB3' ' A' ' 29' ' ' ASP . . . -101.2 175.13 5.69 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.363 -179.117 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 56.8 mtp85 -68.01 -31.45 71.14 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -174.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 19.9 mm-40 -78.31 12.92 1.7 Allowed 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 178.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 69.62 27.78 72.99 Favored Glycine 0 N--CA 1.451 -0.338 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 -174.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.616 ' HB3' ' HB3' ' A' ' 25' ' ' ALA . 13.5 t70 -91.24 144.8 25.23 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.82 -0.69 . . . . 0.0 110.053 -176.11 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.583 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -96.19 112.63 4.47 Favored Glycine 0 N--CA 1.439 -1.158 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 177.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.518 HG23 HG13 ' A' ' 38' ' ' VAL . 74.7 mt -79.14 103.39 6.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.283 0.563 . . . . 0.0 110.71 -175.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.508 ' HB2' HD13 ' A' ' 21' ' ' ILE . . . -105.48 116.43 31.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.221 175.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 25.1 ptt180 -107.5 136.59 47.01 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.476 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.436 HD11 HG12 ' A' ' 19' ' ' VAL . 56.7 mt -124.48 118.25 52.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.608 174.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 59.42 26.94 15.94 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.743 -179.438 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.08 -22.63 39.88 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.762 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -75.55 130.65 39.18 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.518 HG13 HG23 ' A' ' 31' ' ' ILE . 61.9 t -86.26 122.11 38.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.171 0.51 . . . . 0.0 111.689 -175.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.45 HD11 HG11 ' A' ' 11' ' ' VAL . 46.1 mt -115.1 133.4 61.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.182 174.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.455 ' HB3' ' OD2' ' A' ' 29' ' ' ASP . 98.1 m-85 -98.14 130.05 44.91 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.974 0.416 . . . . 0.0 111.206 -177.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 41.6 t -130.34 93.5 32.64 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.862 178.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.521 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 26.1 Cg_exo -62.66 129.16 25.45 Favored 'Trans proline' 0 CA--C 1.528 0.221 0 C-N-CA 123.095 2.53 . . . . 0.0 113.333 -174.35 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.44 50.53 3.36 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.609 174.44 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.583 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 11.1 p -139.72 -178.57 5.48 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.643 -0.327 . . . . 0.0 110.768 177.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.543 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 4.9 ttpm? -133.93 153.69 51.59 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.453 HG23 HG12 ' A' ' 24' ' ' ILE . 38.5 t -58.37 117.0 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 175.048 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.97 -16.44 18.22 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.379 -177.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.543 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.1 m-20 -67.7 115.82 7.7 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.95 178.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.23 90.87 4.49 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.69 174.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.4 m -120.86 169.14 12.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.153 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 64.0 mtp180 -102.07 128.36 48.56 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.035 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.478 HG22 ' HA ' ' A' ' 66' ' ' VAL . 2.8 pp -127.02 150.29 32.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.204 -176.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.551 ' HE2' ' HA2' ' A' ' 14' ' ' GLY . 69.6 tttt -106.07 118.78 37.52 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 172.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.557 HG21 ' HB ' ' A' ' 11' ' ' VAL . 87.1 t -69.27 106.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 171.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 13.5 tp10 -84.87 -36.19 21.71 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.294 -170.178 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 56' ' ' ARG . 7.4 ptp85 -156.44 150.07 24.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.293 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.47 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.1 m -121.25 138.92 50.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.098 0.475 . . . . 0.0 110.925 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.7 mp -110.57 157.89 37.04 Favored Pre-proline 0 C--N 1.319 -0.76 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 174.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -58.89 -1.46 0.8 Allowed 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.162 2.575 . . . . 0.0 114.68 -176.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.4 -16.8 2.36 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -169.03 161.08 10.38 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.605 0.241 . . . . 0.0 110.838 -176.026 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -115.04 152.18 32.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.89 0.376 . . . . 0.0 111.515 -177.33 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.4 t80 -112.14 129.02 56.38 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.416 178.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -128.58 149.52 50.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.313 0.578 . . . . 0.0 111.889 -177.062 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.3 t -109.74 136.02 49.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.166 175.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.567 HG22 ' H ' ' A' ' 68' ' ' GLU . 6.9 p -82.47 123.23 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.333 0.587 . . . . 0.0 111.063 -176.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.5 m -107.45 28.43 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.567 ' H ' HG22 ' A' ' 66' ' ' VAL . 41.8 mt-10 . . . . . 0 C--O 1.251 1.152 0 CA-C-N 115.073 -0.967 . . . . 0.0 111.256 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.1 ttt . . . . . 0 N--CA 1.475 0.8 0 CA-C-O 120.895 0.379 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -155.27 102.18 2.27 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.42 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 44.2 mtm105 -145.72 110.01 4.98 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.023 176.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 61.6 71.0 0.56 Allowed 'General case' 0 C--N 1.33 -0.261 0 O-C-N 123.517 0.511 . . . . 0.0 110.993 174.243 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 42.46 -156.71 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.54 1.136 . . . . 0.0 112.984 -178.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.4 m -133.79 -55.51 0.88 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.408 176.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.434 HH11 ' HD2' ' A' ' 7' ' ' ARG . 5.1 ptp180 -175.8 67.8 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.451 178.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 12.9 m -84.82 23.04 1.24 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.739 -173.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 4.3 m -134.99 112.64 11.36 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-O 121.098 0.475 . . . . 0.0 111.065 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -67.15 -31.01 37.23 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.593 2.195 . . . . 0.0 111.234 175.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.9 m -132.42 151.75 35.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.24 177.478 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.21 155.66 41.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.036 0.446 . . . . 0.0 110.95 -177.302 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -66.42 122.52 17.72 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.355 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.71 21.46 33.92 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.957 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -113.76 164.1 14.17 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.755 0.312 . . . . 0.0 110.369 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.694 ' HB ' ' HE3' ' A' ' 53' ' ' LYS . 14.9 p -129.92 131.85 66.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 120.92 0.39 . . . . 0.0 110.373 -176.176 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -135.96 154.66 51.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.389 -176.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -93.36 123.61 36.77 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 31.9 m -133.37 156.64 42.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.177 0.513 . . . . 0.0 111.709 -173.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.553 HG23 ' HG2' ' A' ' 49' ' ' GLU . 61.0 m -113.16 124.62 52.99 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.248 -0.887 . . . . 0.0 109.622 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.557 HG13 ' HB ' ' A' ' 44' ' ' THR . 48.7 mm -70.41 95.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -86.61 -33.91 20.02 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.315 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.429 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 20.3 t70 -126.73 163.73 22.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.537 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.493 HG13 ' HA2' ' A' ' 30' ' ' GLY . 7.5 tt -141.48 132.19 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 174.235 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.06 162.63 27.35 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.428 -175.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.3 ttm105 -68.74 -12.89 61.98 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.566 0.698 . . . . 0.0 109.463 178.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -72.16 -16.77 61.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.807 172.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.52 17.13 59.12 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.662 -0.699 . . . . 0.0 113.087 176.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 -105.68 143.07 34.35 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 177.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.493 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -68.29 133.83 28.59 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.156 -175.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.49 HG23 HG23 ' A' ' 38' ' ' VAL . 48.0 mm -106.68 109.97 29.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.325 0.584 . . . . 0.0 110.583 -178.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.499 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -101.4 149.77 23.72 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.381 175.124 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 33' ' ' ARG . 1.2 ptm180 -138.37 113.79 9.57 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.98 0.419 . . . . 0.0 110.929 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.0 mt -104.48 105.75 19.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.991 176.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 51.57 27.67 4.09 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.686 -1.143 . . . . 0.0 112.131 -178.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 118.45 -31.81 5.45 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.756 -0.735 . . . . 0.0 113.025 177.076 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.402 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 12.5 t80 -75.51 125.42 28.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.843 0.354 . . . . 0.0 110.252 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.49 HG23 HG23 ' A' ' 31' ' ' ILE . 7.0 p -88.75 135.38 25.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.287 0.565 . . . . 0.0 111.551 -176.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.558 HG12 ' HB3' ' A' ' 62' ' ' ALA . 42.7 mt -124.29 132.13 71.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.943 178.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -93.17 119.63 32.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.81 0.338 . . . . 0.0 110.576 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.39 100.09 45.06 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.963 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.48 127.36 17.95 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 123.226 2.618 . . . . 0.0 113.118 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.85 -9.13 55.04 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.83 173.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.557 ' HB ' HG13 ' A' ' 21' ' ' ILE . 25.8 p -89.12 156.13 19.01 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 117.355 0.578 . . . . 0.0 111.669 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -111.4 157.61 20.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.764 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 88.1 t -58.99 124.12 12.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.281 177.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 108.44 -13.1 36.31 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.512 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -68.84 117.32 10.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.119 0.485 . . . . 0.0 110.966 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.553 ' HG2' HG23 ' A' ' 20' ' ' THR . 44.3 mt-10 -106.64 97.03 6.87 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.636 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.86 173.74 14.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.063 -173.213 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.9 mtp85 -103.23 126.49 50.43 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.75 177.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.1 pt -116.17 143.35 26.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.326 -175.469 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.694 ' HE3' ' HB ' ' A' ' 16' ' ' VAL . 0.9 OUTLIER -97.87 102.84 14.7 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.122 175.824 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.524 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 55.9 t -69.35 108.45 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.56 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.22 -26.41 17.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.738 -173.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 37.8 ttt180 -154.92 144.91 21.72 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.823 0.344 . . . . 0.0 110.731 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 35.7 m -110.19 141.7 24.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.122 175.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.532 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 3.1 mm? -115.59 160.45 34.68 Favored Pre-proline 0 C--N 1.32 -0.687 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.532 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 9.8 Cg_endo -52.69 -28.41 37.5 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.122 2.548 . . . . 0.0 114.177 -175.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -121.79 -2.96 9.24 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -175.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -169.58 162.62 10.01 Favored 'General case' 0 C--O 1.222 -0.382 0 CA-C-N 117.76 0.254 . . . . 0.0 110.941 -175.721 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.558 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -113.87 157.47 22.31 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.685 0.279 . . . . 0.0 110.569 177.726 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -123.2 129.0 50.8 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.524 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -146.69 158.5 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.353 . . . . 0.0 111.677 -176.018 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.2 p -115.73 160.08 20.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.551 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 68' ' ' GLU . 41.4 t -81.62 123.98 38.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.329 -176.771 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.45 33.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.15 0.5 . . . . 0.0 110.539 179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.435 ' H ' HG12 ' A' ' 66' ' ' VAL . 45.9 tt0 . . . . . 0 C--O 1.25 1.116 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.419 177.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.0 mmt . . . . . 0 N--CA 1.478 0.942 0 CA-C-O 120.646 0.26 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.53 ' CD2' ' HG2' ' A' ' 3' ' ' ARG . 53.2 p90 -81.39 157.47 24.99 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.53 ' HG2' ' CD2' ' A' ' 2' ' ' PHE . 32.4 mmt180 73.67 152.45 0.13 Allowed 'General case' 0 N--CA 1.469 0.492 0 O-C-N 123.823 0.702 . . . . 0.0 109.321 -170.603 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -85.7 59.81 5.86 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.414 0.626 . . . . 0.0 109.984 177.687 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -89.81 131.19 35.88 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 121.54 0.686 . . . . 0.0 110.726 -175.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.423 ' C ' ' H ' ' A' ' 8' ' ' SER . 40.7 p -114.48 -53.91 2.62 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 171.056 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.2 mtt-85 67.38 -36.97 0.3 Allowed 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 114.851 -1.068 . . . . 0.0 112.625 177.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.423 ' H ' ' C ' ' A' ' 6' ' ' SER . 49.9 m 62.2 70.79 0.56 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.533 0.682 . . . . 0.0 110.73 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.2 m -95.86 142.36 24.46 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.63 178.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -69.24 -31.21 23.32 Favored 'Trans proline' 0 N--CA 1.463 -0.29 0 C-N-CA 122.427 2.084 . . . . 0.0 112.338 179.335 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.475 HG11 HD11 ' A' ' 39' ' ' ILE . 30.3 m -136.63 156.25 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.786 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.576 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.8 pt-20 -133.24 160.45 37.25 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.42 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.44 ' CG ' HG22 ' A' ' 57' ' ' VAL . 39.3 mt-10 -66.83 132.87 48.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.13 0.49 . . . . 0.0 112.15 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.489 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 77.75 36.14 33.82 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.205 -0.907 . . . . 0.0 112.997 174.387 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.589 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 19.6 mm-40 -125.03 164.62 19.78 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-O 120.791 0.329 . . . . 0.0 111.011 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 55.0 t -121.81 122.99 68.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.719 -174.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 41.9 m-85 -125.89 145.87 50.07 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.86 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -90.92 95.75 10.28 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.517 0.675 . . . . 0.0 109.244 171.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 49' ' ' GLU . 28.5 m -104.76 161.29 4.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.514 -171.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.8 m -110.58 119.57 39.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.041 175.405 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.478 HD13 ' HB2' ' A' ' 32' ' ' ALA . 47.7 mm -69.7 106.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 175.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.4 tp60 -97.84 -22.13 16.54 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.286 -173.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.541 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 29.3 t70 -142.88 164.28 30.53 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.895 -0.322 . . . . 0.0 111.263 -174.131 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.431 HG12 HG23 ' A' ' 46' ' ' VAL . 48.5 mm -124.49 131.94 72.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.473 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -98.55 -150.79 0.37 Allowed 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.382 0.611 . . . . 0.0 111.548 -174.229 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 8.3 ttp180 -47.68 117.37 1.81 Allowed 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.654 -1.157 . . . . 0.0 110.893 173.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.5 tt0 72.65 -74.84 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 O-C-N 123.892 0.745 . . . . 0.0 112.123 169.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -160.75 19.06 0.21 Allowed Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.572 -177.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.562 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 47.7 m-20 -78.01 123.23 26.57 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 176.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.605 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -79.13 137.74 19.64 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.791 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.578 HG22 ' HD3' ' A' ' 33' ' ' ARG . 48.3 mm -108.57 114.26 46.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.271 0.558 . . . . 0.0 110.778 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.478 ' HB2' HD13 ' A' ' 21' ' ' ILE . . . -109.54 112.4 24.47 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.805 176.397 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.661 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 0.6 OUTLIER -97.78 115.02 27.19 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.519 178.448 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 31.8 mt -93.81 107.96 19.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 172.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 55.42 21.92 4.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.701 -1.136 . . . . 0.0 111.921 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.64 -26.69 8.35 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.773 -0.727 . . . . 0.0 113.244 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.661 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 53.5 t80 -69.6 128.04 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.965 0.382 . . . . 0.0 110.715 -176.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.519 HG13 HG23 ' A' ' 31' ' ' ILE . 60.8 t -85.62 116.04 28.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.737 -174.226 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.475 HD11 HG11 ' A' ' 11' ' ' VAL . 54.0 mt -111.41 133.13 58.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.914 174.228 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -94.05 122.94 37.08 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.013 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' A' ' 64' ' ' ALA . 43.9 t -127.67 91.52 45.28 Favored Pre-proline 0 C--N 1.326 -0.434 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 38.4 Cg_exo -60.22 121.27 9.52 Favored 'Trans proline' 0 CA--C 1.528 0.192 0 C-N-CA 122.873 2.382 . . . . 0.0 113.033 -175.092 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.63 60.8 1.33 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.073 175.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.605 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 1.3 p -143.35 175.22 10.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 117.006 0.403 . . . . 0.0 110.72 176.701 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -129.86 150.09 51.31 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -178.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.431 HG23 HG12 ' A' ' 24' ' ' ILE . 67.4 t -58.82 116.62 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.881 0.372 . . . . 0.0 110.85 177.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.85 -9.27 14.32 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.227 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -71.98 105.4 3.86 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.821 0.343 . . . . 0.0 111.556 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 47.1 mt-10 -88.45 97.7 11.22 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 168.417 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.595 ' HA ' ' HG3' ' A' ' 68' ' ' GLU . 16.3 m -128.2 151.98 35.71 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.922 -0.581 . . . . 0.0 112.031 -172.605 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.428 ' H ' ' CG ' ' A' ' 68' ' ' GLU . 25.1 mmt180 -79.64 128.93 34.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.852 172.286 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 2.7 pp -134.57 147.16 29.94 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.706 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 47.6 tttp -102.66 111.74 24.19 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 173.77 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.2 t -67.75 112.91 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 175.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -92.06 -33.19 14.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.912 -169.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -156.45 130.12 8.31 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.997 -172.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.44 HG22 ' CG ' ' A' ' 13' ' ' GLU . 34.3 m -114.42 139.45 40.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.323 0.582 . . . . 0.0 111.198 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 96.9 mt -123.64 153.67 66.49 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 173.242 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.47 -16.6 14.47 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.722 2.282 . . . . 0.0 113.46 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 55.9 tptt -100.92 -34.7 9.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.553 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -170.18 173.52 5.8 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.453 -0.202 . . . . 0.0 110.453 -174.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -133.42 159.64 39.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.889 0.376 . . . . 0.0 111.633 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 39.1 m-85 -108.59 152.44 24.77 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.398 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.456 ' HB1' ' HB ' ' A' ' 52' ' ' ILE . . . -142.45 142.45 32.33 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.162 0.506 . . . . 0.0 111.742 177.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 42.2 m -94.34 139.3 31.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.477 174.454 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.6 t -81.64 118.25 29.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.653 0.263 . . . . 0.0 110.651 -178.041 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.8 m -118.17 20.16 6.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.172 0.511 . . . . 0.0 110.679 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.595 ' HG3' ' HA ' ' A' ' 50' ' ' VAL . 1.1 tm-20 . . . . . 0 C--O 1.244 0.783 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.212 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.402 ' SD ' ' N ' ' A' ' 1' ' ' MET . 1.5 mpt? . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 121.09 0.471 . . . . 0.0 109.854 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -112.93 -20.89 11.39 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.934 -174.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 6.8 mmt180 -150.07 -53.87 0.16 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.636 0.731 . . . . 0.0 110.559 -177.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 177.96 -19.63 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 -172.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 74.3 -158.72 0.07 Allowed 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 113.167 -1.833 . . . . 0.0 110.313 175.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 80.7 p 54.76 31.96 16.53 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 122.254 1.026 . . . . 0.0 108.255 -164.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 48.4 mtm180 -88.92 -159.37 0.56 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 114.062 -1.426 . . . . 0.0 110.327 -178.4 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.2 t -63.78 102.05 0.42 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.216 0.531 . . . . 0.0 111.613 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 2.7 m -138.49 88.04 14.84 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.365 173.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.473 ' HB2' HG22 ' A' ' 34' ' ' ILE . 73.0 Cg_endo -75.49 -15.96 19.4 Favored 'Trans proline' 0 C--O 1.234 0.315 0 C-N-CA 122.728 2.285 . . . . 0.0 113.037 -174.53 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' HG21 ' A' ' 54' ' ' VAL . 19.4 m -131.33 143.7 39.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.745 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -121.58 148.9 43.92 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.681 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.481 ' CG ' HG22 ' A' ' 57' ' ' VAL . 44.1 mt-10 -66.31 129.46 39.89 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.315 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.65 27.17 30.3 Favored Glycine 0 N--CA 1.445 -0.767 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.917 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 72.0 mm-40 -124.05 156.44 36.54 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.256 0.55 . . . . 0.0 111.894 -177.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 57.0 t -113.83 130.65 67.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.149 -175.435 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -132.04 150.82 52.05 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.246 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.85 109.52 21.5 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.526 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.86 144.63 36.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.424 0.63 . . . . 0.0 112.15 -174.34 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.0 m -96.14 139.64 32.01 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 169.527 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.603 HG13 ' HB ' ' A' ' 44' ' ' THR . 45.8 mm -81.1 124.86 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.591 0.234 . . . . 0.0 110.972 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.464 ' OE1' ' HG2' ' A' ' 33' ' ' ARG . 2.3 mp0 -75.47 -56.33 4.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.979 -177.602 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -140.28 -179.41 5.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.15 -177.46 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.0 mm -123.7 127.45 73.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.81 146.69 26.65 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.724 179.074 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 37.2 ttt180 -61.44 -16.65 48.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.833 -173.197 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 85.9 mm-40 -70.19 -23.99 63.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.82 0.343 . . . . 0.0 110.987 177.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.97 17.52 10.89 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.729 -0.748 . . . . 0.0 111.728 -175.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -113.41 153.07 29.2 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.51 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -91.86 144.92 17.43 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.796 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 70.2 mt -100.87 109.84 26.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.952 0.406 . . . . 0.0 110.406 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -111.58 163.43 14.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.447 175.298 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.464 ' HG2' ' OE1' ' A' ' 22' ' ' GLN . 31.5 ptt180 -144.68 132.88 21.66 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.704 0.288 . . . . 0.0 110.822 -178.638 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.473 HG22 ' HB2' ' A' ' 10' ' ' PRO . 49.6 mt -129.06 117.82 44.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.18 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.29 26.82 14.41 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.953 0.882 . . . . 0.0 109.923 -175.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.36 -15.0 63.25 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.639 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.55 ' CE2' ' HB2' ' A' ' 62' ' ' ALA . 14.7 t80 -75.31 119.93 20.08 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.3 t -78.04 128.93 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.234 0.54 . . . . 0.0 111.382 -173.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.534 HG12 ' HB3' ' A' ' 62' ' ' ALA . 24.6 mt -120.11 129.72 75.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.797 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -101.54 125.24 48.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.857 0.36 . . . . 0.0 110.803 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.0 t -122.94 108.33 32.69 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.359 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.12 126.84 21.3 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 123.213 2.608 . . . . 0.0 113.184 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 64.39 2.25 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.066 -0.587 . . . . 0.0 113.384 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.603 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.4 p -134.88 -172.24 2.99 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 176.448 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.459 ' HB3' ' HB2' ' A' ' 48' ' ' ASP . 36.7 ttpt -142.69 153.91 43.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.418 0.151 . . . . 0.0 110.871 -175.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.03 120.6 5.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.74 0.305 . . . . 0.0 111.113 179.176 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.7 4.35 90.27 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.602 177.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.459 ' HB2' ' HB3' ' A' ' 45' ' ' LYS . 40.3 t0 -75.87 122.67 24.47 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.3 106.49 18.26 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.087 0.47 . . . . 0.0 110.02 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.68 146.82 33.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.379 0.609 . . . . 0.0 111.333 -175.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -97.97 117.57 32.62 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 176.325 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.488 HG22 ' HA ' ' A' ' 66' ' ' VAL . 44.5 pt -116.27 155.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.475 -170.55 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.504 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 34.9 ttmt -105.37 118.09 35.67 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.459 HG21 ' HB ' ' A' ' 11' ' ' VAL . 90.2 t -69.19 118.35 13.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 174.34 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -92.84 -45.79 7.83 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.348 1.03 . . . . 0.0 111.217 -175.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 33.2 mtt180 -135.93 144.0 45.23 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.378 -172.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.481 HG22 ' CG ' ' A' ' 13' ' ' GLU . 27.6 m -124.7 116.05 46.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.698 0.761 . . . . 0.0 110.497 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.432 ' C ' ' H ' ' A' ' 60' ' ' LYS . 5.8 mp -112.94 152.22 44.72 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.619 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.13 11.0 0.28 Allowed 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 122.745 2.297 . . . . 0.0 112.481 177.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.432 ' H ' ' C ' ' A' ' 58' ' ' LEU . 56.9 mttm -118.51 -31.78 4.8 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.612 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -177.84 170.25 1.94 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.923 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.55 ' HB2' ' CE2' ' A' ' 37' ' ' PHE . . . -108.75 146.96 32.73 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.808 0.337 . . . . 0.0 110.533 176.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 53.4 t80 -122.0 123.68 42.21 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -134.85 152.02 51.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.873 -176.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 20.9 t -113.48 146.6 39.33 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.52 HG22 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -81.65 117.52 27.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.361 0.601 . . . . 0.0 111.126 -176.361 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.9 p -96.52 8.85 6.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.938 0.875 . . . . 0.0 108.993 178.304 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.52 ' H ' HG22 ' A' ' 66' ' ' VAL . 25.7 tt0 . . . . . 0 C--O 1.251 1.146 0 CA-C-N 113.334 -1.757 . . . . 0.0 111.268 177.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.2 mpp? . . . . . 0 N--CA 1.481 1.116 0 CA-C-O 120.403 0.144 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.491 ' C ' ' H ' ' A' ' 4' ' ' GLU . 86.7 m-85 64.86 95.98 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.117 0.567 . . . . 0.0 110.995 176.037 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.453 ' HB2' ' O ' ' A' ' 2' ' ' PHE . 66.2 mtt180 71.89 -9.69 0.95 Allowed 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 115.344 -0.843 . . . . 0.0 110.38 -171.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.491 ' H ' ' C ' ' A' ' 2' ' ' PHE . 33.8 mm-40 66.14 10.91 7.46 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 114.932 -1.031 . . . . 0.0 113.638 169.541 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 56.44 -154.45 0.33 Allowed 'General case' 0 CA--C 1.529 0.155 0 O-C-N 123.354 0.409 . . . . 0.0 111.078 168.485 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.5 t -87.73 -42.02 12.92 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.01 0.434 . . . . 0.0 109.846 175.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.568 ' C ' ' H ' ' A' ' 9' ' ' VAL . 17.0 mmt180 -116.85 -64.71 1.27 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.19 -0.459 . . . . 0.0 112.053 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 82.1 p 66.62 -20.85 0.1 Allowed 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 125.256 1.423 . . . . 0.0 112.327 -174.499 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.568 ' H ' ' C ' ' A' ' 7' ' ' ARG . 0.4 OUTLIER -158.06 105.22 1.73 Allowed Pre-proline 0 C--N 1.31 -1.132 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.178 177.26 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -62.82 -41.41 30.33 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.775 2.317 . . . . 0.0 112.177 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.5 162.06 37.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.48 -178.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.545 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.0 pt-20 -130.96 156.41 45.15 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.429 178.445 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.4 ' CD ' HH21 ' A' ' 56' ' ' ARG . 56.1 mt-10 -66.46 133.61 50.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.355 -174.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.91 31.08 33.27 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.688 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.545 ' HG3' ' HG3' ' A' ' 12' ' ' GLU . 58.8 mm-40 -127.17 155.86 42.72 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.556 -0.457 . . . . 0.0 110.912 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 7.1 p -118.66 128.23 75.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.09 -174.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.8 m-85 -125.95 132.43 52.08 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.793 -178.579 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 30.2 t70 -81.61 97.0 7.66 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 175.473 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.9 m -111.99 170.45 3.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.392 0.615 . . . . 0.0 111.663 -170.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 49' ' ' GLU . 26.0 m -120.51 128.73 53.39 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.111 171.508 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.587 HG13 ' HB ' ' A' ' 44' ' ' THR . 49.9 mm -68.48 116.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.168 0.508 . . . . 0.0 110.707 -175.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm-40 -84.29 -40.55 17.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.608 -173.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -143.33 179.55 7.02 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -177.332 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.551 HD13 ' HA2' ' A' ' 30' ' ' GLY . 32.0 mm -137.06 119.21 19.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.42 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . -71.69 150.57 44.41 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.943 178.172 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 55.2 ttp180 -47.81 -35.71 10.57 Favored 'General case' 0 C--N 1.329 -0.316 0 O-C-N 123.478 0.486 . . . . 0.0 112.051 -177.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.585 ' HB2' ' OD1' ' A' ' 29' ' ' ASP . 15.5 mt-30 -73.09 -14.19 61.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.767 -175.659 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.41 7.92 41.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.666 -175.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.813 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 6.6 m-20 -80.95 122.82 27.73 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 177.281 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.551 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -72.27 127.75 12.85 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.512 178.572 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.57 HG23 HG13 ' A' ' 38' ' ' VAL . 73.5 mt -95.52 106.49 18.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.339 0.59 . . . . 0.0 111.385 -176.047 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -96.69 94.65 7.43 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 170.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.463 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 9.9 ptm180 -93.91 98.46 11.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.57 0.7 . . . . 0.0 110.968 -174.465 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 45.1 mt -93.17 111.33 24.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.487 -179.329 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 56.64 26.33 11.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.941 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.53 -20.47 39.47 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.457 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 50.7 t80 -75.59 123.44 25.51 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.57 HG13 HG23 ' A' ' 31' ' ' ILE . 64.7 t -90.0 116.37 31.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.897 -173.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.445 HG12 ' HB3' ' A' ' 62' ' ' ALA . 55.4 mt -109.24 125.66 66.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.648 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -94.19 121.14 35.38 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.969 0.414 . . . . 0.0 111.359 -178.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 64' ' ' ALA . 11.0 t -129.53 89.59 46.58 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.126 175.857 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.813 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 32.8 Cg_endo -63.94 137.43 57.69 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.968 2.445 . . . . 0.0 113.239 -175.326 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.38 -10.15 30.87 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.032 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.587 ' HB ' HG13 ' A' ' 21' ' ' ILE . 35.3 p -95.59 -179.62 4.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.522 0.201 . . . . 0.0 110.962 -178.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.533 ' HA ' HD11 ' A' ' 24' ' ' ILE . 34.3 ttmt -142.9 165.29 27.76 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 44.0 t -58.34 118.7 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 CA-C-O 120.664 0.268 . . . . 0.0 111.097 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.94 -5.74 59.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.761 178.323 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.444 ' O ' HG12 ' A' ' 21' ' ' ILE . 29.6 t0 -75.11 112.47 11.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 110.055 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 20' ' ' THR . 8.4 pt-20 -100.29 108.09 20.06 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.743 -178.799 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.0 m -142.15 161.87 19.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.807 -176.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.492 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 66.0 mtm180 -82.95 124.23 30.18 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.796 174.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.6 pt -117.96 136.92 53.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.137 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 56.3 tttm -100.4 114.6 28.27 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.443 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.7 t -69.29 121.19 18.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -94.44 -45.73 7.31 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.209 0.943 . . . . 0.0 110.872 -174.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.4 HH21 ' CD ' ' A' ' 13' ' ' GLU . 1.8 tpm_? -140.68 137.91 33.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.143 -172.336 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 34.4 m -114.78 136.31 51.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.295 0.569 . . . . 0.0 110.858 176.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 5.6 mp -123.02 156.19 62.98 Favored Pre-proline 0 C--N 1.321 -0.652 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -58.47 -16.67 30.48 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.848 2.365 . . . . 0.0 113.518 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.2 ttmm -110.35 -22.52 11.67 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -176.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -172.47 172.14 4.44 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.682 0.277 . . . . 0.0 111.0 -174.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.445 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -128.13 157.47 40.69 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.688 0.28 . . . . 0.0 110.984 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -124.61 136.4 53.91 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.518 ' HB3' HG22 ' A' ' 41' ' ' VAL . . . -136.83 163.2 31.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.956 0.407 . . . . 0.0 111.423 -176.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.1 p -117.27 145.0 44.24 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.854 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 40.6 t -78.39 127.19 38.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.131 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.0 m -123.49 13.88 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.743 0.306 . . . . 0.0 110.465 176.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 . . . . . 0 C--O 1.25 1.119 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.504 -179.634 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.2 mpt? . . . . . 0 N--CA 1.481 1.12 0 CA-C-O 120.488 0.185 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 62.74 -169.28 0.19 Allowed 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.04 -176.03 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 62.0 ttt180 -156.54 -35.99 0.08 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.467 -178.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 75.18 96.52 0.07 Allowed 'General case' 0 N--CA 1.462 0.175 0 O-C-N 124.118 0.886 . . . . 0.0 109.191 -173.252 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -75.7 -163.47 0.27 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.835 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.0 m 73.62 76.64 0.13 Allowed 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.25 -173.068 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 19.1 mmt85 -52.38 138.83 26.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.699 -179.484 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 17.6 m -67.93 96.55 0.6 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.404 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.43 HG12 ' H ' ' A' ' 11' ' ' VAL . 8.4 t 69.97 115.95 0.03 OUTLIER Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.673 173.475 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.07 -7.33 21.17 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 122.944 2.429 . . . . 0.0 113.343 -177.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.43 ' H ' HG12 ' A' ' 9' ' ' VAL . 16.1 m -133.79 130.7 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.706 0.289 . . . . 0.0 110.474 179.14 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -113.09 173.7 6.26 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.541 0.686 . . . . 0.0 111.773 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.525 ' OE1' ' HD3' ' A' ' 56' ' ' ARG . 33.5 mt-10 -67.28 126.63 29.84 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.806 -1.088 . . . . 0.0 112.152 -177.082 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.555 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 91.68 16.35 52.31 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.389 -0.823 . . . . 0.0 112.929 174.039 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.569 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 26.2 mt-10 -99.04 160.42 14.27 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.344 -0.542 . . . . 0.0 111.187 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.51 124.34 68.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.208 -179.244 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -128.54 141.05 51.49 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.858 -177.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -80.51 97.29 7.08 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.4 m -109.66 148.9 13.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.353 0.597 . . . . 0.0 111.764 -173.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.0 m -110.1 119.09 38.18 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.912 172.405 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.64 HG13 ' HB ' ' A' ' 44' ' ' THR . 41.3 mm -69.64 116.77 11.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.746 -175.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -87.17 -51.03 6.22 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.863 -174.538 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.433 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 15.2 m-20 -124.31 -179.26 4.38 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.892 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.603 HD13 ' HA2' ' A' ' 30' ' ' GLY . 39.6 mm -137.82 137.8 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.342 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.584 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . -68.54 -65.75 0.66 Allowed 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 121.912 0.863 . . . . 0.0 109.201 177.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 37.2 ptt180 -172.64 127.46 0.51 Allowed 'General case' 0 N--CA 1.439 -0.987 0 CA-C-N 113.514 -1.676 . . . . 0.0 108.178 172.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 61.7 tt0 79.55 -63.29 0.26 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.402 -0.817 . . . . 0.0 112.099 172.378 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.22 -21.65 0.12 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 119.587 -1.292 . . . . 0.0 114.687 -170.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.584 ' HB2' ' HB3' ' A' ' 25' ' ' ALA . 5.1 m-20 -73.62 108.24 6.35 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 117.799 0.8 . . . . 0.0 109.587 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.603 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -80.21 144.07 25.59 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.294 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.434 HG23 HG13 ' A' ' 38' ' ' VAL . 50.2 mm -105.5 102.69 14.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.105 0.479 . . . . 0.0 110.166 179.607 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.406 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -98.18 147.51 24.52 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 174.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 8.9 ptp85 -138.95 109.43 6.55 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.297 0.57 . . . . 0.0 111.049 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.7 mt -101.65 118.32 48.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 173.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 67.78 -3.1 1.22 Allowed 'General case' 0 CA--C 1.535 0.371 0 O-C-N 124.186 0.929 . . . . 0.0 110.519 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 117.86 -14.49 12.73 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.209 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.474 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 34.8 t80 -74.87 127.76 33.96 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.434 HG13 HG23 ' A' ' 31' ' ' ILE . 46.9 t -81.04 130.49 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.715 -173.721 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.536 HG12 ' HB3' ' A' ' 62' ' ' ALA . 50.7 mt -123.12 125.28 71.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.594 176.449 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.67 133.54 34.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.624 0.249 . . . . 0.0 110.768 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.7 t -132.13 104.23 13.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.247 -179.055 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -69.5 104.21 1.24 Allowed 'Trans proline' 0 C--O 1.233 0.262 0 C-N-CA 122.947 2.432 . . . . 0.0 112.849 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.95 48.17 0.74 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.979 175.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.64 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.8 p -138.08 170.96 15.13 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.752 -0.264 . . . . 0.0 111.29 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.663 ' HE3' ' HA ' ' A' ' 45' ' ' LYS . 0.2 OUTLIER -132.97 166.84 21.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.087 -177.044 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 43.8 t -65.47 116.42 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 178.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 95.62 1.76 61.87 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.407 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -75.12 123.66 25.64 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -103.19 108.57 19.83 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.385 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.5 m -138.18 161.58 31.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.366 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -96.34 123.67 40.06 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.267 172.337 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.472 HG22 ' HA ' ' A' ' 66' ' ' VAL . 46.9 pt -117.46 143.37 28.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.625 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.569 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 49.1 tttp -98.82 109.8 22.51 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 173.073 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.5 t -68.92 107.48 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 176.008 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -88.71 -40.84 12.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.653 0.596 . . . . 0.0 111.21 -172.373 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.525 ' HD3' ' OE1' ' A' ' 13' ' ' GLU . 19.6 mmt180 -139.71 129.59 24.78 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.004 -175.085 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.1 m -97.1 117.96 42.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 172.469 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.506 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 80.1 mt -101.37 162.08 21.61 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.922 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PRO . . . . . 0.506 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 91.1 Cg_exo -43.89 -38.49 10.03 Favored 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 123.57 2.847 . . . . 0.0 114.666 -175.501 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 17.6 tptp -120.29 -3.72 9.98 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -172.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.416 ' CE1' HD12 ' A' ' 58' ' ' LEU . 54.2 p90 -170.74 167.8 7.59 Favored 'General case' 0 C--O 1.222 -0.361 0 CA-C-O 120.613 0.244 . . . . 0.0 110.909 -177.591 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.536 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -108.47 147.35 31.8 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.031 0.443 . . . . 0.0 111.05 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -112.52 126.62 55.53 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.187 176.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -130.26 156.11 45.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.122 0.487 . . . . 0.0 111.468 -176.354 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 6.6 t -105.73 130.46 53.73 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.733 178.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.472 ' HA ' HG22 ' A' ' 52' ' ' ILE . 6.3 p -79.95 122.99 36.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.135 0.493 . . . . 0.0 111.067 -177.713 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 6.2 t -105.11 0.48 10.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.698 0.761 . . . . 0.0 109.639 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 . . . . . 0 C--O 1.247 0.952 0 CA-C-N 114.259 -1.337 . . . . 0.0 110.819 -175.234 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo . . . . . 0 N--CA 1.463 -0.306 0 N-CA-C 112.78 0.261 . . . . 0.0 112.78 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.5 m -126.29 146.62 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.225 0.536 . . . . 0.0 112.268 -172.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -121.07 171.51 8.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 174.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.549 ' HG2' ' HA ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -66.54 125.12 24.74 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.239 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 23.06 17.37 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 116.203 -0.453 . . . . 0.0 113.633 173.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.45 ' O ' ' HD2' ' A' ' 53' ' ' LYS . 45.0 mt-10 -105.28 171.65 7.21 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.278 0.539 . . . . 0.0 110.924 -177.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 7.1 p -141.97 129.28 20.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.857 0.361 . . . . 0.0 110.59 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 87.8 m-85 -134.84 142.47 46.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.388 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -82.03 94.3 7.15 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 32.9 m -111.54 159.11 11.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.304 0.573 . . . . 0.0 111.477 -173.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 m -112.69 125.97 54.88 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.292 -0.867 . . . . 0.0 108.809 172.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.578 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.0 mm -69.59 100.55 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.047 0.451 . . . . 0.0 110.257 -179.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -81.51 -34.72 31.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.283 -175.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.517 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 31.2 t0 -138.57 170.36 16.15 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.264 -178.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.44 HG12 ' HA2' ' A' ' 30' ' ' GLY . 27.8 mt -145.37 131.68 14.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.67 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.784 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.606 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 5.5 m-20 . . . . . 0 CA--C 1.516 -0.333 0 CA-C-O 120.664 0.268 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.44 ' HA2' HG12 ' A' ' 24' ' ' ILE . . . -71.73 126.42 12.39 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.632 177.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.571 HG23 HG13 ' A' ' 38' ' ' VAL . 75.5 mt -94.42 107.19 19.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.192 0.52 . . . . 0.0 110.649 -178.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.409 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -99.81 96.32 7.5 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.157 -0.928 . . . . 0.0 109.183 173.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 14.6 ptm180 -93.26 93.54 8.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.433 -176.276 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 52.5 mt -89.11 109.88 20.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.259 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 57.56 12.89 1.68 Allowed 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.953 -1.022 . . . . 0.0 112.302 -176.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.37 -19.73 12.87 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.313 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.427 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 70.4 t80 -73.72 125.66 28.58 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.571 HG13 HG23 ' A' ' 31' ' ' ILE . 98.0 t -93.18 112.58 26.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.346 0.593 . . . . 0.0 111.652 -173.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.409 ' HB ' ' HB3' ' A' ' 32' ' ' ALA . 57.2 mt -103.21 126.78 57.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.474 173.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -95.17 121.8 37.19 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.011 0.434 . . . . 0.0 111.002 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.526 HG22 ' HB3' ' A' ' 64' ' ' ALA . 21.6 t -120.33 89.9 44.32 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.498 176.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 17.3 Cg_exo -66.15 127.48 17.65 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.899 2.399 . . . . 0.0 112.536 -175.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.79 43.21 3.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.815 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.578 ' HB ' HG13 ' A' ' 21' ' ' ILE . 6.6 p -128.06 -171.7 2.51 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.588 0.232 . . . . 0.0 111.254 179.033 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -140.06 152.94 46.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.237 -176.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 38.9 t -63.01 118.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.74 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.24 1.85 64.42 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.382 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -76.18 119.43 20.08 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.774 0.321 . . . . 0.0 110.621 -178.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -98.67 108.11 20.72 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.577 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.419 ' HB ' HG13 ' A' ' 66' ' ' VAL . 15.3 m -139.79 160.25 27.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -174.195 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -86.14 110.36 19.51 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 44.8 pt -97.55 132.44 42.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.719 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.45 ' HD2' ' O ' ' A' ' 15' ' ' GLU . 51.0 tptt -92.95 104.86 17.05 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 174.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 99.5 t -69.29 97.24 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -65.36 -48.55 72.59 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.549 ' HA ' ' HG2' ' A' ' 13' ' ' GLU . 75.0 mtp180 -150.97 161.77 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.536 -177.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.427 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.7 m -128.98 135.64 61.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.106 0.479 . . . . 0.0 110.576 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -111.61 157.55 39.0 Favored Pre-proline 0 C--N 1.32 -0.682 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.28 -16.42 22.33 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.965 2.443 . . . . 0.0 113.805 -176.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.4 mmtm -117.32 -18.23 9.95 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -176.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -169.88 161.06 8.81 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.425 0.155 . . . . 0.0 110.66 -175.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -120.08 156.63 30.6 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.263 -178.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -114.43 134.2 55.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.346 176.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.526 ' HB3' HG22 ' A' ' 41' ' ' VAL . . . -145.75 154.9 42.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.699 178.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.3 t -128.47 157.14 41.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.041 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.454 HG12 ' H ' ' A' ' 68' ' ' GLU . 99.1 t -84.25 119.64 33.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.823 -177.03 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.7 m -104.59 15.88 6.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.083 0.468 . . . . 0.0 110.813 178.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.454 ' H ' HG12 ' A' ' 66' ' ' VAL . 41.9 mt-10 . . . . . 0 C--O 1.247 0.948 0 CA-C-N 114.547 -1.206 . . . . 0.0 111.307 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo . . . . . 0 N--CA 1.462 -0.343 0 CA-C-O 120.867 0.278 . . . . 0.0 112.82 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 m -113.33 151.22 15.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.806 -178.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.416 ' HB2' ' HG2' ' A' ' 15' ' ' GLU . 43.3 mm-40 -92.31 148.74 21.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.499 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.454 ' CG ' HG22 ' A' ' 57' ' ' VAL . 37.5 mt-10 -68.42 109.56 3.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.243 0.544 . . . . 0.0 110.856 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.474 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 105.33 28.87 5.32 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.001 -178.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 12' ' ' GLU . 8.4 mm-40 -87.04 160.03 18.75 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 175.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.516 HG22 ' HG3' ' A' ' 53' ' ' LYS . 46.5 t -139.02 115.48 10.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.673 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.406 ' CE2' HD11 ' A' ' 52' ' ' ILE . 37.4 p90 -151.25 142.92 23.69 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.404 178.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.608 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 3.7 p-10 -84.47 137.04 33.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.26 0.552 . . . . 0.0 110.446 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 18.2 m -134.63 160.55 41.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.026 -176.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.5 m -103.52 125.92 50.36 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 169.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.558 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.4 mm -67.41 114.38 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -95.75 -32.67 12.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.122 -170.296 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -140.62 165.9 26.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.639 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.552 HD13 ' HA2' ' A' ' 30' ' ' GLY . 43.5 mm -129.79 133.75 64.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.535 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . . . . . . 0 C--N 1.319 -0.756 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -175.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.551 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 38.9 m-20 . . . . . 0 C--O 1.236 0.376 0 CA-C-O 120.692 0.282 . . . . 0.0 110.523 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.552 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -89.97 150.64 21.13 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.813 -176.073 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.535 HD11 ' HB2' ' A' ' 25' ' ' ALA . 43.0 mm -111.0 117.3 54.69 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.161 0.505 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -119.28 102.94 9.06 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.369 -0.832 . . . . 0.0 108.815 172.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 25.0 ptt85 -107.07 114.84 29.16 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.98 0.419 . . . . 0.0 111.444 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.521 HG22 ' HG3' ' A' ' 35' ' ' GLU . 41.6 mt -99.36 119.51 47.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.996 177.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.521 ' HG3' HG22 ' A' ' 34' ' ' ILE . 32.9 mt-10 62.23 26.06 15.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.994 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.65 -19.82 53.1 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.197 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.426 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 58.8 t80 -72.06 108.84 5.48 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 HG23 ' A' ' 31' ' ' ILE . 59.3 t -76.14 124.18 33.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.106 0.479 . . . . 0.0 111.526 -175.32 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.572 HG12 ' HB3' ' A' ' 62' ' ' ALA . 63.7 mt -118.77 129.77 74.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.187 -0.46 . . . . 0.0 109.885 176.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -92.38 124.66 36.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.736 -177.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.414 ' HA ' ' HD2' ' A' ' 42' ' ' PRO . 38.8 t -111.13 109.15 57.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.819 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.551 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 13.6 Cg_endo -57.24 119.62 6.99 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 122.953 2.435 . . . . 0.0 113.191 -175.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 63.58 74.13 0.47 Allowed Glycine 0 CA--C 1.519 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.862 175.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.558 ' HB ' HG13 ' A' ' 21' ' ' ILE . 1.2 p -143.33 161.52 38.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.802 0.334 . . . . 0.0 110.918 176.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 tptm -120.09 151.95 38.3 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.058 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.456 HG23 HG12 ' A' ' 24' ' ' ILE . 80.6 t -60.11 126.17 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 176.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 103.51 -5.07 47.8 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.893 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.81 107.83 4.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.915 0.388 . . . . 0.0 110.601 174.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -87.94 96.17 10.39 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 173.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.519 ' HB ' HG23 ' A' ' 66' ' ' VAL . 19.1 m -134.48 147.79 29.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -169.587 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.608 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 0.2 OUTLIER -79.38 120.15 23.41 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.595 174.76 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.406 HD11 ' CE2' ' A' ' 17' ' ' TYR . 2.7 pp -116.88 141.16 36.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.552 178.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.516 ' HG3' HG22 ' A' ' 16' ' ' VAL . 78.4 tttt -101.57 114.72 29.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 172.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.6 t -69.25 99.13 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 173.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -88.52 -37.53 15.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.085 -169.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -150.47 130.99 13.87 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -174.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.454 HG22 ' CG ' ' A' ' 13' ' ' GLU . 26.9 m -112.69 139.24 38.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.17 0.509 . . . . 0.0 111.662 -177.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -118.28 154.31 51.9 Favored Pre-proline 0 C--N 1.322 -0.627 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 170.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.03 -19.57 26.91 Favored 'Trans proline' 0 CA--C 1.533 0.45 0 C-N-CA 122.634 2.222 . . . . 0.0 113.654 -177.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -105.99 -26.32 11.71 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -168.71 163.75 12.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.426 0.155 . . . . 0.0 110.59 -172.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.572 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -129.88 159.39 36.76 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.117 0.484 . . . . 0.0 111.755 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -105.92 127.82 53.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.565 174.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -141.23 126.89 19.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 11.6 t -100.55 145.92 27.74 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.261 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.519 HG23 ' HB ' ' A' ' 50' ' ' VAL . 4.0 p -82.38 116.67 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.681 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 25.5 m -101.79 4.61 10.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.621 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.542 ' OXT' ' HB2' ' A' ' 51' ' ' ARG . 43.6 mt-10 . . . . . 0 C--O 1.247 0.922 0 CA-C-N 114.254 -1.339 . . . . 0.0 112.361 177.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo . . . . . 0 CA--C 1.53 0.29 0 N-CA-C 113.535 0.552 . . . . 0.0 113.535 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.2 m -122.23 148.23 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.91 0.386 . . . . 0.0 111.459 -175.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.8 mm-40 -102.33 161.88 13.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.327 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.458 ' HG3' HG22 ' A' ' 57' ' ' VAL . 3.5 mp0 -65.98 119.64 11.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.266 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.3 18.7 27.89 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 116.029 -0.532 . . . . 0.0 113.153 173.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 33.0 mt-10 -92.61 166.59 12.42 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.036 -176.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.14 127.11 60.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.954 0.407 . . . . 0.0 110.216 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -129.98 140.81 50.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.764 -176.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -79.97 90.38 5.36 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 171.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.3 m -104.73 148.77 8.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.395 0.616 . . . . 0.0 111.72 -172.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.63 HG23 ' HG2' ' A' ' 49' ' ' GLU . 24.6 m -101.72 124.91 48.15 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.318 173.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.538 HG13 ' HB ' ' A' ' 44' ' ' THR . 43.6 mm -70.33 89.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.3 mt-30 -81.93 -33.1 30.51 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.859 -175.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -128.84 170.67 13.09 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.655 179.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.455 ' HB ' ' CG2' ' A' ' 46' ' ' VAL . 8.4 tt -147.73 150.46 14.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.936 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.557 -178.903 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.616 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 56.7 m-20 . . . . . 0 C--O 1.236 0.387 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.416 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -74.21 141.37 28.89 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.901 -0.591 . . . . 0.0 113.003 -171.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.539 HG23 HG13 ' A' ' 38' ' ' VAL . 47.9 mm -107.73 104.52 17.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.137 0.494 . . . . 0.0 110.154 178.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -97.53 97.02 8.71 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.636 175.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 29.7 ptt85 -96.05 94.51 7.6 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.289 0.566 . . . . 0.0 111.394 -175.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 55.1 mt -86.51 113.47 24.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.99 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.2 mm-40 54.98 24.34 5.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.729 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.52 -17.99 51.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 35.1 t80 -75.95 121.74 23.15 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.539 HG13 HG23 ' A' ' 31' ' ' ILE . 57.9 t -83.35 121.66 36.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.197 0.523 . . . . 0.0 112.079 -173.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.571 HG12 ' HB3' ' A' ' 62' ' ' ALA . 48.2 mt -116.61 126.92 74.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.548 174.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -91.22 125.22 35.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.825 0.345 . . . . 0.0 111.136 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.4 t -119.45 111.79 36.19 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.669 176.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.616 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 45.8 Cg_endo -68.65 114.72 3.61 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 122.631 2.22 . . . . 0.0 113.659 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.53 0.35 58.0 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.805 -0.712 . . . . 0.0 114.738 170.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.538 ' HB ' HG13 ' A' ' 21' ' ' ILE . 16.7 p -89.12 138.41 31.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 118.09 0.945 . . . . 0.0 111.936 -177.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -92.28 155.5 17.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.967 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.455 ' CG2' ' HB ' ' A' ' 24' ' ' ILE . 96.9 t -64.4 128.56 27.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-O 121.069 0.461 . . . . 0.0 110.962 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.66 -17.72 42.11 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.214 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.09 115.08 9.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.952 0.406 . . . . 0.0 110.446 178.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.63 ' HG2' HG23 ' A' ' 20' ' ' THR . 37.2 mt-10 -97.6 97.83 9.38 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.315 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.9 167.29 23.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.799 -173.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 60.3 mtt180 -100.25 120.81 40.48 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.13 0.491 . . . . 0.0 109.885 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 47.7 pt -113.25 144.6 20.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.394 -178.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 46.0 tttp -99.21 108.71 21.36 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.8 t -68.94 98.4 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -86.38 -35.3 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.478 -171.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -141.56 139.5 33.2 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.802 -174.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.458 HG22 ' HG3' ' A' ' 13' ' ' GLU . 15.4 m -123.23 115.51 45.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.4 0.619 . . . . 0.0 110.54 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -97.65 155.05 37.65 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.63 -6.96 8.05 Favored 'Trans proline' 0 CA--C 1.531 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 113.304 -178.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.446 ' NZ ' ' HB2' ' A' ' 60' ' ' LYS . 5.0 ttmp? -111.25 -30.72 7.33 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.056 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -170.86 167.48 7.48 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.365 -175.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.571 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -110.28 156.21 21.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.913 0.387 . . . . 0.0 110.946 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -123.87 136.43 54.36 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 178.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.99 148.61 43.7 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.064 0.459 . . . . 0.0 111.461 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 p -105.82 130.17 53.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.745 174.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.769 HG22 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -77.06 130.51 36.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.056 0.455 . . . . 0.0 110.764 -176.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.5 m -108.24 22.25 4.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.099 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.769 ' H ' HG22 ' A' ' 66' ' ' VAL . 26.5 mm-40 . . . . . 0 C--O 1.246 0.909 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.543 -177.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo . . . . . 0 N--CA 1.456 -0.7 0 N-CA-C 113.316 0.468 . . . . 0.0 113.316 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.1 m -116.67 156.38 17.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.667 0.27 . . . . 0.0 111.001 -175.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -129.1 157.69 41.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.231 -0.441 . . . . 0.0 109.933 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.43 ' HB3' ' HA ' ' A' ' 56' ' ' ARG . 8.8 pt-20 -67.03 127.67 33.47 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.135 0.493 . . . . 0.0 110.978 176.206 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.68 29.45 7.35 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.988 -178.042 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -115.04 170.43 8.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.47 125.35 16.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.182 0.515 . . . . 0.0 110.48 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -136.15 151.51 49.84 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.432 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -91.86 126.52 36.97 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 170.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.9 m -140.48 153.79 21.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.003 0.43 . . . . 0.0 111.552 -174.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -106.75 121.82 45.14 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 171.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.558 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.3 mm -68.95 116.02 8.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 120.886 0.374 . . . . 0.0 110.566 -177.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.86 -54.53 5.52 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.227 -175.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 47.0 t0 -128.4 176.27 7.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.957 -176.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.554 HD13 ' HA2' ' A' ' 30' ' ' GLY . 43.6 mm -134.36 139.05 48.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.028 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.741 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -175.41 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.634 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 1.8 m-20 . . . . . 0 CA--C 1.517 -0.313 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.554 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -78.75 146.48 29.85 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.25 179.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 23' ' ' ASP . 50.9 mm -104.52 99.7 8.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.993 0.425 . . . . 0.0 110.457 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -127.22 110.74 13.19 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.591 175.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.573 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 23.7 ptt180 -108.64 139.49 43.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.216 0.531 . . . . 0.0 111.295 -176.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 61.6 mt -122.03 119.04 57.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.714 175.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.6 mm-40 58.24 32.54 22.17 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.822 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.14 -31.72 7.4 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.739 179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.404 ' HE2' ' HB2' ' A' ' 62' ' ' ALA . 20.0 t80 -76.14 110.16 10.4 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.93 0.395 . . . . 0.0 110.058 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' A' ' 33' ' ' ARG . 7.2 p -84.7 134.64 26.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.182 0.515 . . . . 0.0 111.753 -174.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.537 HG12 ' HB3' ' A' ' 62' ' ' ALA . 51.5 mt -107.99 126.43 64.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.754 176.331 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -92.95 122.35 35.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.524 178.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.537 HG21 HG21 ' A' ' 52' ' ' ILE . 28.2 t -124.41 95.27 43.52 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.176 -0.466 . . . . 0.0 109.808 178.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.634 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 43.3 Cg_endo -68.15 122.19 9.24 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.851 2.367 . . . . 0.0 112.989 -177.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.21 27.9 4.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.34 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.558 ' HB ' HG13 ' A' ' 21' ' ' ILE . 17.3 p -118.99 164.34 15.62 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.991 0.424 . . . . 0.0 111.197 -179.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 48' ' ' ASP . 17.7 tptp -116.21 164.03 15.1 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.785 177.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 61.9 t -65.08 120.5 12.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 177.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.91 62.13 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.01 -178.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.513 ' HB2' ' O ' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -69.25 107.92 3.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.754 0.311 . . . . 0.0 110.604 176.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -92.56 100.45 12.98 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 175.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.4 m -135.89 160.07 39.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.256 0.551 . . . . 0.0 112.131 -172.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -91.66 119.48 31.58 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.524 172.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.537 HG21 HG21 ' A' ' 41' ' ' VAL . 47.6 pt -108.74 139.53 30.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.296 0.569 . . . . 0.0 111.566 -175.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 50.3 tptt -99.26 106.04 18.13 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.516 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 58.1 t -68.9 113.42 4.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -90.57 -37.23 13.97 Favored 'General case' 0 C--N 1.323 -0.552 0 O-C-N 123.609 0.568 . . . . 0.0 110.911 -174.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.43 ' HA ' ' HB3' ' A' ' 13' ' ' GLU . 73.0 mtp180 -143.07 155.75 44.68 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.976 0.417 . . . . 0.0 111.371 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 54.6 t -126.17 125.71 68.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.973 174.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.575 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 5.8 mp -114.01 162.16 24.34 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.575 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 40.4 Cg_exo -36.77 -44.35 1.05 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.347 3.365 . . . . 0.0 115.686 -174.188 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.601 ' HG3' ' HD1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.74 14.47 5.37 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -175.299 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.601 ' HD1' ' HG3' ' A' ' 60' ' ' LYS . 46.9 p90 -169.25 149.47 4.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.938 0.399 . . . . 0.0 111.19 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.537 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -107.16 165.52 11.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.655 179.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -128.17 122.33 31.65 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.516 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -139.79 164.38 30.12 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.824 0.345 . . . . 0.0 111.508 -176.02 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 9.5 p -133.98 158.82 42.53 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.371 176.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.9 t -83.86 115.51 26.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.786 0.327 . . . . 0.0 110.424 -177.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.7 m -118.24 3.34 7.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.016 0.436 . . . . 0.0 110.937 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 . . . . . 0 C--O 1.245 0.85 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.581 -174.027 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo . . . . . 0 N--CA 1.476 0.463 0 N-CA-C 113.999 0.73 . . . . 0.0 113.999 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.557 ' HB ' HG21 ' A' ' 54' ' ' VAL . 24.5 m -135.13 132.5 52.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -118.77 170.75 8.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.245 0.545 . . . . 0.0 111.748 -177.114 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.47 ' HG3' HG22 ' A' ' 57' ' ' VAL . 28.2 mt-10 -65.6 116.98 7.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.196 -0.911 . . . . 0.0 112.355 -172.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.551 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 94.17 31.69 7.89 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.389 171.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -122.77 153.71 39.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.209 -0.597 . . . . 0.0 110.771 178.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 3.9 p -110.45 133.1 56.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.403 -178.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -132.38 150.79 52.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.046 -177.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -94.29 107.58 19.52 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 176.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.436 HG12 HD11 ' A' ' 34' ' ' ILE . 29.4 m -118.47 166.65 12.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.531 0.681 . . . . 0.0 111.834 -171.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.9 m -131.38 127.52 37.74 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.358 174.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.517 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.5 mm -69.0 125.07 26.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.78 -174.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 mm-40 -98.83 -41.52 7.6 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.398 -175.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.405 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 26.3 m-20 -133.77 173.66 11.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.771 0.319 . . . . 0.0 111.144 -177.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.453 HG12 HG23 ' A' ' 46' ' ' VAL . 45.5 mm -122.36 134.11 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.616 ' HB3' ' HB3' ' A' ' 29' ' ' ASP . . . . . . . . 0 C--N 1.323 -0.562 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.363 -179.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.616 ' HB3' ' HB3' ' A' ' 25' ' ' ALA . 13.5 t70 . . . . . 0 N--CA 1.449 -0.48 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.583 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -96.19 112.63 4.47 Favored Glycine 0 N--CA 1.439 -1.158 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 177.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.518 HG23 HG13 ' A' ' 38' ' ' VAL . 74.7 mt -79.14 103.39 6.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.283 0.563 . . . . 0.0 110.71 -175.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.508 ' HB2' HD13 ' A' ' 21' ' ' ILE . . . -105.48 116.43 31.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.221 175.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 25.1 ptt180 -107.5 136.59 47.01 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.476 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.436 HD11 HG12 ' A' ' 19' ' ' VAL . 56.7 mt -124.48 118.25 52.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.608 174.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 59.42 26.94 15.94 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.743 -179.438 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.08 -22.63 39.88 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.762 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -75.55 130.65 39.18 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.518 HG13 HG23 ' A' ' 31' ' ' ILE . 61.9 t -86.26 122.11 38.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.171 0.51 . . . . 0.0 111.689 -175.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.45 HD11 HG11 ' A' ' 11' ' ' VAL . 46.1 mt -115.1 133.4 61.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.182 174.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.455 ' HB3' ' OD2' ' A' ' 29' ' ' ASP . 98.1 m-85 -98.14 130.05 44.91 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.974 0.416 . . . . 0.0 111.206 -177.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 41.6 t -130.34 93.5 32.64 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.862 178.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.521 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 26.1 Cg_exo -62.66 129.16 25.45 Favored 'Trans proline' 0 CA--C 1.528 0.221 0 C-N-CA 123.095 2.53 . . . . 0.0 113.333 -174.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.44 50.53 3.36 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.609 174.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.583 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 11.1 p -139.72 -178.57 5.48 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.643 -0.327 . . . . 0.0 110.768 177.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.543 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 4.9 ttpm? -133.93 153.69 51.59 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.453 HG23 HG12 ' A' ' 24' ' ' ILE . 38.5 t -58.37 117.0 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 175.048 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.97 -16.44 18.22 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.379 -177.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.543 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.1 m-20 -67.7 115.82 7.7 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.95 178.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.23 90.87 4.49 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.69 174.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.4 m -120.86 169.14 12.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.153 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 64.0 mtp180 -102.07 128.36 48.56 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.478 HG22 ' HA ' ' A' ' 66' ' ' VAL . 2.8 pp -127.02 150.29 32.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.204 -176.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.551 ' HE2' ' HA2' ' A' ' 14' ' ' GLY . 69.6 tttt -106.07 118.78 37.52 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 172.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.557 HG21 ' HB ' ' A' ' 11' ' ' VAL . 87.1 t -69.27 106.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 171.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 13.5 tp10 -84.87 -36.19 21.71 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.294 -170.178 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 56' ' ' ARG . 7.4 ptp85 -156.44 150.07 24.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.293 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.47 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.1 m -121.25 138.92 50.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.098 0.475 . . . . 0.0 110.925 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.7 mp -110.57 157.89 37.04 Favored Pre-proline 0 C--N 1.319 -0.76 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 174.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -58.89 -1.46 0.8 Allowed 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.162 2.575 . . . . 0.0 114.68 -176.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.4 -16.8 2.36 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -169.03 161.08 10.38 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.605 0.241 . . . . 0.0 110.838 -176.026 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -115.04 152.18 32.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.89 0.376 . . . . 0.0 111.515 -177.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.4 t80 -112.14 129.02 56.38 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.416 178.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -128.58 149.52 50.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.313 0.578 . . . . 0.0 111.889 -177.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.3 t -109.74 136.02 49.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.166 175.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.567 HG22 ' H ' ' A' ' 68' ' ' GLU . 6.9 p -82.47 123.23 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.333 0.587 . . . . 0.0 111.063 -176.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.5 m -107.45 28.43 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.567 ' H ' HG22 ' A' ' 66' ' ' VAL . 41.8 mt-10 . . . . . 0 C--O 1.251 1.152 0 CA-C-N 115.073 -0.967 . . . . 0.0 111.256 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo . . . . . 0 N--CA 1.465 -0.169 0 CA-C-O 121.21 0.421 . . . . 0.0 111.234 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.9 m -132.42 151.75 35.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.24 177.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.21 155.66 41.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.036 0.446 . . . . 0.0 110.95 -177.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -66.42 122.52 17.72 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.355 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.71 21.46 33.92 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.957 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -113.76 164.1 14.17 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.755 0.312 . . . . 0.0 110.369 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.694 ' HB ' ' HE3' ' A' ' 53' ' ' LYS . 14.9 p -129.92 131.85 66.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 120.92 0.39 . . . . 0.0 110.373 -176.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -135.96 154.66 51.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.389 -176.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -93.36 123.61 36.77 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 31.9 m -133.37 156.64 42.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.177 0.513 . . . . 0.0 111.709 -173.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.553 HG23 ' HG2' ' A' ' 49' ' ' GLU . 61.0 m -113.16 124.62 52.99 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.248 -0.887 . . . . 0.0 109.622 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.557 HG13 ' HB ' ' A' ' 44' ' ' THR . 48.7 mm -70.41 95.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -86.61 -33.91 20.02 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.315 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.429 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 20.3 t70 -126.73 163.73 22.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.537 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.493 HG13 ' HA2' ' A' ' 30' ' ' GLY . 7.5 tt -141.48 132.19 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 174.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.314 -0.957 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.428 -175.949 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 . . . . . 0 C--O 1.235 0.318 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.493 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -68.29 133.83 28.59 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.156 -175.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.49 HG23 HG23 ' A' ' 38' ' ' VAL . 48.0 mm -106.68 109.97 29.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.325 0.584 . . . . 0.0 110.583 -178.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.499 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -101.4 149.77 23.72 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.381 175.124 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 33' ' ' ARG . 1.2 ptm180 -138.37 113.79 9.57 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.98 0.419 . . . . 0.0 110.929 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.0 mt -104.48 105.75 19.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.991 176.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 51.57 27.67 4.09 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.686 -1.143 . . . . 0.0 112.131 -178.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 118.45 -31.81 5.45 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.756 -0.735 . . . . 0.0 113.025 177.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.402 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 12.5 t80 -75.51 125.42 28.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.843 0.354 . . . . 0.0 110.252 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.49 HG23 HG23 ' A' ' 31' ' ' ILE . 7.0 p -88.75 135.38 25.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.287 0.565 . . . . 0.0 111.551 -176.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.558 HG12 ' HB3' ' A' ' 62' ' ' ALA . 42.7 mt -124.29 132.13 71.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.943 178.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -93.17 119.63 32.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.81 0.338 . . . . 0.0 110.576 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.39 100.09 45.06 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.963 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.48 127.36 17.95 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 123.226 2.618 . . . . 0.0 113.118 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.85 -9.13 55.04 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.83 173.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.557 ' HB ' HG13 ' A' ' 21' ' ' ILE . 25.8 p -89.12 156.13 19.01 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 117.355 0.578 . . . . 0.0 111.669 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -111.4 157.61 20.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.764 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 88.1 t -58.99 124.12 12.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.281 177.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 108.44 -13.1 36.31 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.512 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -68.84 117.32 10.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.119 0.485 . . . . 0.0 110.966 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.553 ' HG2' HG23 ' A' ' 20' ' ' THR . 44.3 mt-10 -106.64 97.03 6.87 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.86 173.74 14.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.063 -173.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.9 mtp85 -103.23 126.49 50.43 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.75 177.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.1 pt -116.17 143.35 26.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.326 -175.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.694 ' HE3' ' HB ' ' A' ' 16' ' ' VAL . 0.9 OUTLIER -97.87 102.84 14.7 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.122 175.824 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.524 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 55.9 t -69.35 108.45 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.22 -26.41 17.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.738 -173.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 37.8 ttt180 -154.92 144.91 21.72 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.823 0.344 . . . . 0.0 110.731 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 35.7 m -110.19 141.7 24.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.122 175.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.532 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 3.1 mm? -115.59 160.45 34.68 Favored Pre-proline 0 C--N 1.32 -0.687 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.532 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 9.8 Cg_endo -52.69 -28.41 37.5 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.122 2.548 . . . . 0.0 114.177 -175.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -121.79 -2.96 9.24 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -175.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -169.58 162.62 10.01 Favored 'General case' 0 C--O 1.222 -0.382 0 CA-C-N 117.76 0.254 . . . . 0.0 110.941 -175.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.558 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -113.87 157.47 22.31 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.685 0.279 . . . . 0.0 110.569 177.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -123.2 129.0 50.8 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.524 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -146.69 158.5 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.353 . . . . 0.0 111.677 -176.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.2 p -115.73 160.08 20.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.551 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 68' ' ' GLU . 41.4 t -81.62 123.98 38.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.329 -176.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.45 33.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.15 0.5 . . . . 0.0 110.539 179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.435 ' H ' HG12 ' A' ' 66' ' ' VAL . 45.9 tt0 . . . . . 0 C--O 1.25 1.116 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.419 177.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo . . . . . 0 N--CA 1.463 -0.29 0 CA-C-O 120.554 0.148 . . . . 0.0 112.338 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.475 HG11 HD11 ' A' ' 39' ' ' ILE . 30.3 m -136.63 156.25 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.786 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.576 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.8 pt-20 -133.24 160.45 37.25 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.42 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.44 ' CG ' HG22 ' A' ' 57' ' ' VAL . 39.3 mt-10 -66.83 132.87 48.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.13 0.49 . . . . 0.0 112.15 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.489 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 77.75 36.14 33.82 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.205 -0.907 . . . . 0.0 112.997 174.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.589 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 19.6 mm-40 -125.03 164.62 19.78 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-O 120.791 0.329 . . . . 0.0 111.011 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 55.0 t -121.81 122.99 68.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.719 -174.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 41.9 m-85 -125.89 145.87 50.07 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.86 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -90.92 95.75 10.28 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.517 0.675 . . . . 0.0 109.244 171.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 49' ' ' GLU . 28.5 m -104.76 161.29 4.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.514 -171.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.8 m -110.58 119.57 39.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.041 175.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.478 HD13 ' HB2' ' A' ' 32' ' ' ALA . 47.7 mm -69.7 106.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 175.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.823 ' HA ' HE21 ' A' ' 22' ' ' GLN . 0.0 OUTLIER -97.84 -22.13 16.54 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.286 -173.634 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.541 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 29.3 t70 -142.88 164.28 30.53 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.895 -0.322 . . . . 0.0 111.263 -174.131 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.431 HG12 HG23 ' A' ' 46' ' ' VAL . 48.5 mm -124.49 131.94 72.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.473 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . . . . . . 0 C--N 1.319 -0.752 0 CA-C-O 121.382 0.611 . . . . 0.0 111.548 -174.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.562 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 47.7 m-20 . . . . . 0 CA--C 1.517 -0.307 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.605 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -79.13 137.74 19.64 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.791 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.578 HG22 ' HD3' ' A' ' 33' ' ' ARG . 48.3 mm -108.57 114.26 46.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.271 0.558 . . . . 0.0 110.778 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.478 ' HB2' HD13 ' A' ' 21' ' ' ILE . . . -109.54 112.4 24.47 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.805 176.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.661 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 0.6 OUTLIER -97.78 115.02 27.19 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.519 178.448 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 31.8 mt -93.81 107.96 19.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 172.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 55.42 21.92 4.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.701 -1.136 . . . . 0.0 111.921 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.64 -26.69 8.35 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.773 -0.727 . . . . 0.0 113.244 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.661 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 53.5 t80 -69.6 128.04 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.965 0.382 . . . . 0.0 110.715 -176.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.519 HG13 HG23 ' A' ' 31' ' ' ILE . 60.8 t -85.62 116.04 28.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.737 -174.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.475 HD11 HG11 ' A' ' 11' ' ' VAL . 54.0 mt -111.41 133.13 58.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.914 174.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -94.05 122.94 37.08 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.013 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' A' ' 64' ' ' ALA . 43.9 t -127.67 91.52 45.28 Favored Pre-proline 0 C--N 1.326 -0.434 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 38.4 Cg_exo -60.22 121.27 9.52 Favored 'Trans proline' 0 CA--C 1.528 0.192 0 C-N-CA 122.873 2.382 . . . . 0.0 113.033 -175.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.63 60.8 1.33 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.073 175.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.605 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 1.3 p -143.35 175.22 10.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 117.006 0.403 . . . . 0.0 110.72 176.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -129.86 150.09 51.31 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -178.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.431 HG23 HG12 ' A' ' 24' ' ' ILE . 67.4 t -58.82 116.62 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.881 0.372 . . . . 0.0 110.85 177.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.85 -9.27 14.32 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.227 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -71.98 105.4 3.86 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.821 0.343 . . . . 0.0 111.556 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 47.1 mt-10 -88.45 97.7 11.22 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 168.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.595 ' HA ' ' HG3' ' A' ' 68' ' ' GLU . 16.3 m -128.2 151.98 35.71 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.922 -0.581 . . . . 0.0 112.031 -172.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.428 ' H ' ' CG ' ' A' ' 68' ' ' GLU . 25.1 mmt180 -79.64 128.93 34.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.852 172.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 2.7 pp -134.57 147.16 29.94 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.706 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 47.6 tttp -102.66 111.74 24.19 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 173.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.2 t -67.75 112.91 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 175.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -92.06 -33.19 14.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.912 -169.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -156.45 130.12 8.31 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.997 -172.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.44 HG22 ' CG ' ' A' ' 13' ' ' GLU . 34.3 m -114.42 139.45 40.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.323 0.582 . . . . 0.0 111.198 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 96.9 mt -123.64 153.67 66.49 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 173.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.47 -16.6 14.47 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.722 2.282 . . . . 0.0 113.46 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 55.9 tptt -100.92 -34.7 9.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.553 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -170.18 173.52 5.8 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.453 -0.202 . . . . 0.0 110.453 -174.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -133.42 159.64 39.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.889 0.376 . . . . 0.0 111.633 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 39.1 m-85 -108.59 152.44 24.77 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.456 ' HB1' ' HB ' ' A' ' 52' ' ' ILE . . . -142.45 142.45 32.33 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.162 0.506 . . . . 0.0 111.742 177.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 42.2 m -94.34 139.3 31.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.477 174.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.6 t -81.64 118.25 29.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.653 0.263 . . . . 0.0 110.651 -178.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.8 m -118.17 20.16 6.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.172 0.511 . . . . 0.0 110.679 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.595 ' HG3' ' HA ' ' A' ' 50' ' ' VAL . 1.1 tm-20 . . . . . 0 C--O 1.244 0.783 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.212 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.473 ' HB2' HG22 ' A' ' 34' ' ' ILE . 73.0 Cg_endo . . . . . 0 C--O 1.234 0.315 0 N-CA-C 113.037 0.36 . . . . 0.0 113.037 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' HG21 ' A' ' 54' ' ' VAL . 19.4 m -131.33 143.7 39.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.745 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -121.58 148.9 43.92 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.681 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.481 ' CG ' HG22 ' A' ' 57' ' ' VAL . 44.1 mt-10 -66.31 129.46 39.89 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.315 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.65 27.17 30.3 Favored Glycine 0 N--CA 1.445 -0.767 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.917 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 72.0 mm-40 -124.05 156.44 36.54 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.256 0.55 . . . . 0.0 111.894 -177.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 57.0 t -113.83 130.65 67.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.149 -175.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -132.04 150.82 52.05 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.246 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.85 109.52 21.5 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.86 144.63 36.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.424 0.63 . . . . 0.0 112.15 -174.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.0 m -96.14 139.64 32.01 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 169.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.603 HG13 ' HB ' ' A' ' 44' ' ' THR . 45.8 mm -81.1 124.86 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.591 0.234 . . . . 0.0 110.972 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.464 ' OE1' ' HG2' ' A' ' 33' ' ' ARG . 2.3 mp0 -75.47 -56.33 4.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.979 -177.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -140.28 -179.41 5.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.15 -177.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.0 mm -123.7 127.45 73.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.315 -0.914 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.724 179.074 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 . . . . . 0 CA--C 1.517 -0.322 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.51 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -91.86 144.92 17.43 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.796 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 70.2 mt -100.87 109.84 26.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.952 0.406 . . . . 0.0 110.406 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -111.58 163.43 14.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.447 175.298 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.464 ' HG2' ' OE1' ' A' ' 22' ' ' GLN . 31.5 ptt180 -144.68 132.88 21.66 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.704 0.288 . . . . 0.0 110.822 -178.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.473 HG22 ' HB2' ' A' ' 10' ' ' PRO . 49.6 mt -129.06 117.82 44.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.29 26.82 14.41 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.953 0.882 . . . . 0.0 109.923 -175.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.36 -15.0 63.25 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.639 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.55 ' CE2' ' HB2' ' A' ' 62' ' ' ALA . 14.7 t80 -75.31 119.93 20.08 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.3 t -78.04 128.93 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.234 0.54 . . . . 0.0 111.382 -173.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.534 HG12 ' HB3' ' A' ' 62' ' ' ALA . 24.6 mt -120.11 129.72 75.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.797 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -101.54 125.24 48.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.857 0.36 . . . . 0.0 110.803 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.0 t -122.94 108.33 32.69 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.359 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.12 126.84 21.3 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 123.213 2.608 . . . . 0.0 113.184 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 64.39 2.25 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.066 -0.587 . . . . 0.0 113.384 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.603 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.4 p -134.88 -172.24 2.99 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 176.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.459 ' HB3' ' HB2' ' A' ' 48' ' ' ASP . 36.7 ttpt -142.69 153.91 43.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.418 0.151 . . . . 0.0 110.871 -175.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.03 120.6 5.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.74 0.305 . . . . 0.0 111.113 179.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.7 4.35 90.27 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.602 177.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.459 ' HB2' ' HB3' ' A' ' 45' ' ' LYS . 40.3 t0 -75.87 122.67 24.47 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.3 106.49 18.26 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.087 0.47 . . . . 0.0 110.02 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.68 146.82 33.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.379 0.609 . . . . 0.0 111.333 -175.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -97.97 117.57 32.62 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 176.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.488 HG22 ' HA ' ' A' ' 66' ' ' VAL . 44.5 pt -116.27 155.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.475 -170.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.504 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 34.9 ttmt -105.37 118.09 35.67 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.459 HG21 ' HB ' ' A' ' 11' ' ' VAL . 90.2 t -69.19 118.35 13.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 174.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -92.84 -45.79 7.83 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.348 1.03 . . . . 0.0 111.217 -175.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 33.2 mtt180 -135.93 144.0 45.23 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.378 -172.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.481 HG22 ' CG ' ' A' ' 13' ' ' GLU . 27.6 m -124.7 116.05 46.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.698 0.761 . . . . 0.0 110.497 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.432 ' C ' ' H ' ' A' ' 60' ' ' LYS . 5.8 mp -112.94 152.22 44.72 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.619 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.13 11.0 0.28 Allowed 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 122.745 2.297 . . . . 0.0 112.481 177.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.432 ' H ' ' C ' ' A' ' 58' ' ' LEU . 56.9 mttm -118.51 -31.78 4.8 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.612 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -177.84 170.25 1.94 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.923 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.55 ' HB2' ' CE2' ' A' ' 37' ' ' PHE . . . -108.75 146.96 32.73 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.808 0.337 . . . . 0.0 110.533 176.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 53.4 t80 -122.0 123.68 42.21 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -134.85 152.02 51.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.873 -176.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 20.9 t -113.48 146.6 39.33 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.52 HG22 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -81.65 117.52 27.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.361 0.601 . . . . 0.0 111.126 -176.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.9 p -96.52 8.85 6.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.938 0.875 . . . . 0.0 108.993 178.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.52 ' H ' HG22 ' A' ' 66' ' ' VAL . 25.7 tt0 . . . . . 0 C--O 1.251 1.146 0 CA-C-N 113.334 -1.757 . . . . 0.0 111.268 177.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo . . . . . 0 C--O 1.231 0.149 0 CA-C-O 120.905 0.294 . . . . 0.0 112.177 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.5 162.06 37.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.48 -178.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.545 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.0 pt-20 -130.96 156.41 45.15 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.429 178.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.4 ' CD ' HH21 ' A' ' 56' ' ' ARG . 56.1 mt-10 -66.46 133.61 50.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.355 -174.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.91 31.08 33.27 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.688 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.545 ' HG3' ' HG3' ' A' ' 12' ' ' GLU . 58.8 mm-40 -127.17 155.86 42.72 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.556 -0.457 . . . . 0.0 110.912 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 7.1 p -118.66 128.23 75.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.09 -174.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.8 m-85 -125.95 132.43 52.08 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.793 -178.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 30.2 t70 -81.61 97.0 7.66 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 175.473 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.9 m -111.99 170.45 3.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.392 0.615 . . . . 0.0 111.663 -170.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 49' ' ' GLU . 26.0 m -120.51 128.73 53.39 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.111 171.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.587 HG13 ' HB ' ' A' ' 44' ' ' THR . 49.9 mm -68.48 116.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.168 0.508 . . . . 0.0 110.707 -175.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm-40 -84.29 -40.55 17.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.608 -173.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -143.33 179.55 7.02 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -177.332 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.551 HD13 ' HA2' ' A' ' 30' ' ' GLY . 32.0 mm -137.06 119.21 19.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.42 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . . . . . . 0 C--N 1.317 -0.838 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.943 178.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.813 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 6.6 m-20 . . . . . 0 CA--C 1.519 -0.214 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.551 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -72.27 127.75 12.85 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.512 178.572 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.57 HG23 HG13 ' A' ' 38' ' ' VAL . 73.5 mt -95.52 106.49 18.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.339 0.59 . . . . 0.0 111.385 -176.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -96.69 94.65 7.43 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 170.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.463 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 9.9 ptm180 -93.91 98.46 11.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.57 0.7 . . . . 0.0 110.968 -174.465 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 45.1 mt -93.17 111.33 24.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.487 -179.329 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 56.64 26.33 11.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.941 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.53 -20.47 39.47 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.457 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 50.7 t80 -75.59 123.44 25.51 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.57 HG13 HG23 ' A' ' 31' ' ' ILE . 64.7 t -90.0 116.37 31.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.897 -173.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.445 HG12 ' HB3' ' A' ' 62' ' ' ALA . 55.4 mt -109.24 125.66 66.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.648 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -94.19 121.14 35.38 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.969 0.414 . . . . 0.0 111.359 -178.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 64' ' ' ALA . 11.0 t -129.53 89.59 46.58 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.126 175.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.813 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 32.8 Cg_endo -63.94 137.43 57.69 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.968 2.445 . . . . 0.0 113.239 -175.326 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.38 -10.15 30.87 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.032 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.587 ' HB ' HG13 ' A' ' 21' ' ' ILE . 35.3 p -95.59 -179.62 4.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.522 0.201 . . . . 0.0 110.962 -178.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.533 ' HA ' HD11 ' A' ' 24' ' ' ILE . 34.3 ttmt -142.9 165.29 27.76 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 44.0 t -58.34 118.7 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 CA-C-O 120.664 0.268 . . . . 0.0 111.097 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.94 -5.74 59.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.761 178.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.444 ' O ' HG12 ' A' ' 21' ' ' ILE . 29.6 t0 -75.11 112.47 11.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 110.055 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 20' ' ' THR . 8.4 pt-20 -100.29 108.09 20.06 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.743 -178.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.0 m -142.15 161.87 19.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.807 -176.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.492 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 66.0 mtm180 -82.95 124.23 30.18 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.796 174.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.6 pt -117.96 136.92 53.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.137 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 56.3 tttm -100.4 114.6 28.27 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.7 t -69.29 121.19 18.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -94.44 -45.73 7.31 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.209 0.943 . . . . 0.0 110.872 -174.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.4 HH21 ' CD ' ' A' ' 13' ' ' GLU . 1.8 tpm_? -140.68 137.91 33.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.143 -172.336 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 34.4 m -114.78 136.31 51.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.295 0.569 . . . . 0.0 110.858 176.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 5.6 mp -123.02 156.19 62.98 Favored Pre-proline 0 C--N 1.321 -0.652 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -58.47 -16.67 30.48 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.848 2.365 . . . . 0.0 113.518 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.2 ttmm -110.35 -22.52 11.67 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -176.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -172.47 172.14 4.44 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.682 0.277 . . . . 0.0 111.0 -174.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.445 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -128.13 157.47 40.69 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.688 0.28 . . . . 0.0 110.984 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -124.61 136.4 53.91 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.518 ' HB3' HG22 ' A' ' 41' ' ' VAL . . . -136.83 163.2 31.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.956 0.407 . . . . 0.0 111.423 -176.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.1 p -117.27 145.0 44.24 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.854 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 40.6 t -78.39 127.19 38.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.131 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.0 m -123.49 13.88 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.743 0.306 . . . . 0.0 110.465 176.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 . . . . . 0 C--O 1.25 1.119 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.504 -179.634 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 CA--C 1.531 0.368 0 N-CA-C 113.343 0.478 . . . . 0.0 113.343 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 16.1 m -133.79 130.7 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.706 0.289 . . . . 0.0 110.474 179.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -113.09 173.7 6.26 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.541 0.686 . . . . 0.0 111.773 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.525 ' OE1' ' HD3' ' A' ' 56' ' ' ARG . 33.5 mt-10 -67.28 126.63 29.84 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.806 -1.088 . . . . 0.0 112.152 -177.082 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.555 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 91.68 16.35 52.31 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.389 -0.823 . . . . 0.0 112.929 174.039 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.569 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 26.2 mt-10 -99.04 160.42 14.27 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.344 -0.542 . . . . 0.0 111.187 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.51 124.34 68.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.208 -179.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -128.54 141.05 51.49 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.858 -177.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -80.51 97.29 7.08 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.4 m -109.66 148.9 13.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.353 0.597 . . . . 0.0 111.764 -173.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.0 m -110.1 119.09 38.18 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.912 172.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.64 HG13 ' HB ' ' A' ' 44' ' ' THR . 41.3 mm -69.64 116.77 11.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.746 -175.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -87.17 -51.03 6.22 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.863 -174.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.433 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 15.2 m-20 -124.31 -179.26 4.38 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.892 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.603 HD13 ' HA2' ' A' ' 30' ' ' GLY . 39.6 mm -137.82 137.8 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.584 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . . . . . . 0 C--N 1.312 -1.038 0 CA-C-O 121.912 0.863 . . . . 0.0 109.201 177.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.584 ' HB2' ' HB3' ' A' ' 25' ' ' ALA . 5.1 m-20 . . . . . 0 CA--C 1.519 -0.229 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.603 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -80.21 144.07 25.59 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.294 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.434 HG23 HG13 ' A' ' 38' ' ' VAL . 50.2 mm -105.5 102.69 14.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.105 0.479 . . . . 0.0 110.166 179.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.406 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -98.18 147.51 24.52 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 174.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 8.9 ptp85 -138.95 109.43 6.55 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.297 0.57 . . . . 0.0 111.049 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.7 mt -101.65 118.32 48.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 173.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 67.78 -3.1 1.22 Allowed 'General case' 0 CA--C 1.535 0.371 0 O-C-N 124.186 0.929 . . . . 0.0 110.519 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 117.86 -14.49 12.73 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.209 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.474 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 34.8 t80 -74.87 127.76 33.96 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.434 HG13 HG23 ' A' ' 31' ' ' ILE . 46.9 t -81.04 130.49 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.715 -173.721 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.536 HG12 ' HB3' ' A' ' 62' ' ' ALA . 50.7 mt -123.12 125.28 71.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.594 176.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.67 133.54 34.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.624 0.249 . . . . 0.0 110.768 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.7 t -132.13 104.23 13.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.247 -179.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -69.5 104.21 1.24 Allowed 'Trans proline' 0 C--O 1.233 0.262 0 C-N-CA 122.947 2.432 . . . . 0.0 112.849 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.95 48.17 0.74 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.979 175.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.64 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.8 p -138.08 170.96 15.13 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.752 -0.264 . . . . 0.0 111.29 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.663 ' HE3' ' HA ' ' A' ' 45' ' ' LYS . 0.2 OUTLIER -132.97 166.84 21.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.087 -177.044 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 43.8 t -65.47 116.42 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 178.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 95.62 1.76 61.87 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.407 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -75.12 123.66 25.64 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -103.19 108.57 19.83 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.385 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.5 m -138.18 161.58 31.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.366 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -96.34 123.67 40.06 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.267 172.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.472 HG22 ' HA ' ' A' ' 66' ' ' VAL . 46.9 pt -117.46 143.37 28.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.625 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.569 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 49.1 tttp -98.82 109.8 22.51 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 173.073 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.5 t -68.92 107.48 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 176.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -88.71 -40.84 12.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.653 0.596 . . . . 0.0 111.21 -172.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.525 ' HD3' ' OE1' ' A' ' 13' ' ' GLU . 19.6 mmt180 -139.71 129.59 24.78 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.004 -175.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.1 m -97.1 117.96 42.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 172.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.506 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 80.1 mt -101.37 162.08 21.61 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.922 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PRO . . . . . 0.506 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 91.1 Cg_exo -43.89 -38.49 10.03 Favored 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 123.57 2.847 . . . . 0.0 114.666 -175.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 17.6 tptp -120.29 -3.72 9.98 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -172.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.416 ' CE1' HD12 ' A' ' 58' ' ' LEU . 54.2 p90 -170.74 167.8 7.59 Favored 'General case' 0 C--O 1.222 -0.361 0 CA-C-O 120.613 0.244 . . . . 0.0 110.909 -177.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.536 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -108.47 147.35 31.8 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.031 0.443 . . . . 0.0 111.05 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -112.52 126.62 55.53 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.187 176.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -130.26 156.11 45.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.122 0.487 . . . . 0.0 111.468 -176.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 6.6 t -105.73 130.46 53.73 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.733 178.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.472 ' HA ' HG22 ' A' ' 52' ' ' ILE . 6.3 p -79.95 122.99 36.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.135 0.493 . . . . 0.0 111.067 -177.713 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 6.2 t -105.11 0.48 10.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.698 0.761 . . . . 0.0 109.639 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 . . . . . 0 C--O 1.247 0.952 0 CA-C-N 114.259 -1.337 . . . . 0.0 110.819 -175.234 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.481 1.079 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -82.19 -18.96 40.83 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 175.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -97.62 132.66 43.07 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.728 176.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -64.34 144.08 57.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.226 177.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -80.82 124.1 28.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.9 p -74.06 -9.65 58.84 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.993 0.425 . . . . 0.0 110.489 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.466 ' HD2' ' HA ' ' A' ' 7' ' ' ARG . 0.8 OUTLIER 64.55 23.76 12.93 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 115.47 -0.787 . . . . 0.0 111.559 -178.416 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.8 m -68.12 94.68 0.52 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.991 -0.549 . . . . 0.0 109.689 175.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 15.3 m -111.07 157.23 39.36 Favored Pre-proline 0 N--CA 1.448 -0.546 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.915 -176.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -67.07 -42.86 7.32 Favored 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.792 2.328 . . . . 0.0 112.78 179.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.5 m -126.29 146.62 31.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 121.225 0.536 . . . . 0.0 112.268 -172.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -121.07 171.51 8.62 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 174.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.549 ' HG2' ' HA ' ' A' ' 56' ' ' ARG . 38.9 mt-10 -66.54 125.12 24.74 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.239 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 23.06 17.37 Favored Glycine 0 N--CA 1.451 -0.346 0 CA-C-N 116.203 -0.453 . . . . 0.0 113.633 173.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.45 ' O ' ' HD2' ' A' ' 53' ' ' LYS . 45.0 mt-10 -105.28 171.65 7.21 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 117.278 0.539 . . . . 0.0 110.924 -177.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 7.1 p -141.97 129.28 20.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.857 0.361 . . . . 0.0 110.59 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 87.8 m-85 -134.84 142.47 46.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.388 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -82.03 94.3 7.15 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 32.9 m -111.54 159.11 11.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.304 0.573 . . . . 0.0 111.477 -173.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 m -112.69 125.97 54.88 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.292 -0.867 . . . . 0.0 108.809 172.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.578 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.0 mm -69.59 100.55 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.047 0.451 . . . . 0.0 110.257 -179.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -81.51 -34.72 31.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.283 -175.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.517 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 31.2 t0 -138.57 170.36 16.15 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.264 -178.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.44 HG12 ' HA2' ' A' ' 30' ' ' GLY . 27.8 mt -145.37 131.68 14.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 -179.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -83.63 144.23 29.57 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.416 ' O ' ' HB2' ' A' ' 27' ' ' GLN . 48.8 mtm180 -64.62 92.94 0.1 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.361 0.6 . . . . 0.0 112.086 -173.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.416 ' HB2' ' O ' ' A' ' 26' ' ' ARG . 8.0 tp-100 166.27 -27.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 114.202 -1.363 . . . . 0.0 108.44 -177.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 120.29 7.38 9.21 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.351 -0.84 . . . . 0.0 112.402 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.606 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 5.5 m-20 -83.27 114.67 21.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.664 0.268 . . . . 0.0 110.309 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.44 ' HA2' HG12 ' A' ' 24' ' ' ILE . . . -71.73 126.42 12.39 Favored Glycine 0 N--CA 1.443 -0.848 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.632 177.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.571 HG23 HG13 ' A' ' 38' ' ' VAL . 75.5 mt -94.42 107.19 19.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.192 0.52 . . . . 0.0 110.649 -178.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.409 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -99.81 96.32 7.5 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 115.157 -0.928 . . . . 0.0 109.183 173.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.427 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 14.6 ptm180 -93.26 93.54 8.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.433 -176.276 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 52.5 mt -89.11 109.88 20.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.259 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 57.56 12.89 1.68 Allowed 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.953 -1.022 . . . . 0.0 112.302 -176.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.37 -19.73 12.87 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.313 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.427 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 70.4 t80 -73.72 125.66 28.58 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.571 HG13 HG23 ' A' ' 31' ' ' ILE . 98.0 t -93.18 112.58 26.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.346 0.593 . . . . 0.0 111.652 -173.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.409 ' HB ' ' HB3' ' A' ' 32' ' ' ALA . 57.2 mt -103.21 126.78 57.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.474 173.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -95.17 121.8 37.19 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.011 0.434 . . . . 0.0 111.002 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.526 HG22 ' HB3' ' A' ' 64' ' ' ALA . 21.6 t -120.33 89.9 44.32 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.498 176.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 17.3 Cg_exo -66.15 127.48 17.65 Favored 'Trans proline' 0 N--CA 1.464 -0.22 0 C-N-CA 122.899 2.399 . . . . 0.0 112.536 -175.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.79 43.21 3.16 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.815 177.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.578 ' HB ' HG13 ' A' ' 21' ' ' ILE . 6.6 p -128.06 -171.7 2.51 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.588 0.232 . . . . 0.0 111.254 179.033 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -140.06 152.94 46.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.237 -176.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 38.9 t -63.01 118.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.74 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.24 1.85 64.42 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.382 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -76.18 119.43 20.08 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.774 0.321 . . . . 0.0 110.621 -178.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -98.67 108.11 20.72 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.577 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.419 ' HB ' HG13 ' A' ' 66' ' ' VAL . 15.3 m -139.79 160.25 27.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 112.281 0.474 . . . . 0.0 112.281 -174.195 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -86.14 110.36 19.51 Favored 'General case' 0 CA--C 1.512 -0.481 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 44.8 pt -97.55 132.44 42.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.719 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.45 ' HD2' ' O ' ' A' ' 15' ' ' GLU . 51.0 tptt -92.95 104.86 17.05 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 174.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 99.5 t -69.29 97.24 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -65.36 -48.55 72.59 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.549 ' HA ' ' HG2' ' A' ' 13' ' ' GLU . 75.0 mtp180 -150.97 161.77 42.09 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.536 -177.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.427 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.7 m -128.98 135.64 61.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.106 0.479 . . . . 0.0 110.576 179.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -111.61 157.55 39.0 Favored Pre-proline 0 C--N 1.32 -0.682 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 175.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_exo -57.28 -16.42 22.33 Favored 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.965 2.443 . . . . 0.0 113.805 -176.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.4 mmtm -117.32 -18.23 9.95 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -176.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.2 p90 -169.88 161.06 8.81 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.425 0.155 . . . . 0.0 110.66 -175.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -120.08 156.63 30.6 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.263 -178.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -114.43 134.2 55.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.346 176.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.526 ' HB3' HG22 ' A' ' 41' ' ' VAL . . . -145.75 154.9 42.56 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.699 178.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 22.3 t -128.47 157.14 41.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.041 178.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.454 HG12 ' H ' ' A' ' 68' ' ' GLU . 99.1 t -84.25 119.64 33.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.823 -177.03 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.7 m -104.59 15.88 6.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 121.083 0.468 . . . . 0.0 110.813 178.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.454 ' H ' HG12 ' A' ' 66' ' ' VAL . 41.9 mt-10 . . . . . 0 C--O 1.247 0.948 0 CA-C-N 114.547 -1.206 . . . . 0.0 111.307 178.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 N--CA 1.481 1.092 0 CA-C-O 120.694 0.283 . . . . 0.0 110.758 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.01 -173.45 2.25 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 57.2 mtp180 63.31 42.4 6.96 Favored 'General case' 0 C--O 1.236 0.356 0 O-C-N 123.615 0.572 . . . . 0.0 110.184 -177.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.454 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 1.8 pm0 -60.34 134.21 56.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.555 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 -56.77 118.02 4.49 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.31 -173.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.4 p 57.81 13.07 1.9 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.504 1.122 . . . . 0.0 112.594 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 68.8 mtt-85 66.36 -57.68 0.37 Allowed 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.74 0.816 . . . . 0.0 112.635 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 40.6 m 70.82 14.05 7.05 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.624 0.77 . . . . 0.0 111.066 -175.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 3.3 m -148.38 100.02 3.6 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.284 178.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -83.7 -14.25 7.83 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.529 2.153 . . . . 0.0 112.82 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 m -113.33 151.22 15.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.806 -178.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.416 ' HB2' ' HG2' ' A' ' 15' ' ' GLU . 43.3 mm-40 -92.31 148.74 21.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.499 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.454 ' CG ' HG22 ' A' ' 57' ' ' VAL . 37.5 mt-10 -68.42 109.56 3.73 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.243 0.544 . . . . 0.0 110.856 176.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.474 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 105.33 28.87 5.32 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.001 -178.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 12' ' ' GLU . 8.4 mm-40 -87.04 160.03 18.75 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 175.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.516 HG22 ' HG3' ' A' ' 53' ' ' LYS . 46.5 t -139.02 115.48 10.1 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.673 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.406 ' CE2' HD11 ' A' ' 52' ' ' ILE . 37.4 p90 -151.25 142.92 23.69 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.404 178.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.608 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 3.7 p-10 -84.47 137.04 33.58 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.26 0.552 . . . . 0.0 110.446 179.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 18.2 m -134.63 160.55 41.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.026 -176.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.5 m -103.52 125.92 50.36 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 169.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.558 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.4 mm -67.41 114.38 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -95.75 -32.67 12.61 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.229 -0.896 . . . . 0.0 111.122 -170.296 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -140.62 165.9 26.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.639 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.758 HG22 ' H ' ' A' ' 26' ' ' ARG . 43.5 mm -129.79 133.75 64.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.543 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.535 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -80.88 11.43 3.96 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -175.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.758 ' H ' HG22 ' A' ' 24' ' ' ILE . 17.2 tpt180 57.88 85.63 0.09 Allowed 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.256 -179.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 171.56 -24.85 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.732 -1.122 . . . . 0.0 108.928 -169.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 118.34 -11.44 12.78 Favored Glycine 0 N--CA 1.451 -0.334 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.693 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.551 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 38.9 m-20 -99.01 143.25 29.5 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.692 0.282 . . . . 0.0 110.523 -179.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.552 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -89.97 150.64 21.13 Favored Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.813 -176.073 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.535 HD11 ' HB2' ' A' ' 25' ' ' ALA . 43.0 mm -111.0 117.3 54.69 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-O 121.161 0.505 . . . . 0.0 110.872 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -119.28 102.94 9.06 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.369 -0.832 . . . . 0.0 108.815 172.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.426 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 25.0 ptt85 -107.07 114.84 29.16 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.98 0.419 . . . . 0.0 111.444 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.521 HG22 ' HG3' ' A' ' 35' ' ' GLU . 41.6 mt -99.36 119.51 47.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.996 177.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.521 ' HG3' HG22 ' A' ' 34' ' ' ILE . 32.9 mt-10 62.23 26.06 15.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.994 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.65 -19.82 53.1 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.197 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.426 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 58.8 t80 -72.06 108.84 5.48 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 -179.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 HG23 ' A' ' 31' ' ' ILE . 59.3 t -76.14 124.18 33.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.106 0.479 . . . . 0.0 111.526 -175.32 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.572 HG12 ' HB3' ' A' ' 62' ' ' ALA . 63.7 mt -118.77 129.77 74.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.187 -0.46 . . . . 0.0 109.885 176.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -92.38 124.66 36.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.736 -177.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.414 ' HA ' ' HD2' ' A' ' 42' ' ' PRO . 38.8 t -111.13 109.15 57.08 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.819 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.551 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 13.6 Cg_endo -57.24 119.62 6.99 Favored 'Trans proline' 0 CA--C 1.53 0.285 0 C-N-CA 122.953 2.435 . . . . 0.0 113.191 -175.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 63.58 74.13 0.47 Allowed Glycine 0 CA--C 1.519 0.337 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.862 175.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.558 ' HB ' HG13 ' A' ' 21' ' ' ILE . 1.2 p -143.33 161.52 38.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.802 0.334 . . . . 0.0 110.918 176.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 tptm -120.09 151.95 38.3 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.058 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.456 HG23 HG12 ' A' ' 24' ' ' ILE . 80.6 t -60.11 126.17 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 176.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 103.51 -5.07 47.8 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.893 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.81 107.83 4.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.915 0.388 . . . . 0.0 110.601 174.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -87.94 96.17 10.39 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 173.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.519 ' HB ' HG23 ' A' ' 66' ' ' VAL . 19.1 m -134.48 147.79 29.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -169.587 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.608 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 0.2 OUTLIER -79.38 120.15 23.41 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.199 -0.91 . . . . 0.0 109.595 174.76 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.406 HD11 ' CE2' ' A' ' 17' ' ' TYR . 2.7 pp -116.88 141.16 36.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.552 178.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.516 ' HG3' HG22 ' A' ' 16' ' ' VAL . 78.4 tttt -101.57 114.72 29.01 Favored 'General case' 0 N--CA 1.444 -0.759 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 172.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.6 t -69.25 99.13 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 173.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -88.52 -37.53 15.67 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.085 -169.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -150.47 130.99 13.87 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -174.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.454 HG22 ' CG ' ' A' ' 13' ' ' GLU . 26.9 m -112.69 139.24 38.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.17 0.509 . . . . 0.0 111.662 -177.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -118.28 154.31 51.9 Favored Pre-proline 0 C--N 1.322 -0.627 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 170.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.03 -19.57 26.91 Favored 'Trans proline' 0 CA--C 1.533 0.45 0 C-N-CA 122.634 2.222 . . . . 0.0 113.654 -177.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -105.99 -26.32 11.71 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.262 0.467 . . . . 0.0 112.262 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -168.71 163.75 12.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.426 0.155 . . . . 0.0 110.59 -172.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.572 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -129.88 159.39 36.76 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.117 0.484 . . . . 0.0 111.755 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -105.92 127.82 53.38 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.565 174.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -141.23 126.89 19.0 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.717 0.294 . . . . 0.0 110.599 179.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 11.6 t -100.55 145.92 27.74 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.261 -179.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.519 HG23 ' HB ' ' A' ' 50' ' ' VAL . 4.0 p -82.38 116.67 27.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.101 0.477 . . . . 0.0 110.681 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 25.5 m -101.79 4.61 10.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.621 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.542 ' OXT' ' HB2' ' A' ' 51' ' ' ARG . 43.6 mt-10 . . . . . 0 C--O 1.247 0.922 0 CA-C-N 114.254 -1.339 . . . . 0.0 112.361 177.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.431 ' O ' ' HB2' ' A' ' 2' ' ' PHE . 24.9 ttt . . . . . 0 N--CA 1.479 0.989 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.652 ' HD1' ' HG2' ' A' ' 3' ' ' ARG . 22.6 t80 176.37 -77.84 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 175.212 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.652 ' HG2' ' HD1' ' A' ' 2' ' ' PHE . 32.9 ptt180 -175.12 22.92 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.58 174.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -95.37 122.59 38.25 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.805 -170.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 67.61 -170.47 0.19 Allowed 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.464 -178.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.1 m 66.01 26.92 10.8 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.12 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.4 mtp85 -106.57 155.8 19.25 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.417 -178.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.4 m -82.39 33.86 0.41 Allowed 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -170.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 2.1 m -130.19 101.36 17.88 Favored Pre-proline 0 C--N 1.323 -0.586 0 CA-C-O 120.958 0.409 . . . . 0.0 110.579 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_exo -71.74 -30.3 14.61 Favored 'Trans proline' 0 CA--C 1.53 0.29 0 C-N-CA 123.083 2.522 . . . . 0.0 113.535 -175.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.2 m -122.23 148.23 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.91 0.386 . . . . 0.0 111.459 -175.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.8 mm-40 -102.33 161.88 13.35 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.327 178.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.458 ' HG3' HG22 ' A' ' 57' ' ' VAL . 3.5 mp0 -65.98 119.64 11.71 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.266 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.3 18.7 27.89 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 116.029 -0.532 . . . . 0.0 113.153 173.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 33.0 mt-10 -92.61 166.59 12.42 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.036 -176.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.4 p -131.14 127.11 60.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.954 0.407 . . . . 0.0 110.216 179.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -129.98 140.81 50.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.764 -176.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -79.97 90.38 5.36 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 171.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 34.3 m -104.73 148.77 8.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.395 0.616 . . . . 0.0 111.72 -172.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.63 HG23 ' HG2' ' A' ' 49' ' ' GLU . 24.6 m -101.72 124.91 48.15 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.318 173.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.538 HG13 ' HB ' ' A' ' 44' ' ' THR . 43.6 mm -70.33 89.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 174.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 96.3 mt-30 -81.93 -33.1 30.51 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.859 -175.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -128.84 170.67 13.09 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.655 179.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.455 ' HB ' ' CG2' ' A' ' 46' ' ' VAL . 8.4 tt -147.73 150.46 14.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.571 ' HB3' ' OE1' ' A' ' 27' ' ' GLN . . . -97.25 175.13 6.39 Favored 'General case' 0 C--N 1.314 -0.936 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.557 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 29.2 mtm180 -71.18 -22.13 62.07 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -171.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.571 ' OE1' ' HB3' ' A' ' 25' ' ' ALA . 0.1 OUTLIER -80.6 -17.28 51.84 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.297 -0.561 . . . . 0.0 110.048 177.536 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.91 19.83 11.39 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.919 -0.582 . . . . 0.0 113.342 174.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.616 ' OD1' ' HA ' ' A' ' 42' ' ' PRO . 56.7 m-20 -99.75 144.86 28.33 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 175.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.416 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -74.21 141.37 28.89 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.901 -0.591 . . . . 0.0 113.003 -171.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.539 HG23 HG13 ' A' ' 38' ' ' VAL . 47.9 mm -107.73 104.52 17.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.137 0.494 . . . . 0.0 110.154 178.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -97.53 97.02 8.71 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.636 175.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 29.7 ptt85 -96.05 94.51 7.6 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.289 0.566 . . . . 0.0 111.394 -175.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 55.1 mt -86.51 113.47 24.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.99 178.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.2 mm-40 54.98 24.34 5.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.729 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.52 -17.99 51.95 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.44 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 35.1 t80 -75.95 121.74 23.15 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.539 HG13 HG23 ' A' ' 31' ' ' ILE . 57.9 t -83.35 121.66 36.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 121.197 0.523 . . . . 0.0 112.079 -173.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.571 HG12 ' HB3' ' A' ' 62' ' ' ALA . 48.2 mt -116.61 126.92 74.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.548 174.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -91.22 125.22 35.93 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.825 0.345 . . . . 0.0 111.136 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.4 t -119.45 111.79 36.19 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.669 176.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.616 ' HA ' ' OD1' ' A' ' 29' ' ' ASP . 45.8 Cg_endo -68.65 114.72 3.61 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 122.631 2.22 . . . . 0.0 113.659 -173.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.53 0.35 58.0 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 120.805 -0.712 . . . . 0.0 114.738 170.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.538 ' HB ' HG13 ' A' ' 21' ' ' ILE . 16.7 p -89.12 138.41 31.44 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 118.09 0.945 . . . . 0.0 111.936 -177.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -92.28 155.5 17.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.967 -179.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.455 ' CG2' ' HB ' ' A' ' 24' ' ' ILE . 96.9 t -64.4 128.56 27.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.198 0 CA-C-O 121.069 0.461 . . . . 0.0 110.962 179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.66 -17.72 42.11 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.214 -179.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.09 115.08 9.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.952 0.406 . . . . 0.0 110.446 178.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.63 ' HG2' HG23 ' A' ' 20' ' ' THR . 37.2 mt-10 -97.6 97.83 9.38 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 175.315 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.8 m -127.9 167.29 23.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.799 -173.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 60.3 mtt180 -100.25 120.81 40.48 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.13 0.491 . . . . 0.0 109.885 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 66' ' ' VAL . 47.7 pt -113.25 144.6 20.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.394 -178.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 46.0 tttp -99.21 108.71 21.36 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.8 t -68.94 98.4 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -86.38 -35.3 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.478 -171.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 70.0 mtm180 -141.56 139.5 33.2 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.802 -174.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.458 HG22 ' HG3' ' A' ' 13' ' ' GLU . 15.4 m -123.23 115.51 45.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.4 0.619 . . . . 0.0 110.54 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -97.65 155.05 37.65 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.63 -6.96 8.05 Favored 'Trans proline' 0 CA--C 1.531 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 113.304 -178.054 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.446 ' NZ ' ' HB2' ' A' ' 60' ' ' LYS . 5.0 ttmp? -111.25 -30.72 7.33 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.056 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -170.86 167.48 7.48 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.365 -175.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.571 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -110.28 156.21 21.01 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.913 0.387 . . . . 0.0 110.946 179.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -123.87 136.43 54.36 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 178.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -138.99 148.61 43.7 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.064 0.459 . . . . 0.0 111.461 -176.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.4 p -105.82 130.17 53.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.745 174.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.769 HG22 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -77.06 130.51 36.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.056 0.455 . . . . 0.0 110.764 -176.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.5 m -108.24 22.25 4.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.099 179.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.769 ' H ' HG22 ' A' ' 66' ' ' VAL . 26.5 mm-40 . . . . . 0 C--O 1.246 0.909 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.543 -177.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.0 mmt . . . . . 0 N--CA 1.481 1.077 0 CA-C-O 120.637 0.255 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -86.75 163.27 17.39 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 178.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 7.7 mtt180 66.66 -165.87 0.22 Allowed 'General case' 0 C--O 1.233 0.222 0 O-C-N 123.4 0.437 . . . . 0.0 110.15 -176.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -78.83 82.41 5.04 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.447 0.641 . . . . 0.0 111.052 -178.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 55.3 mt-10 63.62 16.45 9.68 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 114.67 -1.15 . . . . 0.0 111.652 177.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.5 m 59.77 14.37 4.09 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.253 -0.885 . . . . 0.0 112.205 178.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.6 mtp180 62.6 -76.97 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.1 t 66.51 -161.31 0.25 Allowed 'General case' 0 C--O 1.235 0.309 0 CA-C-N 114.978 -1.01 . . . . 0.0 108.494 -164.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 17.1 m 35.33 70.65 0.94 Allowed Pre-proline 0 N--CA 1.473 0.679 0 C-N-CA 123.917 0.887 . . . . 0.0 113.028 -178.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -90.16 -7.74 4.26 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.506 2.138 . . . . 0.0 113.316 -177.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 29.1 m -116.67 156.38 17.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.667 0.27 . . . . 0.0 111.001 -175.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -129.1 157.69 41.04 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.231 -0.441 . . . . 0.0 109.933 179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.43 ' HB3' ' HA ' ' A' ' 56' ' ' ARG . 8.8 pt-20 -67.03 127.67 33.47 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.135 0.493 . . . . 0.0 110.978 176.206 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.68 29.45 7.35 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.988 -178.042 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -115.04 170.43 8.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 -179.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.47 125.35 16.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-O 121.182 0.515 . . . . 0.0 110.48 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -136.15 151.51 49.84 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.432 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -91.86 126.52 36.97 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 170.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.9 m -140.48 153.79 21.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.003 0.43 . . . . 0.0 111.552 -174.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.5 m -106.75 121.82 45.14 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 171.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.558 HG13 ' HB ' ' A' ' 44' ' ' THR . 50.3 mm -68.95 116.02 8.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 120.886 0.374 . . . . 0.0 110.566 -177.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.86 -54.53 5.52 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.227 -175.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 47.0 t0 -128.4 176.27 7.85 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.957 -176.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.554 HD13 ' HA2' ' A' ' 30' ' ' GLY . 43.6 mm -134.36 139.05 48.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -179.028 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -82.45 26.87 0.53 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 -175.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.42 ' H ' HG22 ' A' ' 24' ' ' ILE . 52.4 mtm180 60.85 35.45 19.35 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 175.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -158.6 -36.06 0.07 Allowed 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.436 0.636 . . . . 0.0 109.652 -177.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 150.06 -29.43 1.11 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.243 -0.979 . . . . 0.0 112.381 178.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.634 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 1.8 m-20 -64.13 118.11 8.09 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 176.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.554 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -78.75 146.48 29.85 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 121.17 -0.538 . . . . 0.0 112.25 179.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 23' ' ' ASP . 50.9 mm -104.52 99.7 8.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.993 0.425 . . . . 0.0 110.457 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -127.22 110.74 13.19 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.591 175.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.573 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 23.7 ptt180 -108.64 139.49 43.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.216 0.531 . . . . 0.0 111.295 -176.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 61.6 mt -122.03 119.04 57.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.714 175.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.6 mm-40 58.24 32.54 22.17 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.822 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.14 -31.72 7.4 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.789 -0.641 . . . . 0.0 112.739 179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.404 ' HE2' ' HB2' ' A' ' 62' ' ' ALA . 20.0 t80 -76.14 110.16 10.4 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.93 0.395 . . . . 0.0 110.058 -177.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' A' ' 33' ' ' ARG . 7.2 p -84.7 134.64 26.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.182 0.515 . . . . 0.0 111.753 -174.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.537 HG12 ' HB3' ' A' ' 62' ' ' ALA . 51.5 mt -107.99 126.43 64.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.754 176.331 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -92.95 122.35 35.22 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.524 178.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.537 HG21 HG21 ' A' ' 52' ' ' ILE . 28.2 t -124.41 95.27 43.52 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.176 -0.466 . . . . 0.0 109.808 178.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.634 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 43.3 Cg_endo -68.15 122.19 9.24 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.851 2.367 . . . . 0.0 112.989 -177.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.21 27.9 4.32 Favored Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.34 177.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.558 ' HB ' HG13 ' A' ' 21' ' ' ILE . 17.3 p -118.99 164.34 15.62 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.991 0.424 . . . . 0.0 111.197 -179.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 48' ' ' ASP . 17.7 tptp -116.21 164.03 15.1 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.785 177.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 61.9 t -65.08 120.5 12.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 177.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.91 62.13 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.01 -178.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.513 ' HB2' ' O ' ' A' ' 45' ' ' LYS . 0.5 OUTLIER -69.25 107.92 3.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.754 0.311 . . . . 0.0 110.604 176.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -92.56 100.45 12.98 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 175.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.4 m -135.89 160.07 39.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.256 0.551 . . . . 0.0 112.131 -172.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -91.66 119.48 31.58 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.524 172.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.537 HG21 HG21 ' A' ' 41' ' ' VAL . 47.6 pt -108.74 139.53 30.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.296 0.569 . . . . 0.0 111.566 -175.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 50.3 tptt -99.26 106.04 18.13 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 173.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.516 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 58.1 t -68.9 113.42 4.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -90.57 -37.23 13.97 Favored 'General case' 0 C--N 1.323 -0.552 0 O-C-N 123.609 0.568 . . . . 0.0 110.911 -174.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.43 ' HA ' ' HB3' ' A' ' 13' ' ' GLU . 73.0 mtp180 -143.07 155.75 44.68 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.976 0.417 . . . . 0.0 111.371 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 54.6 t -126.17 125.71 68.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.973 174.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.575 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 5.8 mp -114.01 162.16 24.34 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.575 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 40.4 Cg_exo -36.77 -44.35 1.05 Allowed 'Trans proline' 0 C--N 1.351 0.667 0 C-N-CA 124.347 3.365 . . . . 0.0 115.686 -174.188 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.601 ' HG3' ' HD1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.74 14.47 5.37 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -175.299 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.601 ' HD1' ' HG3' ' A' ' 60' ' ' LYS . 46.9 p90 -169.25 149.47 4.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.938 0.399 . . . . 0.0 111.19 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.537 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -107.16 165.52 11.3 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.655 179.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 75.2 t80 -128.17 122.33 31.65 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.516 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -139.79 164.38 30.12 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.824 0.345 . . . . 0.0 111.508 -176.02 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 9.5 p -133.98 158.82 42.53 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.371 176.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.9 t -83.86 115.51 26.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.786 0.327 . . . . 0.0 110.424 -177.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 32.7 m -118.24 3.34 7.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.016 0.436 . . . . 0.0 110.937 -179.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 . . . . . 0 C--O 1.245 0.85 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.581 -174.027 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 mpt? . . . . . 0 N--CA 1.483 1.219 0 CA-C-O 120.86 0.362 . . . . 0.0 110.224 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -137.1 151.82 49.3 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.619 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.402 ' HD3' HH11 ' A' ' 3' ' ' ARG . 20.2 ttm-85 -145.78 143.06 29.45 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.582 175.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -77.69 171.87 14.28 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.184 0.516 . . . . 0.0 111.412 -178.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -90.37 159.88 16.37 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.962 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.7 m -137.88 -51.49 0.61 Allowed 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.498 -178.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 17.6 mmt180 64.55 120.25 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.546 0 O-C-N 123.676 0.61 . . . . 0.0 111.291 -172.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.624 ' O ' HG22 ' A' ' 9' ' ' VAL . 2.8 m -77.35 80.36 3.85 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 174.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.685 ' HB ' ' HD2' ' A' ' 10' ' ' PRO . 1.5 m 60.39 170.26 0.07 OUTLIER Pre-proline 0 CA--C 1.549 0.935 0 O-C-N 124.395 1.059 . . . . 0.0 109.804 -169.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.685 ' HD2' ' HB ' ' A' ' 9' ' ' VAL . 30.0 Cg_endo -63.65 -11.15 25.0 Favored 'Trans proline' 0 C--N 1.353 0.812 0 C-N-CA 121.983 1.789 . . . . 0.0 113.999 -173.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.557 ' HB ' HG21 ' A' ' 54' ' ' VAL . 24.5 m -135.13 132.5 52.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.494 ' HG2' ' HB2' ' A' ' 8' ' ' SER . 43.8 mt-10 -118.77 170.75 8.72 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.245 0.545 . . . . 0.0 111.748 -177.114 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.47 ' HG3' HG22 ' A' ' 57' ' ' VAL . 28.2 mt-10 -65.6 116.98 7.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.196 -0.911 . . . . 0.0 112.355 -172.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.551 ' HA2' ' HE2' ' A' ' 53' ' ' LYS . . . 94.17 31.69 7.89 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.389 171.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -122.77 153.71 39.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.209 -0.597 . . . . 0.0 110.771 178.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 3.9 p -110.45 133.1 56.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.403 -178.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -132.38 150.79 52.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.046 -177.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -94.29 107.58 19.52 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 176.258 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.436 HG12 HD11 ' A' ' 34' ' ' ILE . 29.4 m -118.47 166.65 12.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.531 0.681 . . . . 0.0 111.834 -171.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 32.9 m -131.38 127.52 37.74 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.358 174.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.517 HG13 ' HB ' ' A' ' 44' ' ' THR . 46.5 mm -69.0 125.07 26.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.78 -174.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.0 mm-40 -98.83 -41.52 7.6 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.398 -175.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.405 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 26.3 m-20 -133.77 173.66 11.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.771 0.319 . . . . 0.0 111.144 -177.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.453 HG12 HG23 ' A' ' 46' ' ' VAL . 45.5 mm -122.36 134.11 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 178.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.616 ' HB3' ' HB3' ' A' ' 29' ' ' ASP . . . -101.2 175.13 5.69 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.363 -179.117 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 56.8 mtp85 -68.01 -31.45 71.14 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -174.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.609 HE21 ' HA ' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -78.31 12.92 1.7 Allowed 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 178.778 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 69.62 27.78 72.99 Favored Glycine 0 N--CA 1.451 -0.338 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 -174.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.616 ' HB3' ' HB3' ' A' ' 25' ' ' ALA . 13.5 t70 -91.24 144.8 25.23 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.82 -0.69 . . . . 0.0 110.053 -176.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.583 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -96.19 112.63 4.47 Favored Glycine 0 N--CA 1.439 -1.158 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 177.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.518 HG23 HG13 ' A' ' 38' ' ' VAL . 74.7 mt -79.14 103.39 6.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.283 0.563 . . . . 0.0 110.71 -175.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.508 ' HB2' HD13 ' A' ' 21' ' ' ILE . . . -105.48 116.43 31.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.221 175.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 25.1 ptt180 -107.5 136.59 47.01 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.476 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.436 HD11 HG12 ' A' ' 19' ' ' VAL . 56.7 mt -124.48 118.25 52.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.608 174.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 59.42 26.94 15.94 Favored 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.743 -179.438 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.08 -22.63 39.88 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.044 -0.598 . . . . 0.0 112.762 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -75.55 130.65 39.18 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 -178.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.518 HG13 HG23 ' A' ' 31' ' ' ILE . 61.9 t -86.26 122.11 38.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.171 0.51 . . . . 0.0 111.689 -175.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.45 HD11 HG11 ' A' ' 11' ' ' VAL . 46.1 mt -115.1 133.4 61.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.182 174.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.455 ' HB3' ' OD2' ' A' ' 29' ' ' ASP . 98.1 m-85 -98.14 130.05 44.91 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.974 0.416 . . . . 0.0 111.206 -177.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 41.6 t -130.34 93.5 32.64 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.862 178.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.521 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 26.1 Cg_exo -62.66 129.16 25.45 Favored 'Trans proline' 0 CA--C 1.528 0.221 0 C-N-CA 123.095 2.53 . . . . 0.0 113.333 -174.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.44 50.53 3.36 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.609 174.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.583 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 11.1 p -139.72 -178.57 5.48 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.643 -0.327 . . . . 0.0 110.768 177.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.543 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 4.9 ttpm? -133.93 153.69 51.59 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.453 HG23 HG12 ' A' ' 24' ' ' ILE . 38.5 t -58.37 117.0 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 175.048 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.97 -16.44 18.22 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.379 -177.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.543 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.1 m-20 -67.7 115.82 7.7 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.95 178.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -100.23 90.87 4.49 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.69 174.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.4 m -120.86 169.14 12.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.153 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 64.0 mtp180 -102.07 128.36 48.56 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.478 HG22 ' HA ' ' A' ' 66' ' ' VAL . 2.8 pp -127.02 150.29 32.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.204 -176.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.551 ' HE2' ' HA2' ' A' ' 14' ' ' GLY . 69.6 tttt -106.07 118.78 37.52 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 172.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.557 HG21 ' HB ' ' A' ' 11' ' ' VAL . 87.1 t -69.27 106.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 171.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 13.5 tp10 -84.87 -36.19 21.71 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.294 -170.178 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 56' ' ' ARG . 7.4 ptp85 -156.44 150.07 24.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.293 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.47 HG22 ' HG3' ' A' ' 13' ' ' GLU . 27.1 m -121.25 138.92 50.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.098 0.475 . . . . 0.0 110.925 -179.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 6.7 mp -110.57 157.89 37.04 Favored Pre-proline 0 C--N 1.319 -0.76 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 174.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -58.89 -1.46 0.8 Allowed 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.162 2.575 . . . . 0.0 114.68 -176.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.4 -16.8 2.36 Favored 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -169.03 161.08 10.38 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.605 0.241 . . . . 0.0 110.838 -176.026 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -115.04 152.18 32.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.89 0.376 . . . . 0.0 111.515 -177.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 49.4 t80 -112.14 129.02 56.38 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.416 178.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -128.58 149.52 50.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.313 0.578 . . . . 0.0 111.889 -177.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.3 t -109.74 136.02 49.74 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.166 175.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.567 HG22 ' H ' ' A' ' 68' ' ' GLU . 6.9 p -82.47 123.23 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.333 0.587 . . . . 0.0 111.063 -176.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.5 m -107.45 28.43 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 -178.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.567 ' H ' HG22 ' A' ' 66' ' ' VAL . 41.8 mt-10 . . . . . 0 C--O 1.251 1.152 0 CA-C-N 115.073 -0.967 . . . . 0.0 111.256 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.1 ttt . . . . . 0 N--CA 1.475 0.8 0 CA-C-O 120.895 0.379 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -155.27 102.18 2.27 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.42 177.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 44.2 mtm105 -145.72 110.01 4.98 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.023 176.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 61.6 71.0 0.56 Allowed 'General case' 0 C--N 1.33 -0.261 0 O-C-N 123.517 0.511 . . . . 0.0 110.993 174.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 42.46 -156.71 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 124.54 1.136 . . . . 0.0 112.984 -178.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.4 m -133.79 -55.51 0.88 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.408 176.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.434 HH11 ' HD2' ' A' ' 7' ' ' ARG . 5.1 ptp180 -175.8 67.8 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.451 178.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 12.9 m -84.82 23.04 1.24 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.739 -173.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 4.3 m -134.99 112.64 11.36 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-O 121.098 0.475 . . . . 0.0 111.065 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -67.15 -31.01 37.23 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.593 2.195 . . . . 0.0 111.234 175.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.9 m -132.42 151.75 35.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.406 -0.816 . . . . 0.0 109.24 177.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.21 155.66 41.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.036 0.446 . . . . 0.0 110.95 -177.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -66.42 122.52 17.72 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.355 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.71 21.46 33.92 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.957 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -113.76 164.1 14.17 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.755 0.312 . . . . 0.0 110.369 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.694 ' HB ' ' HE3' ' A' ' 53' ' ' LYS . 14.9 p -129.92 131.85 66.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 120.92 0.39 . . . . 0.0 110.373 -176.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -135.96 154.66 51.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.389 -176.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -93.36 123.61 36.77 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 31.9 m -133.37 156.64 42.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.177 0.513 . . . . 0.0 111.709 -173.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.553 HG23 ' HG2' ' A' ' 49' ' ' GLU . 61.0 m -113.16 124.62 52.99 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.248 -0.887 . . . . 0.0 109.622 173.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.557 HG13 ' HB ' ' A' ' 44' ' ' THR . 48.7 mm -70.41 95.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.3 tp60 -86.61 -33.91 20.02 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.315 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.429 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 20.3 t70 -126.73 163.73 22.88 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.537 -178.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.493 HG13 ' HA2' ' A' ' 30' ' ' GLY . 7.5 tt -141.48 132.19 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 174.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -77.06 162.63 27.35 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.428 -175.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.3 ttm105 -68.74 -12.89 61.98 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.566 0.698 . . . . 0.0 109.463 178.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -72.16 -16.77 61.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.807 172.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.52 17.13 59.12 Favored Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 115.662 -0.699 . . . . 0.0 113.087 176.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 -105.68 143.07 34.35 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 177.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.493 ' HA2' HG13 ' A' ' 24' ' ' ILE . . . -68.29 133.83 28.59 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.156 -175.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.49 HG23 HG23 ' A' ' 38' ' ' VAL . 48.0 mm -106.68 109.97 29.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.325 0.584 . . . . 0.0 110.583 -178.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.499 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -101.4 149.77 23.72 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.381 175.124 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 33' ' ' ARG . 1.2 ptm180 -138.37 113.79 9.57 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.98 0.419 . . . . 0.0 110.929 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.0 mt -104.48 105.75 19.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.991 176.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 51.57 27.67 4.09 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 114.686 -1.143 . . . . 0.0 112.131 -178.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 118.45 -31.81 5.45 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.756 -0.735 . . . . 0.0 113.025 177.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.402 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 12.5 t80 -75.51 125.42 28.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.843 0.354 . . . . 0.0 110.252 -177.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.49 HG23 HG23 ' A' ' 31' ' ' ILE . 7.0 p -88.75 135.38 25.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.287 0.565 . . . . 0.0 111.551 -176.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.558 HG12 ' HB3' ' A' ' 62' ' ' ALA . 42.7 mt -124.29 132.13 71.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.943 178.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -93.17 119.63 32.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.81 0.338 . . . . 0.0 110.576 177.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.39 100.09 45.06 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.963 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.48 127.36 17.95 Favored 'Trans proline' 0 CA--C 1.529 0.264 0 C-N-CA 123.226 2.618 . . . . 0.0 113.118 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 102.85 -9.13 55.04 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.83 173.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.557 ' HB ' HG13 ' A' ' 21' ' ' ILE . 25.8 p -89.12 156.13 19.01 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 117.355 0.578 . . . . 0.0 111.669 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -111.4 157.61 20.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.764 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 88.1 t -58.99 124.12 12.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.281 177.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 108.44 -13.1 36.31 Favored Glycine 0 N--CA 1.44 -1.059 0 C-N-CA 120.98 -0.629 . . . . 0.0 112.512 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -68.84 117.32 10.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.119 0.485 . . . . 0.0 110.966 179.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.553 ' HG2' HG23 ' A' ' 20' ' ' THR . 44.3 mt-10 -106.64 97.03 6.87 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.86 173.74 14.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.063 -173.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 76.9 mtp85 -103.23 126.49 50.43 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.75 177.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.1 pt -116.17 143.35 26.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.326 -175.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.694 ' HE3' ' HB ' ' A' ' 16' ' ' VAL . 0.9 OUTLIER -97.87 102.84 14.7 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.122 175.824 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.524 ' HA ' ' HB2' ' A' ' 64' ' ' ALA . 55.9 t -69.35 108.45 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.22 -26.41 17.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.738 -173.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 37.8 ttt180 -154.92 144.91 21.72 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.823 0.344 . . . . 0.0 110.731 174.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 35.7 m -110.19 141.7 24.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.122 175.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.532 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 3.1 mm? -115.59 160.45 34.68 Favored Pre-proline 0 C--N 1.32 -0.687 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.532 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 9.8 Cg_endo -52.69 -28.41 37.5 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 123.122 2.548 . . . . 0.0 114.177 -175.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -121.79 -2.96 9.24 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -175.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -169.58 162.62 10.01 Favored 'General case' 0 C--O 1.222 -0.382 0 CA-C-N 117.76 0.254 . . . . 0.0 110.941 -175.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.558 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -113.87 157.47 22.31 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 120.685 0.279 . . . . 0.0 110.569 177.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -123.2 129.0 50.8 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.524 ' HB2' ' HA ' ' A' ' 54' ' ' VAL . . . -146.69 158.5 43.92 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.353 . . . . 0.0 111.677 -176.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.2 p -115.73 160.08 20.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.551 177.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 68' ' ' GLU . 41.4 t -81.62 123.98 38.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.329 -176.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.0 m -120.45 33.67 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 121.15 0.5 . . . . 0.0 110.539 179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.435 ' H ' HG12 ' A' ' 66' ' ' VAL . 45.9 tt0 . . . . . 0 C--O 1.25 1.116 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.419 177.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.0 mmt . . . . . 0 N--CA 1.478 0.942 0 CA-C-O 120.646 0.26 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.53 ' CD2' ' HG2' ' A' ' 3' ' ' ARG . 53.2 p90 -81.39 157.47 24.99 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.53 ' HG2' ' CD2' ' A' ' 2' ' ' PHE . 32.4 mmt180 73.67 152.45 0.13 Allowed 'General case' 0 N--CA 1.469 0.492 0 O-C-N 123.823 0.702 . . . . 0.0 109.321 -170.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -85.7 59.81 5.86 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.414 0.626 . . . . 0.0 109.984 177.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 14.8 pt-20 -89.81 131.19 35.88 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 121.54 0.686 . . . . 0.0 110.726 -175.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.423 ' C ' ' H ' ' A' ' 8' ' ' SER . 40.7 p -114.48 -53.91 2.62 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 171.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.2 mtt-85 67.38 -36.97 0.3 Allowed 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 114.851 -1.068 . . . . 0.0 112.625 177.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.423 ' H ' ' C ' ' A' ' 6' ' ' SER . 49.9 m 62.2 70.79 0.56 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.533 0.682 . . . . 0.0 110.73 -179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 18.2 m -95.86 142.36 24.46 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.63 178.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -69.24 -31.21 23.32 Favored 'Trans proline' 0 N--CA 1.463 -0.29 0 C-N-CA 122.427 2.084 . . . . 0.0 112.338 179.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.475 HG11 HD11 ' A' ' 39' ' ' ILE . 30.3 m -136.63 156.25 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.786 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.576 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.8 pt-20 -133.24 160.45 37.25 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.42 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.44 ' CG ' HG22 ' A' ' 57' ' ' VAL . 39.3 mt-10 -66.83 132.87 48.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.13 0.49 . . . . 0.0 112.15 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.489 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 77.75 36.14 33.82 Favored Glycine 0 N--CA 1.448 -0.545 0 CA-C-N 115.205 -0.907 . . . . 0.0 112.997 174.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.589 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 19.6 mm-40 -125.03 164.62 19.78 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-O 120.791 0.329 . . . . 0.0 111.011 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 55.0 t -121.81 122.99 68.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.719 -174.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 41.9 m-85 -125.89 145.87 50.07 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.86 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -90.92 95.75 10.28 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.517 0.675 . . . . 0.0 109.244 171.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 49' ' ' GLU . 28.5 m -104.76 161.29 4.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.514 -171.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.8 m -110.58 119.57 39.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.041 175.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.478 HD13 ' HB2' ' A' ' 32' ' ' ALA . 47.7 mm -69.7 106.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 175.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.823 ' HA ' HE21 ' A' ' 22' ' ' GLN . 0.0 OUTLIER -97.84 -22.13 16.54 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.286 -173.634 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.541 ' HB3' ' HB ' ' A' ' 31' ' ' ILE . 29.3 t70 -142.88 164.28 30.53 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.895 -0.322 . . . . 0.0 111.263 -174.131 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.431 HG12 HG23 ' A' ' 46' ' ' VAL . 48.5 mm -124.49 131.94 72.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.473 ' HB2' HD11 ' A' ' 31' ' ' ILE . . . -98.55 -150.79 0.37 Allowed 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.382 0.611 . . . . 0.0 111.548 -174.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 8.3 ttp180 -47.68 117.37 1.81 Allowed 'General case' 0 N--CA 1.448 -0.553 0 CA-C-N 114.654 -1.157 . . . . 0.0 110.893 173.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 52.5 tt0 72.65 -74.84 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 O-C-N 123.892 0.745 . . . . 0.0 112.123 169.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -160.75 19.06 0.21 Allowed Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.572 -177.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.562 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 47.7 m-20 -78.01 123.23 26.57 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 176.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.605 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -79.13 137.74 19.64 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.527 -0.844 . . . . 0.0 111.791 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.578 HG22 ' HD3' ' A' ' 33' ' ' ARG . 48.3 mm -108.57 114.26 46.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.271 0.558 . . . . 0.0 110.778 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.478 ' HB2' HD13 ' A' ' 21' ' ' ILE . . . -109.54 112.4 24.47 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.805 176.397 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.661 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 0.6 OUTLIER -97.78 115.02 27.19 Favored 'General case' 0 C--N 1.321 -0.639 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.519 178.448 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 31.8 mt -93.81 107.96 19.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 172.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 55.42 21.92 4.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 114.701 -1.136 . . . . 0.0 111.921 -174.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 116.64 -26.69 8.35 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.773 -0.727 . . . . 0.0 113.244 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.661 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 53.5 t80 -69.6 128.04 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.965 0.382 . . . . 0.0 110.715 -176.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.519 HG13 HG23 ' A' ' 31' ' ' ILE . 60.8 t -85.62 116.04 28.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.737 -174.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.475 HD11 HG11 ' A' ' 11' ' ' VAL . 54.0 mt -111.41 133.13 58.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.914 174.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -94.05 122.94 37.08 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.013 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.426 HG22 ' HB3' ' A' ' 64' ' ' ALA . 43.9 t -127.67 91.52 45.28 Favored Pre-proline 0 C--N 1.326 -0.434 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 38.4 Cg_exo -60.22 121.27 9.52 Favored 'Trans proline' 0 CA--C 1.528 0.192 0 C-N-CA 122.873 2.382 . . . . 0.0 113.033 -175.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.63 60.8 1.33 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.073 175.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.605 ' OG1' ' HA3' ' A' ' 30' ' ' GLY . 1.3 p -143.35 175.22 10.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 117.006 0.403 . . . . 0.0 110.72 176.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 4.1 tppp? -129.86 150.09 51.31 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -178.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.431 HG23 HG12 ' A' ' 24' ' ' ILE . 67.4 t -58.82 116.62 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-O 120.881 0.372 . . . . 0.0 110.85 177.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 117.85 -9.27 14.32 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.107 -0.568 . . . . 0.0 112.227 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -71.98 105.4 3.86 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 120.821 0.343 . . . . 0.0 111.556 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 19' ' ' VAL . 47.1 mt-10 -88.45 97.7 11.22 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 168.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.595 ' HA ' ' HG3' ' A' ' 68' ' ' GLU . 16.3 m -128.2 151.98 35.71 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.922 -0.581 . . . . 0.0 112.031 -172.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.428 ' H ' ' CG ' ' A' ' 68' ' ' GLU . 25.1 mmt180 -79.64 128.93 34.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.852 172.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 16' ' ' VAL . 2.7 pp -134.57 147.16 29.94 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.706 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.589 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 47.6 tttp -102.66 111.74 24.19 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 173.77 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 90.2 t -67.75 112.91 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.633 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 175.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -92.06 -33.19 14.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.912 -169.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -156.45 130.12 8.31 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.997 -172.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.44 HG22 ' CG ' ' A' ' 13' ' ' GLU . 34.3 m -114.42 139.45 40.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.323 0.582 . . . . 0.0 111.198 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 96.9 mt -123.64 153.67 66.49 Favored Pre-proline 0 C--N 1.319 -0.73 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 173.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.47 -16.6 14.47 Favored 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.722 2.282 . . . . 0.0 113.46 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 55.9 tptt -100.92 -34.7 9.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.549 -0.296 . . . . 0.0 111.553 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -170.18 173.52 5.8 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.453 -0.202 . . . . 0.0 110.453 -174.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -133.42 159.64 39.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.889 0.376 . . . . 0.0 111.633 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 39.1 m-85 -108.59 152.44 24.77 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.456 ' HB1' ' HB ' ' A' ' 52' ' ' ILE . . . -142.45 142.45 32.33 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.162 0.506 . . . . 0.0 111.742 177.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 42.2 m -94.34 139.3 31.25 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.477 174.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 25.6 t -81.64 118.25 29.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 120.653 0.263 . . . . 0.0 110.651 -178.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.8 m -118.17 20.16 6.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.172 0.511 . . . . 0.0 110.679 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.595 ' HG3' ' HA ' ' A' ' 50' ' ' VAL . 1.1 tm-20 . . . . . 0 C--O 1.244 0.783 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.212 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.402 ' SD ' ' N ' ' A' ' 1' ' ' MET . 1.5 mpt? . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 121.09 0.471 . . . . 0.0 109.854 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -112.93 -20.89 11.39 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.934 -174.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 6.8 mmt180 -150.07 -53.87 0.16 Allowed 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.636 0.731 . . . . 0.0 110.559 -177.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.9 tt0 177.96 -19.63 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 -172.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 74.3 -158.72 0.07 Allowed 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 113.167 -1.833 . . . . 0.0 110.313 175.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 80.7 p 54.76 31.96 16.53 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 122.254 1.026 . . . . 0.0 108.255 -164.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 48.4 mtm180 -88.92 -159.37 0.56 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 114.062 -1.426 . . . . 0.0 110.327 -178.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 36.2 t -63.78 102.05 0.42 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.216 0.531 . . . . 0.0 111.613 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 2.7 m -138.49 88.04 14.84 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.365 173.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.473 ' HB2' HG22 ' A' ' 34' ' ' ILE . 73.0 Cg_endo -75.49 -15.96 19.4 Favored 'Trans proline' 0 C--O 1.234 0.315 0 C-N-CA 122.728 2.285 . . . . 0.0 113.037 -174.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' HG21 ' A' ' 54' ' ' VAL . 19.4 m -131.33 143.7 39.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.745 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -121.58 148.9 43.92 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.681 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.481 ' CG ' HG22 ' A' ' 57' ' ' VAL . 44.1 mt-10 -66.31 129.46 39.89 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.315 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.65 27.17 30.3 Favored Glycine 0 N--CA 1.445 -0.767 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.917 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.504 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 72.0 mm-40 -124.05 156.44 36.54 Favored 'General case' 0 CA--C 1.51 -0.587 0 CA-C-O 121.256 0.55 . . . . 0.0 111.894 -177.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 52' ' ' ILE . 57.0 t -113.83 130.65 67.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.149 -175.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -132.04 150.82 52.05 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.246 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -94.85 109.52 21.5 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.86 144.63 36.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.424 0.63 . . . . 0.0 112.15 -174.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.0 m -96.14 139.64 32.01 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 169.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.603 HG13 ' HB ' ' A' ' 44' ' ' THR . 45.8 mm -81.1 124.86 39.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.591 0.234 . . . . 0.0 110.972 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.464 ' OE1' ' HG2' ' A' ' 33' ' ' ARG . 2.3 mp0 -75.47 -56.33 4.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.979 -177.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -140.28 -179.41 5.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.15 -177.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 38.0 mm -123.7 127.45 73.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.81 146.69 26.65 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.724 179.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 37.2 ttt180 -61.44 -16.65 48.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.833 -173.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -70.19 -23.99 63.05 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.82 0.343 . . . . 0.0 110.987 177.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.97 17.52 10.89 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.729 -0.748 . . . . 0.0 111.728 -175.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -113.41 153.07 29.2 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.51 ' HA3' ' OG1' ' A' ' 44' ' ' THR . . . -91.86 144.92 17.43 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.796 179.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 70.2 mt -100.87 109.84 26.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-O 120.952 0.406 . . . . 0.0 110.406 -178.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -111.58 163.43 14.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.447 175.298 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.464 ' HG2' ' OE1' ' A' ' 22' ' ' GLN . 31.5 ptt180 -144.68 132.88 21.66 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.704 0.288 . . . . 0.0 110.822 -178.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.473 HG22 ' HB2' ' A' ' 10' ' ' PRO . 49.6 mt -129.06 117.82 44.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.29 26.82 14.41 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.953 0.882 . . . . 0.0 109.923 -175.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.36 -15.0 63.25 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.639 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.55 ' CE2' ' HB2' ' A' ' 62' ' ' ALA . 14.7 t80 -75.31 119.93 20.08 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 54.3 t -78.04 128.93 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.234 0.54 . . . . 0.0 111.382 -173.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.534 HG12 ' HB3' ' A' ' 62' ' ' ALA . 24.6 mt -120.11 129.72 75.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.797 179.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 -101.54 125.24 48.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 120.857 0.36 . . . . 0.0 110.803 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.0 t -122.94 108.33 32.69 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.359 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.12 126.84 21.3 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 123.213 2.608 . . . . 0.0 113.184 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.75 64.39 2.25 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 121.066 -0.587 . . . . 0.0 113.384 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.603 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.4 p -134.88 -172.24 2.99 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 176.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.459 ' HB3' ' HB2' ' A' ' 48' ' ' ASP . 36.7 ttpt -142.69 153.91 43.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.418 0.151 . . . . 0.0 110.871 -175.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 60.8 t -59.03 120.6 5.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-O 120.74 0.305 . . . . 0.0 111.113 179.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.7 4.35 90.27 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.602 177.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.459 ' HB2' ' HB3' ' A' ' 45' ' ' LYS . 40.3 t0 -75.87 122.67 24.47 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -88.3 106.49 18.26 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.087 0.47 . . . . 0.0 110.02 179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.68 146.82 33.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.379 0.609 . . . . 0.0 111.333 -175.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 68.9 mtt180 -97.97 117.57 32.62 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 176.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.488 HG22 ' HA ' ' A' ' 66' ' ' VAL . 44.5 pt -116.27 155.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.475 -170.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.504 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 34.9 ttmt -105.37 118.09 35.67 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.459 HG21 ' HB ' ' A' ' 11' ' ' VAL . 90.2 t -69.19 118.35 13.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 174.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 19.8 mm-40 -92.84 -45.79 7.83 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.348 1.03 . . . . 0.0 111.217 -175.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 33.2 mtt180 -135.93 144.0 45.23 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.378 -172.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.481 HG22 ' CG ' ' A' ' 13' ' ' GLU . 27.6 m -124.7 116.05 46.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.698 0.761 . . . . 0.0 110.497 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.432 ' C ' ' H ' ' A' ' 60' ' ' LYS . 5.8 mp -112.94 152.22 44.72 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.619 -179.507 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.13 11.0 0.28 Allowed 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 122.745 2.297 . . . . 0.0 112.481 177.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.432 ' H ' ' C ' ' A' ' 58' ' ' LEU . 56.9 mttm -118.51 -31.78 4.8 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.612 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -177.84 170.25 1.94 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.923 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.55 ' HB2' ' CE2' ' A' ' 37' ' ' PHE . . . -108.75 146.96 32.73 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.808 0.337 . . . . 0.0 110.533 176.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 53.4 t80 -122.0 123.68 42.21 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 178.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -134.85 152.02 51.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.873 -176.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 20.9 t -113.48 146.6 39.33 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.52 HG22 ' H ' ' A' ' 68' ' ' GLU . 7.2 p -81.65 117.52 27.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.361 0.601 . . . . 0.0 111.126 -176.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 9.9 p -96.52 8.85 6.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.938 0.875 . . . . 0.0 108.993 178.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.52 ' H ' HG22 ' A' ' 66' ' ' VAL . 25.7 tt0 . . . . . 0 C--O 1.251 1.146 0 CA-C-N 113.334 -1.757 . . . . 0.0 111.268 177.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.2 mpp? . . . . . 0 N--CA 1.481 1.116 0 CA-C-O 120.403 0.144 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.491 ' C ' ' H ' ' A' ' 4' ' ' GLU . 86.7 m-85 64.86 95.98 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.117 0.567 . . . . 0.0 110.995 176.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.453 ' HB2' ' O ' ' A' ' 2' ' ' PHE . 66.2 mtt180 71.89 -9.69 0.95 Allowed 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 115.344 -0.843 . . . . 0.0 110.38 -171.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.491 ' H ' ' C ' ' A' ' 2' ' ' PHE . 33.8 mm-40 66.14 10.91 7.46 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 114.932 -1.031 . . . . 0.0 113.638 169.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 56.44 -154.45 0.33 Allowed 'General case' 0 CA--C 1.529 0.155 0 O-C-N 123.354 0.409 . . . . 0.0 111.078 168.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.5 t -87.73 -42.02 12.92 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.01 0.434 . . . . 0.0 109.846 175.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.568 ' C ' ' H ' ' A' ' 9' ' ' VAL . 17.0 mmt180 -116.85 -64.71 1.27 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.19 -0.459 . . . . 0.0 112.053 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 82.1 p 66.62 -20.85 0.1 Allowed 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 125.256 1.423 . . . . 0.0 112.327 -174.499 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.568 ' H ' ' C ' ' A' ' 7' ' ' ARG . 0.4 OUTLIER -158.06 105.22 1.73 Allowed Pre-proline 0 C--N 1.31 -1.132 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.178 177.26 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_exo -62.82 -41.41 30.33 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.775 2.317 . . . . 0.0 112.177 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.6 m -129.5 162.06 37.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.48 -178.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.545 ' HG3' ' HG3' ' A' ' 15' ' ' GLU . 10.0 pt-20 -130.96 156.41 45.15 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.429 178.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.4 ' CD ' HH21 ' A' ' 56' ' ' ARG . 56.1 mt-10 -66.46 133.61 50.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.355 -174.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.91 31.08 33.27 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.688 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.545 ' HG3' ' HG3' ' A' ' 12' ' ' GLU . 58.8 mm-40 -127.17 155.86 42.72 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 120.556 -0.457 . . . . 0.0 110.912 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 53' ' ' LYS . 7.1 p -118.66 128.23 75.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.09 -174.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 35.8 m-85 -125.95 132.43 52.08 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.793 -178.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 51' ' ' ARG . 30.2 t70 -81.61 97.0 7.66 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 175.473 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 33.9 m -111.99 170.45 3.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 121.392 0.615 . . . . 0.0 111.663 -170.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.434 ' HA ' ' HA ' ' A' ' 49' ' ' GLU . 26.0 m -120.51 128.73 53.39 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.111 171.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.587 HG13 ' HB ' ' A' ' 44' ' ' THR . 49.9 mm -68.48 116.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 121.168 0.508 . . . . 0.0 110.707 -175.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.0 mm-40 -84.29 -40.55 17.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.608 -173.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -143.33 179.55 7.02 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -177.332 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.551 HD13 ' HA2' ' A' ' 30' ' ' GLY . 32.0 mm -137.06 119.21 19.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.42 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . -71.69 150.57 44.41 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.943 178.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 55.2 ttp180 -47.81 -35.71 10.57 Favored 'General case' 0 C--N 1.329 -0.316 0 O-C-N 123.478 0.486 . . . . 0.0 112.051 -177.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.585 ' HB2' ' OD1' ' A' ' 29' ' ' ASP . 15.5 mt-30 -73.09 -14.19 61.34 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.767 -175.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.41 7.92 41.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.666 -175.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.813 ' HA ' ' HA ' ' A' ' 42' ' ' PRO . 6.6 m-20 -80.95 122.82 27.73 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 177.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.551 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -72.27 127.75 12.85 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.512 178.572 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.57 HG23 HG13 ' A' ' 38' ' ' VAL . 73.5 mt -95.52 106.49 18.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.339 0.59 . . . . 0.0 111.385 -176.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -96.69 94.65 7.43 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 170.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.463 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 9.9 ptm180 -93.91 98.46 11.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.57 0.7 . . . . 0.0 110.968 -174.465 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 45.1 mt -93.17 111.33 24.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.487 -179.329 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 56.64 26.33 11.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.941 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.53 -20.47 39.47 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.457 179.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 50.7 t80 -75.59 123.44 25.51 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.191 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.57 HG13 HG23 ' A' ' 31' ' ' ILE . 64.7 t -90.0 116.37 31.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.897 -173.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.445 HG12 ' HB3' ' A' ' 62' ' ' ALA . 55.4 mt -109.24 125.66 66.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.648 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -94.19 121.14 35.38 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.969 0.414 . . . . 0.0 111.359 -178.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 64' ' ' ALA . 11.0 t -129.53 89.59 46.58 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.126 175.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.813 ' HA ' ' HA ' ' A' ' 29' ' ' ASP . 32.8 Cg_endo -63.94 137.43 57.69 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.968 2.445 . . . . 0.0 113.239 -175.326 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.38 -10.15 30.87 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.032 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.587 ' HB ' HG13 ' A' ' 21' ' ' ILE . 35.3 p -95.59 -179.62 4.81 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.522 0.201 . . . . 0.0 110.962 -178.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.533 ' HA ' HD11 ' A' ' 24' ' ' ILE . 34.3 ttmt -142.9 165.29 27.76 Favored 'General case' 0 CA--C 1.532 0.274 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 44.0 t -58.34 118.7 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 CA-C-O 120.664 0.268 . . . . 0.0 111.097 -178.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 98.94 -5.74 59.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.761 178.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.444 ' O ' HG12 ' A' ' 21' ' ' ILE . 29.6 t0 -75.11 112.47 11.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.893 0.378 . . . . 0.0 110.055 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 20' ' ' THR . 8.4 pt-20 -100.29 108.09 20.06 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.743 -178.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.0 m -142.15 161.87 19.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.807 -176.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.492 ' HA ' ' HA ' ' A' ' 18' ' ' ASP . 66.0 mtm180 -82.95 124.23 30.18 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.796 174.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.6 pt -117.96 136.92 53.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.137 177.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 56.3 tttm -100.4 114.6 28.27 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 96.7 t -69.29 121.19 18.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 9.3 mm-40 -94.44 -45.73 7.31 Favored 'General case' 0 C--N 1.327 -0.383 0 O-C-N 124.209 0.943 . . . . 0.0 110.872 -174.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.4 HH21 ' CD ' ' A' ' 13' ' ' GLU . 1.8 tpm_? -140.68 137.91 33.89 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.143 -172.336 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 34.4 m -114.78 136.31 51.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.295 0.569 . . . . 0.0 110.858 176.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . . . . . . . . . 5.6 mp -123.02 156.19 62.98 Favored Pre-proline 0 C--N 1.321 -0.652 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -58.47 -16.67 30.48 Favored 'Trans proline' 0 CA--C 1.53 0.318 0 C-N-CA 122.848 2.365 . . . . 0.0 113.518 -177.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 24.2 ttmm -110.35 -22.52 11.67 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -176.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -172.47 172.14 4.44 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.682 0.277 . . . . 0.0 111.0 -174.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.445 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -128.13 157.47 40.69 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.688 0.28 . . . . 0.0 110.984 177.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -124.61 136.4 53.91 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.735 179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.518 ' HB3' HG22 ' A' ' 41' ' ' VAL . . . -136.83 163.2 31.2 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.956 0.407 . . . . 0.0 111.423 -176.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 23.1 p -117.27 145.0 44.24 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.854 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 40.6 t -78.39 127.19 38.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.131 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.0 m -123.49 13.88 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.743 0.306 . . . . 0.0 110.465 176.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 . . . . . 0 C--O 1.25 1.119 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.504 -179.634 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.2 mpt? . . . . . 0 N--CA 1.481 1.12 0 CA-C-O 120.488 0.185 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 62.74 -169.28 0.19 Allowed 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.04 -176.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 62.0 ttt180 -156.54 -35.99 0.08 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.467 -178.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 75.18 96.52 0.07 Allowed 'General case' 0 N--CA 1.462 0.175 0 O-C-N 124.118 0.886 . . . . 0.0 109.191 -173.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -75.7 -163.47 0.27 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.835 -175.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 50.0 m 73.62 76.64 0.13 Allowed 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.25 -173.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 19.1 mmt85 -52.38 138.83 26.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.699 -179.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 17.6 m -67.93 96.55 0.6 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.404 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.43 HG12 ' H ' ' A' ' 11' ' ' VAL . 8.4 t 69.97 115.95 0.03 OUTLIER Pre-proline 0 CA--C 1.534 0.331 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.673 173.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -71.07 -7.33 21.17 Favored 'Trans proline' 0 CA--C 1.531 0.368 0 C-N-CA 122.944 2.429 . . . . 0.0 113.343 -177.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.43 ' H ' HG12 ' A' ' 9' ' ' VAL . 16.1 m -133.79 130.7 56.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.706 0.289 . . . . 0.0 110.474 179.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -113.09 173.7 6.26 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.541 0.686 . . . . 0.0 111.773 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.525 ' OE1' ' HD3' ' A' ' 56' ' ' ARG . 33.5 mt-10 -67.28 126.63 29.84 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.806 -1.088 . . . . 0.0 112.152 -177.082 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.555 ' HA2' ' HE3' ' A' ' 53' ' ' LYS . . . 91.68 16.35 52.31 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.389 -0.823 . . . . 0.0 112.929 174.039 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.569 ' O ' ' HA ' ' A' ' 53' ' ' LYS . 26.2 mt-10 -99.04 160.42 14.27 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.344 -0.542 . . . . 0.0 111.187 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.51 124.34 68.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.208 -179.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -128.54 141.05 51.49 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.858 -177.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -80.51 97.29 7.08 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 169.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 35.4 m -109.66 148.9 13.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.353 0.597 . . . . 0.0 111.764 -173.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.0 m -110.1 119.09 38.18 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.912 172.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.64 HG13 ' HB ' ' A' ' 44' ' ' THR . 41.3 mm -69.64 116.77 11.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.746 -175.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 12.4 mm-40 -87.17 -51.03 6.22 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.863 -174.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.433 ' HB2' ' HB ' ' A' ' 31' ' ' ILE . 15.2 m-20 -124.31 -179.26 4.38 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.892 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.603 HD13 ' HA2' ' A' ' 30' ' ' GLY . 39.6 mm -137.82 137.8 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.584 ' HB3' ' HB2' ' A' ' 29' ' ' ASP . . . -68.54 -65.75 0.66 Allowed 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 121.912 0.863 . . . . 0.0 109.201 177.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 37.2 ptt180 -172.64 127.46 0.51 Allowed 'General case' 0 N--CA 1.439 -0.987 0 CA-C-N 113.514 -1.676 . . . . 0.0 108.178 172.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 61.7 tt0 79.55 -63.29 0.26 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.402 -0.817 . . . . 0.0 112.099 172.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -146.22 -21.65 0.12 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 119.587 -1.292 . . . . 0.0 114.687 -170.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.584 ' HB2' ' HB3' ' A' ' 25' ' ' ALA . 5.1 m-20 -73.62 108.24 6.35 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 117.799 0.8 . . . . 0.0 109.587 -179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.603 ' HA2' HD13 ' A' ' 24' ' ' ILE . . . -80.21 144.07 25.59 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.906 -0.664 . . . . 0.0 112.294 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.434 HG23 HG13 ' A' ' 38' ' ' VAL . 50.2 mm -105.5 102.69 14.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.105 0.479 . . . . 0.0 110.166 179.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.406 ' HB3' ' HB ' ' A' ' 39' ' ' ILE . . . -98.18 147.51 24.52 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 174.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 37' ' ' PHE . 8.9 ptp85 -138.95 109.43 6.55 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.297 0.57 . . . . 0.0 111.049 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 42.7 mt -101.65 118.32 48.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 173.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 67.78 -3.1 1.22 Allowed 'General case' 0 CA--C 1.535 0.371 0 O-C-N 124.186 0.929 . . . . 0.0 110.519 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 117.86 -14.49 12.73 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.209 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.474 ' O ' ' HA ' ' A' ' 33' ' ' ARG . 34.8 t80 -74.87 127.76 33.96 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.434 HG13 HG23 ' A' ' 31' ' ' ILE . 46.9 t -81.04 130.49 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.715 -173.721 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.536 HG12 ' HB3' ' A' ' 62' ' ' ALA . 50.7 mt -123.12 125.28 71.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.594 176.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -89.67 133.54 34.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.624 0.249 . . . . 0.0 110.768 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.7 t -132.13 104.23 13.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.247 -179.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_exo -69.5 104.21 1.24 Allowed 'Trans proline' 0 C--O 1.233 0.262 0 C-N-CA 122.947 2.432 . . . . 0.0 112.849 -178.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.95 48.17 0.74 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.979 175.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.64 ' HB ' HG13 ' A' ' 21' ' ' ILE . 2.8 p -138.08 170.96 15.13 Favored 'General case' 0 C--N 1.323 -0.577 0 O-C-N 122.752 -0.264 . . . . 0.0 111.29 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.663 ' HE3' ' HA ' ' A' ' 45' ' ' LYS . 0.2 OUTLIER -132.97 166.84 21.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.087 -177.044 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 43.8 t -65.47 116.42 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 178.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 95.62 1.76 61.87 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.407 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -75.12 123.66 25.64 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -103.19 108.57 19.83 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.385 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.5 m -138.18 161.58 31.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.366 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -96.34 123.67 40.06 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.267 172.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.472 HG22 ' HA ' ' A' ' 66' ' ' VAL . 46.9 pt -117.46 143.37 28.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.625 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.569 ' HA ' ' O ' ' A' ' 15' ' ' GLU . 49.1 tttp -98.82 109.8 22.51 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 173.073 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 92.5 t -68.92 107.48 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 176.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -88.71 -40.84 12.96 Favored 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.653 0.596 . . . . 0.0 111.21 -172.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.525 ' HD3' ' OE1' ' A' ' 13' ' ' GLU . 19.6 mmt180 -139.71 129.59 24.78 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.004 -175.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.1 m -97.1 117.96 42.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 172.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.506 ' HB3' ' HD2' ' A' ' 59' ' ' PRO . 80.1 mt -101.37 162.08 21.61 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.922 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PRO . . . . . 0.506 ' HD2' ' HB3' ' A' ' 58' ' ' LEU . 91.1 Cg_exo -43.89 -38.49 10.03 Favored 'Trans proline' 0 C--N 1.348 0.528 0 C-N-CA 123.57 2.847 . . . . 0.0 114.666 -175.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 17.6 tptp -120.29 -3.72 9.98 Favored 'General case' 0 CA--C 1.534 0.336 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -172.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.416 ' CE1' HD12 ' A' ' 58' ' ' LEU . 54.2 p90 -170.74 167.8 7.59 Favored 'General case' 0 C--O 1.222 -0.361 0 CA-C-O 120.613 0.244 . . . . 0.0 110.909 -177.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.536 ' HB3' HG12 ' A' ' 39' ' ' ILE . . . -108.47 147.35 31.8 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.031 0.443 . . . . 0.0 111.05 179.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -112.52 126.62 55.53 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.187 176.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -130.26 156.11 45.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.122 0.487 . . . . 0.0 111.468 -176.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 6.6 t -105.73 130.46 53.73 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.733 178.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.472 ' HA ' HG22 ' A' ' 52' ' ' ILE . 6.3 p -79.95 122.99 36.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.135 0.493 . . . . 0.0 111.067 -177.713 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 6.2 t -105.11 0.48 10.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.698 0.761 . . . . 0.0 109.639 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 . . . . . 0 C--O 1.247 0.952 0 CA-C-N 114.259 -1.337 . . . . 0.0 110.819 -175.234 . . . . . . . . 0 0 . 1 stop_ save_